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1. Abstract 
 
1.1. Zusammenfassung 
Die Zulassung mehrerer bispezifischer Antikörper (bsAbs) und Antikörper-Wirkstoff-Konjugate (ADC) in 
den letzten Jahren unterstreicht die Chancen dieser Wirkstoffklassen auf einen verbesserten 
therapeutischen Nutzen für Patienten. (Diamantis & Banerji, 2016; Garber, 2014) Zumeist sind jedoch 
Tumor-assoziierte Antigene, die ein breites Expressionsprofil nicht nur im Tumorgewebe aufweisen, statt 
Tumor-spezifischer Antigene die Zielstrukturen für hochpotente ADCs. Dies macht eine frühe 
Sicherheitsprüfung auf schwere Nebenwirkungen der ADCs in Normalgeweben notwendig. (Diamantis 
& Banerji, 2016) Kürzlich konnte elegant gezeigt werden, dass mit Bindung zweier verschiedener 
Antigene und der Verwendung von Bindeeinheiten mit verringerter Affinität im bispezifischen Format 
die Tumorselektivität gesteigert werden kann. (Mazor et al, 2015a; Mazor et al, 2015b; Robinson et al, 
2008) 
 
In der vorliegenden Studie wurde ein bispezifischer Antikörper entwickelt und evaluiert, der simultan 
die zwei klinisch validierten Krebsantigene c-MET und EGFR bindet. Deren Interaktion und redundante 
Signalwege können zu c-MET vermittelter, erworbener Wirkstoffresistenz während einer EGFR 
Monotherapie führen. (Engelman et al, 2007; Guo et al, 2008; Jo et al, 2000) Darüber hinaus ist die 
Inhibition von EGFR in Normalgewebe wie der Haut mit schwerer Toxizität assoziiert (Lacouture, 2006), 
welches eine sorgfältige Abwägung von Wirksamkeit und Selektivität von gegen EGFR gerichteten 
Bindeproteinen erfordert. In dieser Arbeit wurden nach unserem Wissen zum ersten Mal Affinitäts-
optimierte, bispezifische Antikörper mit der Potenz eines ADC-Ansatzes kombiniert. Dabei konnte für 
c-MET und EGFR bispezifische Antikörper erhöhte Selektivität durch Avidität zu Tumormodellen im 
Vergleich zu Normalgewebemodellen in Zellmischungsexperimenten nachgewiesen werden. Die 
verbesserte Selektivität war dabei proportional zu der verringerten Affinität des EGFR Binderanteils, was 
jedoch gleichzeitig die Inhibition von EGFR verschlechterte. Sowohl die erhöhte Selektivität als auch die 
Internalisierung demonstrierten die Eignung als ADC. Bispezifische ADCs zeigten neben gleichbleibend 
hoher Tumorselektivität auch eine hohe zytotoxische Potenz in c-MET und EGFR exprimierenden 
Tumorzelllinien, nicht aber in primären Keratinozyten als Normalgewebeäquivalent. 
 
Diese Studie stellt ein illustratives Beispiel für die Kombination von Tumor-spezifischen bispezifischen 
Antikörpern in Verbindung mit potenter ADC-Technologie zur Erweiterung des therapeutischen Fensters 
dar. Das Ausbalancieren von Selektivität und Wirksamkeit bispezifischer Antikörper durch Optimierung 
von Affinität und Epitopen ist ein vielversprechender Ansatz für die Erweiterung der 
Anwendungsmöglichkeiten von ADCs gegen breit exprimierte Antigene. 
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1.2. Abstract  
Next generation antibodies such as bispecific antibodies (bsAbs) and antibody-drug conjugates (ADC) 
have reached market maturity demonstrating strong therapeutic benefit for patients. (Diamantis & 
Banerji, 2016; Garber, 2014) However, targeting broadly expressed, tumor-associated rather than 
tumor-specific antigens by highly potent ADCs warrants early safety assessment due to the risk of severe 
on-target side effects in normal tissues. (Diamantis & Banerji, 2016) Recently, it was elegantly shown 
that tumor selectivity can be increased by bispecific engagement of two antigens and the application of 
affinity attenuated binding moieties within a bispecific format. (Mazor et al., 2015a; Mazor et al., 2015b; 
Robinson et al., 2008)  
 
In the presented study, simultaneous targeting of two clinically validated cancer antigens, c-MET and 
EGFR, was evaluated, as receptor cross-talk and signaling redundancies give rise to c-MET mediated 
resistance mechanism during anti-EGFR monotherapy. (Engelman et al., 2007; Guo et al., 2008; Jo et 
al., 2000) Furthermore, EGFR inhibition in normal tissue such as skin is associated with severe toxicities 
(Lacouture, 2006) which require careful balancing of efficacy and selectivity for EGFR targeting and 
combinatorial approaches. Herein, we combined to our knowledge for the first time bispecific antibodies 
carrying affinity-optimized binding moieties with the potency of ADC methodologies. Increased 
selectivity of c-MET x EGFR bispecific antibodies towards tumor models with high expression in both 
antigens by avidity over normal tissue models was confirmed by mixed cell flow cytometry. Improved 
tumor selectivity thereby was proportional to decreased affinity of the EGFR binding moiety, but 
concurrently reduced EGFR inhibition. High selectivity and internalization demonstrated ADC suitability 
for delivery of potent cytotoxic agents. As a result, bispecific ADCs retained increased selectivity and 
mediated high tumor efficacy in EGFR and c-MET overexpressing cells whereas toxicity in primary 
keratinocytes as normal tissue equivalent was conjointly reduced. 
 
Hence, the presented study is an illustrative example demonstrating the promising combination of 
affinity optimization of bispecific antibodies for improved tumor selectivity by avidity with the powerful 
ADC technology for potentially broadening the therapeutic window. Balancing selectivity and efficacy in 
bispecific ADCs by affinity and epitope optimization could be a viable route to expand the target space 
of ADCs to ubiquitously expressed antigens. 
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2. Introduction 
 
2.1. Role of antibodies in the immune system 
The immune system serves for the recognition and protection of the host against environmental threats, 
e.g. infectious pathogens and foreign or toxic substances, and is divided into innate and adaptive defense 
mechanisms. The innate immune response thereby represents the first line of defense, is fast and displays 
a broad specificity for common pathogen-associated molecular patterns (PAMPs) on invading microbes 
recognized by receptors on macrophages and neutrophils, e.g. toll-like receptors. (Medzhitov et al, 1997) 
During innate immune response, also pro-inflammatory molecules, e.g. cytokines and chemokines, are 
secreted and the complement system becomes activated. The acquired immunity in contrast is delayed 
and is characterized by adaptive mechanisms including the generation of antigen specific molecules, the 
antibodies or immunoglobulins (Ig), as well as the manifestation of immunological memory and thus 
protection of re-infection in form of memory lymphocytes. Antibodies are thereby part of the humoral 
(from Latin “umor” = fluid) immune response building the link between the adaptive immune system 
and the effector functions of the cellular response of innate immunology. Antibodies and the cells they 
are secreted from (B- lymphocytes) occur in evolution since the class of gnathostomata (vertebrates with 
jaw). (Du, 1993) These cells carry B-cell receptors (BCR) with a unique specificity. BCRs can be 
structurally seen as membrane bound antibodies and variability of antibodies and BCRs is genetically 
encoded. Naïve recirculating B-cells, which are derived from the bone marrow, become activated in 
spleen and lymph nodes when they get contact with their respective antigen. The antigen in turn is 
presented by dendritic cells which has beforehand recognized a pathogen, engulfed and subsequently 
fragmented it. Based on the clonal selection theory by Burnet (1950s), one progenitor B-cell gives rise 
to many lymphocytes with the same BCR whereas cells recognizing self-antigens are eliminated in form 
of a negative selection step. This ensures the crucial discrimination of self and non-self-antigens as well 
as the high selectivity of antibodies. After activation, B-cells enlarge to lymphoblasts, and divide 
repeatedly and maturate to antibody secreting plasma cells. The majority of matured B-cells are 
eliminated after short time, but some survive and differentiate to memory cells. These cells genetically 
store immunological information and increase the immune reactivity for second antigen contact. 
(Janeway et al, 2001) 
 
The first antigen contact is made by pentameric Igs of the isotype M. In response of antigen stimulation 
in combination with co-stimulatory signals, antibody class switching occurs by chromosomal 
recombination. This mechanism is mediated by the enzyme activation-induced cytidine deaminase (AID) 
which catalyzes the conversion from cytosine to uracil. (Stavnezer et al, 2008) Different antibody 
isotypes display different characteristics, e.g. the ability to oligomerize or the induction of effector 
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functions. One of these effector functions is antibody-dependent cellular cytotoxicity (ADCC) which 
describes the recruitment of innate immune effector cells (e.g. monocytes, eosinophils, neutrophils, 
macrophages and natural killer cells) via Fcγ-receptors (FcγRs) recognizing antibodies bound to specific 
target cells. Activation of effector cells by FcγR crosslinking then induces cytolysis by the secretion of 
perforin and granzyme. Another effector function comprises the activation of the complement system 
via protein C1q. A complex system of simultaneously expressed receptors which are either activating or 
inhibitory thereby determines prevention or induction of immune responses. Another feature of 
antibodies is their long half-life which is mediated by the neonatal Fc receptor (FcRn). It belongs to the 
family of major histocompatibility complex (MHC) class I and is expressed on endothelial and myeloid 
cells. The main function is the recycling of immunoglobulins after internalization as well as the placental 
transport of IgG. (Janeway et al., 2001; Roopenian & Akilesh, 2007) 
 
2.1.1. Antibody structure and function 
Around 1960, both the peptide structure of papain cleaved antibody fragments and the first complete 
antibody sequence were elucidated by Porter and Edelman, respectively, which was rewarded with the 
Nobel Prize in 1972. (Ribatti, 2015) Antibodies are Y-shaped, symmetrical, disulfide-bond linked 
heterotetramers with a molecular mass of 150 kDa consisting of two identical heavy and two identical 
light chains (Figure 1A-C). By papain cleavage, antibodies can be split into two identical Fabs (fragment 
of antibody binding) responsible for antigen recognition and one Fc (constant fragment or fragment 
crystalline) mediating effector functions, e.g. ADCC, CDC as well as FcRn mediated recycling and half-
life extension. Fab and Fc are connected with a region of high flexibility, the hinge region. Reduction of 
disulfide bonds located in the hinge region separates the antibody in light and heavy chains. Within each 
light and heavy chain, sequence analysis revealed the presence of regions with high variability at the N-
terminus, denoted as variable region VH and VL for heavy and light chain, respectively. The diversity of 
variable regions is encoded by combinatory design of the genetic locus of variable heavy and light chain 
consisting of germline encoded V for variable, D for diversity (VH only) and J for joining gene segments. 
Recombination of V(D)J gene segments gives rise to the antibody’s variability. Additionally, introduction 
of somatic hypermutations mediated by the enzyme AID (activation-induced cytidine deaminase) further 
increases diversity. Both VH and VL contain three hypervariable regions, denoted as complementary 
determining regions 1 to 3 (CDR1-3), which are flanked by more conserved regions, named framework 
regions 1 to 4 (FR1-4). The three CDRs of the VH and the three CDRs of the VL built up six loop structures 
responsible for antigen recognition which are stabilized by the framework regions. The middle part of 
the CDR3 of the heavy chain is encoded by the D gene segment. Consequently, the CDR-H3 is thought 
to contain the highest variability, both in composition and length, and it might be therefore the driving 
force for antigen binding. (Nimmerjahn & Ravetch, 2010; Vidarsson et al, 2014) 
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Figure 1: Antibody structure.  
Crystal structure of IgG1 (from PDB: 1hzh) with sphere model (A) or ribbon structure (B) (both generated by PyMOL ver. 1.3r1) 
as well as schematic presentation (C). Heavy chains are colored in light blue (VH), dark blue (CH1), yellow (CH2) and red 
(CH3). Light chains are illustrated in light green (VL) and dark green (CL). Heavy chain CH1 and CH2 are connected with a 
flexible region, denoted as hinge (grey) which built up two disulfide bonds between the two heavy chains. The C-termini of CL 
and CH1 are same wise linked with a disulfide bond. By papain cleavage, antibodies are cleaved into two Fab antibody fragments 
(fragment antigen binding) and one Fc (fragment crystalline). The Fab is thereby composed of the light chain and domain VH 
and CH1 of the heavy chain. Within the four domains of the Fab, intramolecular disulfide bonds stabilize each domain. Each 
variable domains contains three hypervariable domains, named complementary determining regions (CDRs) of VH and VL 
building up six loop structures for antigen recognition. Within the CH2 domain, glycosylation sites (squares) are located being 
involved in FcγR binding and complement binding. (D) Smaller antibody-based fragment formats are the Fab composed of light 
chain and VH and CH1 as well as the genetically linked scFv, e.g. by glycine serine peptide linker, consisting solely of the VH 
and the VL which are sufficient for antigen binding. The figure is adapted from Doerner et al. (Doerner et al, 2014) 
 
C-terminal regions of both chains are highly conserved and therefore named constant regions of the 
heavy chain (CH) as well as of the light chain (CL). For heavy chains, five different antibody constant 
domain classes or isotypes can be distinguished, namely IgM, IgD, IgG, IgA and IgE. Among those, IgG 
is the most abundant immunoglobulin isotype in serum (up to 10 mg/ml) and is further divided into 
four subclasses (IgG1-4). For the IgG subclasses, also genetic polymorphism based on allelic variations 
have been described (cf. IMGT database). Within the constant region of the heavy chains, globular 
domains can be recognized in the crystal structure, denoted as CH1, CH2 and CH3 (Figure 1). IgM and 
IgE contain an additional globular domain, named CH4. The constant subunit of a light chain consists 
of a single domain (CL) and can be discriminated by two different classes, denoted lambda (λ) and kappa 
(κ) with corresponding distinct gene loci. (Vidarsson et al., 2014) Beside the disulfide bonds in the hinge 
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region, heavy chains are connect via non-covalent interactions in the CH3 domains. The C-terminus of 
the light chain is again linked to the CH1 domain via a disulfide bond. The hinge and the upper CH2 
domain contain the overlapping epitopes for FcγR and complement binding (C1q). This region also 
displays the most difference among the Ig classes and even IgG subclasses resulting in different 
propensities to activate ADCC and CDC. Furthermore, the glycosylation pattern at the CH2-CH3 interface 
plays a pivotal role for the quaternary conformation of the FcγR epitope, in particular the conserved 
glycosylation site asparagine 297 (N297). The lack of core fucosylation of IgG-Fc for example increases 
binding to FcγRIIIa via glycan-glycan interactions translating into higher ADCC. (Ferrara et al, 2011; 
Shields et al, 2002) The FcRn binding site for antibody recycling and half-life elongation is also located 
in the CH2-CH3 domains of IgG. (Vidarsson et al., 2014) Since the variable regions of heavy and light 
chain are sufficient for antigen recognition, smaller antibody formats have been developed to enable 
better tissue penetration in comparison to the large whole antibody with 150 kDa. These antibody 
fragments are for example Fab or genetically fused VH-VL domains, denoted as single chain variable 
fragment or scFv (Figure 1D). However, due to small size (50 kDa for Fab and 25 kDa for scFv) and lack 
of the Fc moiety, antibody fragments display shorter plasma half-life and usually lower stability. 
(Nimmerjahn & Ravetch, 2010; Vidarsson et al., 2014) 
 
2.2. Antibody engineering 
Considering the highly diverse genetic repertoire of 1011 to 1012 different variants of the immune system 
in vivo, antibodies can be theoretically generated against every imaginable antigen. (Dübel, 2007) Due 
to their high target specificity, mAbs have become powerful and versatile tools for molecular biological 
methods as well as for diagnostic and therapeutic applications. Dependent on the usage, different 
antibody fragments, formats and even artificial scaffolds have therefore been engineered for optimizing 
binding molecule characteristics, e.g. ameliorated tissue penetration, improved pharmacokinetics and 
enhanced effector functions. The first approved therapeutic antibody was muromomab (Orthoclone 
OKT3) targeting CD3 on T-cells for suppressing the rejection of organ transplants in the year 1986. 
(Emmons & Hunsicker, 1987) Ten years later, the first anti-tumor antibody was approved, rituximab 
(Rituxan), targeting CD20 on B-cells for non-Hodgkin’s lymphoma. (Anderson et al, 1997) By the end of 
2014, 47 monoclonal antibody and antibody related products have been approved in the US and Europe 
for several clinical indications including cancer as well as inflammatory and infectious diseases and over 
300 were in clinical development. (Ecker et al, 2015) 
 
First approaches to generate antibodies against a specific target protein relied on the immunization of 
animals. However, not every target protein is suitable for immunization, in particular toxic agents, 
immune suppressive targets or proteins with high homology of human or mammalian species. Sera of 
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immunized animals contain a variety of different antibodies against the target protein used for 
immunization, denoted as polyclonal antibodies (pAb). In order to produce monoclonal antibodies 
(mAb), continuous culture of antibody secreting cells with desired specificity is required. For this, the 
hybridoma technology by Köhler and Milstein is used by fusion of isolated B cells from immunized 
animals with immortalized myeloma cells resulting in a hybrid cell called hybridoma. (Kohler & Milstein, 
1992) However, the cell hybridization process is tedious and inefficient. Moreover, the method also 
struggles with the instability of aneuploid cells. Another limitation of immunization and hybridoma 
technology is the non-human origin of the resulting antibodies leading to immunogenicity and eventually 
the development of anti-drug antibodies in patients, e.g. human anti-mouse antibodies (HAMA). 
(Khazaeli et al, 1994) One approach was the humanization of for example murine antibodies by 
transferring either the variable domains to human constant antibody domains (Gussow & Seemann, 
1991), resulting in chimeric antibodies, or by grafting the CDRs to human framework regions 
(Kettleborough et al, 1991), yielding in humanized antibodies.  Another strategy to tackle the 
immunogenicity issue was accomplished with the generation of knock-out mice and the subsequent 
development of transgenic rats or mice with genetic human antibody repertoires. (Jakobovits, 1995) 
Fully human antibodies can also be generated by the application of recombinant antibody technologies 
which will be elucidated in the next chapter (2.2.1) in more detail. By use of a naïve human library, for 
instance an anti-TNF-α antibody was isolated, denoted adalimumab (Humira) and approved in 2002. 
(Ecker et al., 2015) 
 
2.2.1. Display technologies 
For the in vitro selection of antibodies from naïve, synthetic or immune libraries, display technologies in 
combination with high-throughput screening technologies, e.g. fluorescence activated cell sorting 
(FACS) and liquid handling system, have been developed and applied. A key prerequisite within display 
technologies is the genotype-phenotype linkage in order to derive the genetic information of a selected 
binder. Display technologies can be divided into the following groups: phage, cell (prokaryotic and 
eukaryotic), ribosomal, mRNA, and DNA display. While the presentation of full length antibodies is 
mainly restricted to eukaryotic systems due to the need of the respective expression system, smaller 
antibody fragments, e.g. Fab and scFv, as well as single domain antibodies from other species such as 
single heavy chain variable domains from camelids (VHH) or sharks (vNARs), can be presented in every 
of the above mentioned display formats. (Doerner et al., 2014) 
 
Phage display was pioneered by Smith in 1985 using the fusion of the protein of interest, in case of 
antibody display a scFv or a Fab, to the pIII envelope protein of filamentous bacteriophage for screening 
of protein libraries. (McCafferty et al, 1990; Smith, 1985; Smith & Petrenko, 1997) The bacteriophage 
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strain M13 is a single stranded, circular DNA virus which is encompassed by a protein envelope mainly 
composed of the major coat protein pVIII. At one end of the rod-like bacteriophage, five copies of the 
minor coat protein pIII and pVI are displayed while pIII is involved in the infection of E. coli cells over 
the bacterial F-pilus. (Smith & Petrenko, 1997) After transcription and translation of phage proteins, 
phage particles are secreted into the periplasmatic room without inducing bacterial cell death. When 
using a phagemid system, E. coli cells are transformed with a “phagemid” encoding the antibody-
fragment-pIII fusion protein and an autonomous replication signal. For phage packaging, E. coli cells are 
subsequently infected with a replication deficient M13KO7 strain (called helperphage). The use of an 
amber stop codon thereby allows soluble production of antibody fragments without pIII protein in E. coli 
non suppressor strains, e.g. supE. This enables analysis of antibody fragments for antigen binding, e.g. 
by enzyme-linked immunosorbent assay (ELISA). The panning of antibody fragment libraries on phage 
is an iterative process composed of binding to immobilized antigen (e.g. microtiter plates or magnetic 
beads), removal of non-binding phages by washing, elution of bound, antigen-specific phages by addition 
of trypsin, and infection of E. coli by detached phages in combination with helperphage enabling phage 
amplification and packaging. The selection of binders with slow off-rates can thereby be increased, when 
applying stringent washing, reducing the antigen concentration or adding soluble antigen for 
competition. (Dübel, 2007) 
 
Noteworthy, cellular display systems, in particular in combination with FACS, are potent alternatives for 
robust and real-time adaptable selection of mAbs. Examples are the yeast surface display of antibody 
fragments and full IgGs by fusion to the yeast surface proteins Aga2p (Boder & Wittrup, 1997) or 
mammalian display technologies employing HEK293-T or CHO cells using the transmembrane domain 
of the human platelet-derived growth factor receptor for antibody presentation. (Ho & Pastan, 2009) 
Despite lower transformation rates in yeast and mammalian cells compared to phage display, the 
advantage of cellular display systems is the compatibility with the powerful technology of FACS for 
enriching binders with high affinities. (Boder & Wittrup, 1997) 
 
2.2.2. Affinity maturation 
Affinity maturation describes the process occurring in germinal centers of secondary lymphoid tissue 
yielding in antibodies with increased affinity and activity against pathogens in comparison to BCRs. This 
process involves somatic hypermutation of light and heavy chain variable genes in B-lymphocytes during 
antibody class switching mediated by enzymes, in particular activation-induced cytidine deaminase 
(AID). Martin and colleagues for example demonstrated that AID expression alone is sufficient to induce 
somatic hypermutation in B-cells. (Martin & Scharff, 2002) Naïve libraries, which have been built up of 
the highly diverse repertoire of IgM presenting B-lymphocytes, are consequently devoid of affinity 
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maturation with potentially comparably low affinities. Therefore, in vitro methods are required for 
affinity maturation for the introduction of random mutations. Since the 1990s, an engineering process 
denoted as “directed evolution” has been developed which mimics natural selection by inducing random 
mutations, e.g. by error-prone PCR (epPCR), in order to select for proteins with user-defined properties 
or functions. (Chen et al, 1991) In addition, several other strategies have been introduced for 
randomization: Using antibody chain shuffling (Kang et al, 1991), a new light or heavy chain is selected 
to a given antibody chain. Parsimonious mutagenesis describes the use of amino acids coding mixtures 
for a certain antibody residues which allows the reservation of the original coding amino acid to a certain 
percentage. (Balint & Larrick, 1993) DNA shuffling of antibody gene fragments and subsequent random 
assembly by PCR (Stemmer, 1994) or the use of E. coli mutator strains (Irving et al, 1996) has also been 
reported. Besides the application of random mutagenesis, also rational design by in silico engineering of 
antibody crystal structures can be a viable approach. (Barderas et al, 2008) 
 
2.2.3. Bispecific antibodies 
A bispecific antibody (bsAb) describes a molecule format enabling simultaneous and selective 
engagement of two antigens, either soluble or bound to the cell surface. Moreover, bsAbs can address 
two epitopes on the same molecule or epitopes of two – preferentially interacting – molecules displayed 
on the same cell surface or on two different cell surfaces of interacting cells, e.g. immune and cancer 
cells. There is also one case of bsAbs described in nature: Under redox conditions, disulfide bonds of 
IgG4 are randomly reduced resulting in two IgG4 half-molecules. This can give rise to the assembly of 
two half-molecules with different Fab arms to bispecific molecules which is also called Fab arm exchange. 
(van der Neut et al, 2007; van der Zee et al, 1986) This naturally occurring phenomenon is for example 
used in the “DuoBody” technology by introducing Fab arm exchange of IgG1 by introducing relevant 
mutations in the CH3 domain of IgG1. (Labrijn et al., 2011; Labrijn et al, 2013) In comparison to 
combination therapies, bsAbs offer several potential advantages such as: (a) improved efficacy due to 
extensive receptor crosslinking inducing internalization and degradation as well as synergistic effects in 
inhibiting receptor signaling via simultaneous targeting (Jarantow et al, 2015; Lee et al, 2016b), 
(b) increased tumor cell selectivity due to dual specificities (Mazor et al., 2015b), (e) effector cell 
recruitment, e.g. BiTEs (Wolf et al, 2005), and (f) lower cost during the development and approval 
process of a single molecule in comparison to the marketing of a combination of two single therapeutics 
(Holmes, 2011). As a consequence, both pharmaceutical industry and academic research gained high 
interest in developing strategies for the generation of bsAbs. Amgen for example spent 1.16 billion US 
dollar for the acquisition of Micromet which is the developer of the BiTE format. (Garber, 2014) 
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Figure 2: Technologies for correct heavy and light chain assembly in bispecific antibodies. 
(A) - (D) represent exemplary technologies for heavy chain heterodimerization, while (E) - (H) illustrate exemplary solutions 
for cognate heavy-light chain pairing. (A) Strand-exchange engineered domain (SEED) technology (Davis et al, 2010) in 
combination with scFv-technology for one binding arm (Muda et al, 2011). Alternating segments of IgG and IgA were 
engineered in two asymmetrical chains SEED-AG and SEED-GA favoring heterodimerization. The model structure of 
asymmetrical CH3 chain assembly was adapted from Davis and colleagues. (Davis et al., 2010) (B) For the knobs-into-holes 
technology (Ridgway et al, 1996; Spiess et al, 2015), bulky amino acid residues create a “knob” in one chain while mutations 
into smaller amino acids in the other chain built up a “hole”. Displayed is the structure of a one-armed knobs-into-holes 
monovalent antibody. (Merchant et al, 2013) (C) Oppositely charged amino acids in both chains induce electrostatic steering 
favoring heterodimerization while repulsive forces prevent homodimerization. (Gunasekaran et al, 2010) (D) Based on the 
natural process of Fab arm exchange of IgG4, corresponding mutations were introduced in the IgG1 format to allow controlled 
in vitro Fab arm exchange under mild reducing conditions. (Labrijn et al, 2011; Labrijn et al, 2013) (E) The use of common 
light chains in combination with engineering technologies for heavy chain heterodimerization, e.g. knobs-into-holes technology, 
can circumvent the light chain pairing problem. (Jackman et al, 2010) (F) Domain swapping of CH1 and CL in one Fab-antibody 
fragment arm can enforce cognate light to heavy chain assembly. (Schaefer et al, 2011b) (G) Fischer and colleagues introduced 
κλ-bodies composed of a common heavy chain in combination with one κ and one λ light chain allowing purification of bsAbs 
via three step affinity chromatography. (Fischer et al, 2015) (H) For the orthogonal Fab engineering, mutations were introduced 
at the Fab antibody fragment interface ensuring cognate light and heavy chain pairing. (Lewis et al, 2014) Heavy chain 
heterodimerization can be forced for example by electrostatic steering. (Gunasekaran et al., 2010) 
 
The first approaches for the generation of bsAbs were based on the hybridoma technology by Köhler and 
Milstein (1975) via fusion of two hybridoma cell lines leading to hyperploid cells, or quadroma. (Milstein 
& Cuello, 1983) However, co-expression of two different heavy and two different light chains results in 
sixteen theoretical different combinations for the antibody tetramer assembly based on stochastic 
calculations while only one combination consists of the desired chain pairing. Besides employing 
chemical coupling for the generation of bispecific antibodies with two different heavy chains (Brennan 
et al, 1985), a plethora of genetic approaches has evolved in the last years. (Kontermann & Brinkmann, 
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2015) In general, bsAb formats are classified into (a) lacking a Fc portion or (b) IgG-like. These can be 
further subdivided into symmetrical or asymmetrical. Heavy chain engineering for heterodimerization 
can reduce the combinatory probability of sixteen different antibody chain assemblies down to four. 
Consequently, the probability for the production of the desired bsAb accounts 25%. Elegant methods for 
heterodimerization are among others the herein used strand-exchange engineered domain (SEED) 
technology (Davis et al., 2010) (Figure 2A). Davis et al. recognized structural similarity of 
immunoglobulin classes G and A. In silico engineering of alternating IgG and IgA segments in the CH3 
domain yielded in two non-identical, antiparallel chains, designated as GA and AG chain. These two 
chains built up an asymmetric interface favoring heterodimerization whereas homodimerization is 
disfavored. (Davis et al., 2010) Further methods for heavy chain heterodimerization are the knobs-into-
holes technology (Ridgway et al, 1996; Spiess et al, 2015) introducing large amino acid residues in one 
chain while mutating to smaller residues in the other chain (Figure 2B), electrostatic steering by 
introduction of oppositely charged amino acids pairs (aspartate and lysine) on both chains (Gunasekaran 
et al., 2010) (Figure 2C), and the “DuoBody” platform based on the introduction of essential amino 
acids responsible for the IgG4 half-antibody exchange under mild reduced conditions into IgG1 (Labrijn 
et al., 2011; Labrijn et al, 2013) (Figure 2D).  
 
Cognate light and heavy chain interaction is another issue to address in order to increase the product 
homogeneity of bsAb. Correct light chain pairing can be achieved for example by the use of common 
light chains (Jackman et al., 2010) (Figure 2E) or the application of artificial linkers as in scFv (Muda 
et al., 2011) (Figure 2A). In case of common light chains, several companies developed transgenic 
rodents carrying the human antibody repertoire in combination with a common light chain (patent 
McWhirter et al. 2011, WO2011097603). Engineering approaches comprise the CrossMab technology 
(Schaefer et al., 2011b) (Figure 2F) in which CH1 and CL domains are swapped, the development of 
κλ-bodies with common heavy chains (Fischer et al., 2015) enabling a three step purification via κ or λ 
light chain specific affinity chromatography (Figure 2G) or the introducing of orthogonal Fab mutations 
via Fab interface engineering (Lewis et al., 2014) (Figure 2H). Nevertheless, the versatility of the 
common light or heavy chain approach is not available when aiming at combination of existing, e.g. 
already approved, binding moieties. Besides, Fab interface engineering and CrossMab technology cannot 
be applied as generic approach but might be associated with extensive engineering efforts for individual 
mAbs. Facing these issues, a modular toolbox approach was chosen for this study using SEED technology 
for heterodimerization and scFv technology for one binding arm to assure correct light chain pairing 
(Figure 2A). (Muda et al., 2011) Other mentionable engineering approaches for the generation of 
bispecific antibodies are the engineering of a binding site by randomization of loop structures (AB and 
EF loop) at the C-terminal end of the Fc-fragment denoted as Fcabs (Wozniak-Knopp et al, 2010) and 
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engineering of an additional binding specificity to the variable region of an anti-EGFR antibody yielding 
in “2in1 mAbs” with two specificities against EGFR and HER3, denoted as MEHD7945A (Schaefer et al, 
2011a). Another “2in1” approach is the DutaMab-technology (Dutalys/Roche) which is based on 
screening synthetic libraries employing two independent paratopes within the natural human CDRs (US 
patent Beckmann, US2014/0206846 A1). In recent years, two bsAbs emerged to the market: 
catumaxomab (Removab) directed against CD3 and EpCAM, which was approved 2009, and the 
bispecific T-cell engager (BiTE) blinatumomab (Blincyto) directed against CD3 and CD19, approved in 
2014/15. (Holmes, 2011; Kontermann & Brinkmann, 2015; Wolf et al., 2005; Zeidler et al, 1999) 
 
2.2.4. Antibody-drug conjugates (ADCs) 
Since Paul Ehrlich envisioned the concept of tumor-selective transport of toxins as a “magic bullet” in 
1913, it took eighty-seven years until the launching of the first antibody-drug conjugate (ADC) directed 
against CD33 (Mylotarg, gemtuzumab ozogamicin) to the market. However, due to multidrug resistance 
and lack of efficacy improvement in patients, it was later withdrawn. (Perez et al, 2014) Until today, 
two ADCs received approval: Adcetris (brentuximab vedotin) against CD20 and Kadcyla (trastuzumab 
emtansine) targeting HER2 in 2011 and 2013, respectively. (Perez et al., 2014) The growing interest in 
this class of next generation biotherapeutics is indicated by a robust clinical pipeline with over 40 ADCs 
for solid and hematological tumors. (Polakis, 2016) 
 
The concept of ADCs is to broaden the therapeutic window by increasing the maximum tolerated dose 
and decreasing the minimum effective dose (Figure 3A). This is achieved via selective delivery of the 
highly potent cytotoxic agent by the antibody moiety to antigen-expressing tumor cells and subsequent 
internalization and intracellular release of toxin. (Perez et al., 2014) The safety profile of an ADC is 
therefore dependent on the single building blocks: the antibody, the antibody conjugation site for the 
linker, the linker itself, and the cytotoxic agent (Figure 3B). The anti-tumor selectivity of the antibody 
is correlated with the expression pattern of the antigen characterized by high tumor expression and low 
normal tissue occurrence as well as of the affinity of the antibody. So-called cancer-associated targets 
with normal tissue expression, e.g. EGFR and c-MET (chapter 2.3), could therefore give rise to on-target 
off-tumor adverse events. Furthermore, target binding of the antibody should ideally induce 
internalization. (Ritchie et al, 2013) Thus, fast internalization rates are preferred which can be 
dependent on the epitope of the target protein, the epitope or target specific internalization mechanisms 
as well as the ability to induce target clustering and the antibody’s affinity. However, strategies have 
been developed for non-internalizing targets utilizing triggered drug release by click reaction. (Rossin et 
al, 2016) The antibody format can also affect the ADC’s efficacy: inherent effector functions of the Fc, 
e.g. ADCC, CDC and FcRn recycling, could be beneficial for efficacy and half-life of the ADC on the one 
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hand, but could also hinder intracellular delivery of the toxin or induce off-tumor toxicity due to cellular 
uptake mediated by FcRn and FcγR on lymphocytes or their progenitor cells on the other hand. 
(McDonagh et al, 2008; Perez et al., 2014) Intracellular toxin delivery of Kadcyla for example diminished 
megakaryocyte maturation via FcγRIIa. (Uppal et al, 2015) Silencing of FcRn binding could therefore 
result in a beneficial safety profile but also yield in lower pharmacokinetics. 
 
 
Figure 3: Definition of therapeutic window (A), antibody-toxin conjugation via sortase A (B), and structural formula of 
GGG-vc-MMAE (C). 
(A) Definition of therapeutic window in the ADC context. Cytotoxic agents alone (left side) have a small (or even negative) 
difference between maximum tolerated dose (MTD) and minimal effective dose (MED). By selective delivery of the toxin 
mediated by the antibody, the therapeutic window between MTD and MED is theoretically increased. The figure was adapted 
from Panowksi et al.. (Panowski et al, 2014) (B) Schematic representation for the sortase A mediated conjugation of cytotoxic 
agents including three N-terminal glycines to the C-terminus of both antibody heavy chains containing of the sortase recognition 
sequence LPXTG, while X is an arbitrary amino acid. (C) Structural formula of the toxin conjugate triple glycine-valine-citrulline-
monomethyl auristatin E (GGG-vc-MMAE). The triple glycine is highlighted in green, valine-citrulline in blue and monomethyl 
auristatin E in red. The three building blocks are connected via spacer. 
 
Regarding linkers, cleavable and non-cleavable are distinguished. Ideally, linkers should have two 
functionalizations for efficient antibody and toxin conjugation on either side. Moreover, high stability in 
the blood circulation and fast intracellular toxin release are desired in order to ensure high efficacy and 
low toxicity in normal tissue. The most common linkers are protease cleavable, e.g. valine-citrulline 
(Figure 3C) for cleavage by lysosomal protease cathepsin B used in Adcetris. (Perez et al., 2014; Ritchie 
et al., 2013) Acid sensitive linkers, e.g. hydrazones, depend on acidification within the endosome, but 
suffer from instability, lower half-life and related unspecific toxicities. (Perez et al., 2014) Non-cleavable 
linkers in contrast display high stability in serum, but are only slowly released in the process of antibody 
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degradation. (Perez et al., 2014) For the last building block, the toxin, microtubule inhibitors and DNA 
alkylating agents can be discriminated. The first adds a second layer of selectivity since only fast dividing 
cells are targeted. Common tubulin inhibitors are auristatins, e.g. monomethyl auristatin E (MMAE) 
(Figure 3C), which are based on dolastatin 10, and maytansinoids. (Banerjee et al, 2008) DNA alkylators 
often bind within the minor groove of the DNA. Duocarmycin analogs for example alkylate adenine-N3. 
(Lin & Patel, 1995) Since only a small fraction of the ADC (1-2%) is proposed to be internalized in the 
tumor, high potencies of the payload are needed. Moreover, toxin efflux by ABC-transporters conferring 
to multidrug resistance, e.g. P-glycoprotein, need to be taken into consideration. (Perez et al., 2014) 
 
The selectivity and the homogeneity of the ADC product depend on the conjugation method. Since 
cysteine or lysine conjugation with maleimides or N-hydroxysuccinimide ester occur randomly, the 
stoichiometry of drug molecules per antibody moiety, denoted as drug-to-antibody ratio (DAR), and the 
conjugation sites have a wide and heterogeneous distribution. The DAR as well as the site of conjugation 
in turn can influence the biophysics of the antibody, e.g. hydrophobicity and solubility, as well as the 
efficacy due to varying payload. Enzyme mediated conjugation or introduction and reaction with 
unnatural amino acids in contrast are both site-specific methods and result in a clearly defined, 
homogenous DAR with defined conjugation sites. While bacterial transglutaminase catalyzes the ligation 
of glutamine side chains with lysine residues, sortase A mediates the hydrolysis of the threonine-glycine 
bond in the LPXTG motif (Figure 3B) followed by formation of a peptide bond between threonine and 
a glycine motif, e.g. triple glycine. (Perez et al., 2014) 
 
2.3. Cancer associated antigens as therapeutic targets 
Due to the multifactorial nature of cancer, redundant receptor signaling, and the development of cancer 
resistance, monotherapies for a specific cancer target often struggle with poor efficacy. Consequently, 
there is the need for combinatory treatment approaches. However, many existing therapies face mild to 
severe adverse events as a result of basal target antigen expression in normal tissue which could be 
multiplied by the combination of two or more therapeutic agents. One protein family, which has been 
extensively studied as cancer targets, is the receptor tyrosine kinase (RTK) superfamily. Their 
involvement in the development and progression of tumors has been elucidated more than 30 years ago. 
(Downward et al, 1984) RTKs are membrane receptors which usually become activated by binding of 
growth factors and subsequent phosphorylation of tyrosine residues within the intracellular kinase 
domain. Endogenous functions comprise the regulation of many essential cellular processes in 
development, normal cell function, intercellular communication, and tissue homeostasis. (Downward et 
al., 1984) Deregulation of ligand secretion, receptor expression as well as receptor activation and 
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mutational status, which are all tightly controlled in normal cells, can lead to unconstrained cellular 
growth. 
 
2.3.1. The epidermal growth factor receptor (EGFR) 
The epidermal growth factor receptor (EGFR, also known as: ErbB1, HER1) is part of the ErbB family of 
RTKs consisting of EGFR, ErbB2, ErbB3, and ErbB4 as well as c-MET among various membrane receptors. 
Several molecules have been identified as ligands: epidermal growth factor (EGF), transforming growth 
factor-α, amphiregulin, epigen, epiregulin, β-cellulin, and heparin bound-EGF. (Yarden & Sliwkowski, 
2001) EGFR is expressed in cells of epithelial, mesenchymal as well as neuronal origin and is involved 
in cell-cell interactions in embryogenesis and adult tissue. Around 1980, EGFR signaling has been 
implicated with cell transformation and cancer, e.g. an aberrant from of EGFR, v-erbB, had been 
identified as an oncogene of avian erythroblastosis tumor virus. (Downward et al., 1984) EGFR is a 
heavily N-glycosylated, 170 kDa protein consisting of a large extracellular domain (ECD) composed of 
four subdomains, a single transmembrane spanning domain, and an intracellular catalytic kinase domain 
(Figure 4). Ligand binding to domain III and I induces dramatic conformational changes from a tethered 
to an extended conformation of the ECD. Domain rearrangement thereby exposes a receptor 
dimerization interface on domain II and subsequent interaction of intracellular domains leads to 
transphosphorylation of tyrosine residues within the kinase domain (Figure 4). EGFR does not 
exclusively forms homodimers, but also heterodimerizes with various other receptors. Interestingly, the 
distinct phosphorylation pattern of tyrosine residues is dependent on the ligand. (Yewale et al, 2013)  
The phosphorylation sites within the kinase domain serve as docking sites for adaptor proteins, e.g. Gab1 
and Grb2, containing Src homology domains or phospho-tyrosine binding domains. This in turn induces 
the activation of signaling pathways, including mitogen-activated protein kinase pathway (MAPK) and 
phosphaidylinositol-3-OH kinase (PI3K)-AKT-mTOR pathway, STAT3/5, PLCγ-PKC, regulating 
proliferation, cell survival, DNA synthesis, and migration (Figure 4). (Ferguson et al, 2003; Yarden & 
Sliwkowski, 2001; Yewale et al., 2013) 
 
Deregulation of EGFR signaling via constitutive activation by genetic mutations, overexpression and/or 
gene amplification, as well as ligand upregulation can lead to uncontrolled tumor growth and metastasis. 
Additionally, increased EGFR expression has been correlated with poor prognosis. (Nicholson et al, 
2001) Consequently, EGFR has emerged to a highly evaluated anti-cancer target by small molecule 
tyrosine kinase inhibitors (e.g. gefitinib and erlotinib) as well as antibody entities. (Yewale et al., 2013) 
The first anti-EGFR antibody approved was the human-murine chimeric IgG1 cetuximab for colorectal 
cancer and squamous cell carcinoma of the head and neck. (Li et al, 2005) It binds to domain III of the 
EGFR ECD and competes for EGF binding by steric hindrance. (Li et al, 2005)  
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Figure 4: Redundant signaling of c-MET and EGFR. 
Schematic representation of c-MET and EGFR dimerization induced by HGF and EGF binding, respectively. Crystal structures 
were derived from PDB (1shy for c-MET SEMA and PSI domain with HGF-β and 1nql for EGFR ECD in truncated conformation) 
or were adapted from Niemann et al., Birchmeier et al. and Ferguson et al.. (Birchmeier et al, 2003; Ferguson et al., 2003; 
Niemann, 2013) c-MET is processed from a single precursor protein by furin cleavage resulting in a disulfide linked α-chain-β-
chain heterodimer. The cleavage site is located within the seven bladed β-propeller domain, called SEMA. The PSI domain is 
located, adjacently to the SEMA domain, standing for the homology to plexins, semaphorins, and integrins. This is followed by 
four immunoglobulin, plexins and transcription factor like domains (IPT 1-4), a single-spanning transmembrane domain as 
wells as an intracellular tyrosine-kinase domain. The only known ligand is HGF (hepatocyte growth factor or scatter factor) 
which is also a disulfide linked α-chain-β-chain heterodimer. Binding of HGF to c-MET induces receptor dimerization in a 
ligand:receptor 2:2 complex, transphosphorylation of tyrosine residues within the kinase domain, and recruitment of 
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intracellular signaling adaptor proteins, e.g. Gab1, Grb2 and Shp2. This is followed by activation of the PI3K-AKT-mTOR 
pathway stimulating cell survival as well as the Ras-Raf-MAPK/ERK signaling cascade inducing proliferation, cell-cycle 
progression, alterations of cell junctions, migration and invasion. PLCγ-PKC are also activated as well as STAT3/5 triggering 
proliferation and survival, respectively. 
The epidermal growth factor receptor is composed of four extracellular domains (I-IV). Binding of EGF to domain I and III 
induces domain rearrangements from a tethered to an elongated conformation exposing receptor dimerization sites in domain 
II and IV. Receptor dimerization leads to transphosphorylation of tyrosine residues within the intracellular kinase domain 
activating AKT, MAPK, PLCγ, and STAT3/5 signaling. (Ferguson et al., 2003; Yarden & Sliwkowski, 2001; Yewale et al., 2013) 
ECD = extracellular domain, ERK= extracellular signal-regulated kinase, MAPK = mitogen-activated protein kinase, PI3K = 
phosphatidylinositol-3-OH kinase, PKC = protein kinase C, PLCγ = phospholipase Cγ, Ras = rat sarcoma, Raf = rat 
fibrosarcoma, STAT = Signal transducer and activators of transcription 
 
Therefore, cetuximab functions via the inhibition of EGFR phosphorylation and downstream signaling, 
receptor internalization (Mendelsohn & Baselga, 2003) as well as the initiation of ADCC (Kimura et al, 
2007). However, good anti-tumor response mediated by cetuximab correlates with severe adverse events 
due to basal expression of EGFR in normal tissue, in particular the skin. (Lacouture, 2006) Acne-form 
skin rash, e.g. papulopustular rash, dry and itchy skin, is a characteristic adverse event during EGFR 
blockade by both small molecules and antibodies mediating growth arrest and the stimulation of 
inflammation. (Cunningham et al, 2004; Lacouture, 2006; Melosky et al, 2009) In particular, 
proliferating keratinocytes in the basal layer of the epidermis are predominantly affected due to high 
EGFR expression levels. (Lacouture, 2006) Until today, there are two other mAbs approved for anti-
EGFR targeted therapy: panitumumab and nimotuzumab. Panitumumab (ABX-EGF, Vectibix), approved 
for colorectal cancer, is a fully human IgG2 antibody which was isolated by immunization of transgenic 
mice carrying human antibody repertoire (“XenoMouse”) with A431 cells. (Giusti et al, 2007; Yang et al, 
2001) Due to the IgG2 isotype, panitumumab is deficient of effector functions and its mode of action 
can be described by ligand blockade as well as the induction of internalization. (Giusti et al., 2007) 
Similar to cetuximab, the epitope of panitumumab is located on domain III of EGFR and both antibody 
epitopes partially overlap with the EGF binding site. (Voigt et al, 2012) Nimotuzumab (h-R3, Theraloc) 
is a humanized IgG1 derived by mouse immunization and subsequent CDR grafting. It was approved for 
squamous cell carcinoma of head and neck, nasopharyngeal cancer and glioma. (Ramakrishnan et al, 
2009) Interestingly, also nimotuzumab binds to EGFR domain III. (Tundidor et al, 2014) In course of 
this work, another humanized anti-EGFR antibody was used again targeting the domain III of EGFR, 
called matuzumab (425, EMD720000). (Murthy et al, 1987) In contrast to cetuximab, matuzumab’s 
inhibition of EGFR signaling is ligand-independent and it acts via sterically blocking the conformation 
domain rearrangement required for the receptor dimerization process. (Schmiedel et al, 2008) 
 
2.3.2. The hepatocyte growth factor receptor (c-MET) 
The hepatocyte growth factor receptor (HGFR), also known as c-MET (for mesenchymal-epithelial 
transition), is a type I transmembrane protein RTK which was first identified as oncogenic TPR-MET 
(translocated promoter region fused to c-MET) fusion protein in chemically transformed human 
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osteosarcoma cells. (Cooper et al, 1984) Expression of c-MET and secretion of its ligand, hepatocyte 
growth factor (HGF, or scatter factor, SF), by mesenchymal cells are involved in cell differentiation, 
proliferation, survival, cytoskeleton rearrangement, cell detachment, scattering, motility and 
invasiveness. (Birchmeier et al., 2003) The proteoglycan decorin has been also described as a ligand for 
c-MET. (Goldoni et al, 2009) On a macro-cellular level, c-MET plays a role in embryogenesis, wound 
healing and organ regeneration. (Birchmeier et al., 2003) Tumorigenesis is characterized by 
morphological changes of cancer cells from epithelial to mesenchymal features enabling metastatic cell 
spreading. In general, higher c-MET expression can be found on metastatic lesions compared to primary 
tumor highlighting the involvement in metastasis. (Cipriani et al, 2009) c-MET is a disulfide linked α-
chain-β-chain heterodimer proteolytically cleaved from a single precursor protein. It is composed of a 
large extracellular domain composed of a seven-bladed propeller domain called SEMA, a PSI domain 
related to plexins, semaphorins and integrins as well as four IPT domain repeats displaying homology to 
immunoglobulins, plexins and transcription factors (Figure 4). The furin cleavage site between α- and 
β-chain is located between blade 4 and 5. The single spanning transmembrane domain is followed by an 
intracellular tyrosine kinase domain. Ligand binding to the receptor induces its dimerization and 
autophosphorylation of tyrosine residues 1003, 1234 and 1235 leading to transphosphorylation of 
tyrosines 1349 and 1356 building up docking sites for Src homology 2 proteins (SH2). (Birchmeier et 
al., 2003) This in turn activates intracellular signaling cascades including PI3K/AKT and Ras/MAPK 
pathways (Figure 4). The exact dimerization and receptor activation mechanism has still to be 
elucidated. HGF is a disulfide linked α-chain-β-chain heterodimer which is also processed from a single 
precursor protein. (Lokker et al, 1992) The HGF α-chain is composed of a N-terminal domain followed 
by four kringle domains, while the HGF β-chain consists only of one serine proteinase homology domain 
(SPH). (Lokker et al, 1992) It binds the proteoglycan heparin and forms HGF-homodimers in solution. 
(Birchmeier et al., 2003) It was proposed that the ligand potentially induces dimerization of a 2:2 c-
MET:HGF complex. (Niemann, 2013; Stamos et al, 2004) There are two proposed binding sites for HGF 
on c-MET: the HGF β-chain binds with low affinity to blades two and three of the SEMA domain. 
(Gherardi et al, 2003; Stamos et al., 2004) The location of the high affinity binding site for the HGF α-
chain is more controversially discussed: One group has described binding to IPT domains 3 and 4 by the 
shortened, N-terminal HGF fragment, called NK1. (Basilico et al, 2008) However, others suggest binding 
of NK1 to SEMA domain blade 5. (Niemann, 2013; Youles et al, 2008)  
 
Due to the involvement of c-MET in tumorigenesis and metastasis, several HGF and c-MET directed 
antibodies have been developed recently and in parts have been evaluated in clinical trials. (Prat et al, 
2014) HGF-neutralizing antibodies, e.g. rilotumumab and ficlatuzumab, only target the ligand and are 
therefore inefficient in cancer with constitutive c-MET activation. (Prat et al., 2014) Furthermore, HGF 
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is stored in high abundance as an unprocessed precursor protein in the extracellular matrix of tissue 
hampering the efficiency of anti-HGF antibodies. (Prat et al., 2014) Regarding c-MET, antibodies have 
been developed against several epitopes of the receptor: Onartuzumab (oa 5D5, MetMAb, RO5490258) 
and emibetuzumab (LY2875358) are the most advanced in clinical development with phase III and II 
trails, respectively. Even though the binding epitope of both antibodies is located within the c-MET SEMA 
domain, the monovalent onartuzumab predominantly acts via HGF-competition (Merchant et al, 2013) 
whereas the bivalent emibetuzumab induces receptor degradation besides the blockade of ligand binding 
(Liu et al, 2014). Three more anti-c-MET antibodies are currently evaluated in clinical phase I: the 
bivalent ABT-700 (h224G11) (Goetsch et al, 2010), the ADDC-enhanced ARGX-111 (WT52-E) (Basilico 
et al, 2014; Hultberg et al, 2015), and the bivalent c-MET degrading antibody SAIT301 (Oh et al, 2012). 
While ARGX-111 and emibetuzumab occupy an overlapping epitope, the exact binding site of SAIT301 
is unknown. The latter induces c-MET degradation via LRIG1 (LRR and immunoglobulin-like domain-
containing protein 1)-mediated lysosomal pathway. (Lee et al, 2014) This is presumably the same mode 
of action as described for another anti-c-MET antibody, LMH 87, binding to the top of the SEMA propeller 
on blade 3 and 4. (Greenall et al, 2012; Prat et al., 2014) However, SAIT301 and LMH 87 do not display 
an overlapping epitope. (Lee et al., 2014) Another c-MET degrading antibody is DN30 which binds to 
the forth IPT domain, induces degradation via the metalloprotease ADAM-10 and does not compete with 
ligand binding. (Vigna et al, 2015) Some anti-c-MET binders are prone to trigger partial or full agonism 
in the bivalent format (Liu et al., 2014; Merchant et al., 2013; Oh et al., 2012; Pacchiana et al, 2010) 
requiring monovalency in parts for therapeutic application. Adverse events of the c-MET targeting 
antibody, e.g. onartuzumab, are mainly edema and thrombotic events being associated with the blockade 
of the c-MET/HGF axis regulating epithelial integrity and wound healing. (Morley et al, 2015) 
 
2.3.3. Interplay of c-MET and EGFR 
As described in the two former chapters, c-MET and EGFR display redundant signaling pathways, 
including GAB1 mediated activation of Ras-Raf-MAPK and PI3K-AKT pathways as well as induction of 
PLCγ-PKC and STAT3/5 signaling cascade (Figure 4). (Birchmeier et al., 2003; Guo et al., 2008; Yewale 
et al., 2013) Due to pathway redundancies, one receptor is able to compensate for the loss of the other 
one upon single targeted inhibition. Furthermore, EGFR and c-MET also display interaction confirmed 
by co-immunoprecipitation and c-MET can also be trans-activated by the EGFR ligand TGFα. (Jo et al., 
2000) Beside signaling redundancies, upregulation and/or amplification of HGF and c-MET are critically 
involved in the development of acquired resistance in response to EGFR inhibition. Engelman and co-
workers elucidated that c-MET amplification contributes to gefitinib resistance in NSCLC cells via 
activation of ErbB3 signaling. (Engelman et al., 2007) In parts, c-MET amplification occurs in 
combination with the EGFR activating, drug-sensitive mutation T790M in lung cancer samples. (Bean et 
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al, 2007) HGF-secreting stromal fibroblasts in co-culture with lung cancer cells can induce insensitivity 
to EGFR inhibitors (Wang et al, 2009) and elevated HGF levels in the tumor micro-environment also 
contribute to innate resistance to Raf inhibitors via the activation of c-MET and subsequent MAPK as 
well as PI3K-AKT signaling (Straussman et al, 2012). In colorectal cancer, HGF and c-MET mediate 
intrinsic and acquired resistance in response to cetuximab. (Kammula et al, 2007; Liska et al, 2011) 
Beside c-MET activation, mutational status of KRAS (Kirsten rat sarcoma) negatively contributes to 
responsiveness to cetuximab treatment in colorectal cancer. (Knickelbein & Zhang, 2015) Due to 
redundant signaling and implication in resistance mechanisms, c-MET and EGFR inhibitors are currently 
under extensive preclinical and clinical development for both mono- and combination therapies as 
summarized in Prat et al., Sharma and Adjei as well as Yewale et al.. (Prat et al., 2014; Sharma & Adjei, 
2011; Yewale et al., 2013) 
 
2.3.4. Bispecific antibodies directed against c-MET and EGFR 
In the last three years, several bispecific antibodies targeting c-MET and EGFR have been developed 
which demonstrated synergistic effects in tumor proliferation and metastasis. (Castoldi et al, 2012; 
Castoldi et al, 2013; Garber, 2014; Jarantow et al., 2015; Lee et al, 2016a; Lee et al., 2016b; Lewis et al., 
2014; Spiess et al, 2013) In 2012, Castoldi and co-workers first described trispecific antibodies (TriMAbs, 
Roche) directed against c-MET, EGFR and IGF1R with a binder stoichiometry of 1:1:1 (Castoldi et al., 
2012) followed by a bispecific c-MET x EGFR, denoted as MetHer1 (Castoldi et al., 2013). The latter was 
composed of a cetuximab IgG with knob-into-holes technology with a C-terminally genetically fused 
single chain Fab of onartuzumab to the knob-chain. The resulting molecule expressed in mammalian 
cells demonstrated an additive effect on the inhibition of proliferation in comparison to the treatment 
with the respective monospecific agents. In the same year, Genentech developed a knob-into-hole bsAb 
consisting of the bacterial expressed half antibodies anti-EGFR (D1.5) and onartuzumab. (Spiess et al., 
2013) Due to bacterial expression, this antibody lacked glycosylation and is therefore devoid of effector 
functions. Lewis et al. mentioned the generation of a bsAb targeting c-MET and EGFR by employing Fab 
interface engineering in order to ensure cognate light chain pairing. (Lewis et al., 2014) However, the 
bsAb currently in clinical phase 1, LY3164530 (Eli Lilly), (Garber, 2014; Spiess et al., 2015), presumably 
has a 2:2 stoichiometry. JNJ-61186372 (Janssen/Genmab) also recently moved to the clinic employing 
controlled Fab-arm exchange with a 1:1 stoichiometry. (Jarantow et al., 2015; Labrijn et al., 2011; Zheng 
et al, 2016) Interestingly, synergistic effects could be detected for the lower expressed target. (Jarantow 
et al., 2015) By Samsung, Lee and colleagues introduced ME22S which induces internalization and 
degradation of c-MET and EGFR. (Lee et al., 2016a; Lee et al., 2016b) The underlying molecule is based 
on a 2:2 stoichiometry and the c-MET degrading antibody SAIT301. (Oh et al., 2012) In summary, bsAbs 
with different binder stoichiometry have been developed. Stoichiometry and epitope combinations 
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thereby potentially influence agonistic behavior via receptor interaction and functionality via ligand 
competition or the induction of receptor degradation. However, tumor-selectivity has not been addressed 
for targeting c-MET and EGFR in a bispecific molecule. 
 
2.4. Aim of this study 
The presented work aims to evaluate the effects of bispecific targeting of two prominent tumor-
associated antigens, namely c-MET and EGFR, and the application of affinity-optimized binders in order 
to balance high anti-tumor efficacy and reduced on-target off-tumor toxicities in normal tissue with basal 
expression of respective antigens (Figure 5). When increased tumor selectivity could be achieved by this 
engineering approach, the generated bsAbs could be armed with a cytotoxic agent for evaluation in an 
ADC context. Thus, anti-c-MET and anti-EGFR binders were selected based on their functionality, 
targeting of different epitopes, and distinct kinetic variants obtained by either in vitro affinity maturation 
or in silico screening. By combination of binders in the bispecific format in a modular toolbox approach 
employing SEED- and scFv-technology as well as transient transfection in mammalian cells, the 
appropriate affinity to retain biological function while enhancing the tumor selectivity by avidity effect 
should be determined. Finally, the efficacy of bsAbs could be evaluated in an ADC approach in c-MET 
and EGFR overexpressing cell lines in comparison to toxicity in normal tissue models, including primary 
keratinocytes and hepatocytes. This could lead to an in vitro proof of concept for enhancing the 
therapeutic window by application of affinity-optimized bispecific ADCs. 
 
Figure 5: Strategy for bispecific anti-c-MET and anti-EGFR mAb and ADC generation. 
By the combination of affinity attenuated anti-EGFR binders with anti-c-MET binders in the bispecific format in a ratio of 1:1, 
increased anti-tumor selectivity was aimed while retaining the efficacy for inhibiting c-MET and EGFR signaling. Receptor cross-
linking by bsAbs could also lead to synergistic effects: improved efficacy due to simultaneous inhibition of both signaling 
pathways, increased internalization and concurrent degradation, and reduced inhibition of basally expressed EGFR in normal 
tissue cells which leads to attenuated EGFR-related adverse events and therefore improved tumor selectivity. Due to higher 
tumor selectivity, conjugation with cytotoxic agents could be considered for broadening the therapeutic window. 
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3. Material 
 
3.1. Bacterial strains, bacteriophages, and human cell lines 
Bacterial strains 
E. coli One Shot TOP10 chemically competent cells (#C4040-10, Life Technologies, Karlsruhe, 
Germany); Genotype: F- mcrA Δ (mrr-hsdRMS-mcrBC) φ 80lacZΔ M15 Δ lacX74 recA1 araD139 Δ 
(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG 
 
E. coli XL1 blue MRF’ electrocompetent cells (#200158, Agilent Technologies, Waldbronn, Germany) 
E. coli XL1 blue MRF’ chemically supercompetent cells (#200230, Agilent Technologies, Waldbronn, 
Germany); Genotype: (mcrA)183 (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac [F’ proAB lacIqZM15 Tn10 (Tetr)] 
 
Bacteriophages 
Helper phage M13K07 (‘N0315S, New England BioLabs, Ipswich, MA, USA) 
 
Mammalian cell lines 
All mammalian cell lines were cultivated at 37°C, 10% CO2. Cells were obtained from the American Type 
Culture Collection (ATCC®, Manassas, VA, USA), the Japanese Collection of Research Bioresources Cell 
Bank (JRCB), Riken Bioresource Center Cell Bank (RCB, Tsukuba, Japan), the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany), or companies as summarized in 
the following table (s. Table 1). 
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Table 1: List of mammalian cell lines. 
Cell type and cell origin are listed for each cell line. 
 
Cell line Cell type Origin 
A431 human epidermoid carcinoma ATCC® CRL 1555TM 
A549 human lung carcinoma ATCC® CCL 185TM 
CHO-S Chinese hamster ovary Life Technologies, Darmstadt, 
Germany (R80007) 
EBC-1 human lung carcinoma JCRB0920 031496 
Expi293FTM human embryonic kidney Life Technologies, Darmstadt, 
Germany (A14527) 
HCC-827 human lung adenocarcinoma ATCC® CRL-2868TM 
HepG2 human hepatocellular 
carcinoma 
Lipha / Merck, Darmstadt, Germany 
KP-4 human pancreatic ductal cell 
carcinoma 
RCB1005 
MDA-MB-468 human breast adenocarcinoma 
(mammary gland) 
ATCC® HTB 132TM 
MKN45 human gastric adenocarcinoma DSMZ ACC 409 
NCI-H1975 human NSCLC 
adenocarcinoma,  
ATCC® CRL-5908TM 
NCI-H441 human lung adenocarcinoma ATCC® HTB-174TM 
NCI-H596 human lung adenosquamous 
carcinoma 
ATCC® HTB-178TM 
NHEK.f-c. normal human primary 
keratinocytes 
PromoCell, Heidelberg, Germany 
Recombinant Jurkat cells effector cells for ADCC assay Promega, Mannheim, Germany 
(G701A) 
SK-MEL2 human metastatic sit on skin of 
thigh 
ATCC® HTB-68TM 
T47D human metastatic site of 
mammary gland (pleural 
effusion) 
ATCC® HTB-133TM 
U87MG Human glioblastoma, 
astrocytoma 
ATCC® HTB-14TM 
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3.2. Plasmids 
In the following Figure 6 depicts the composition of the used plasmids. 
 
Figure 6: Schematic structure of plasmids. 
(A) The pDF phagemid (kindly provided by Merck, Darmstadt, Germany) contains VL-CL and VH-CH1 sequences upstream 
flanked by pelB leader sequences under control of the lacZ promoter. pelB is thereby the signal sequence of the pectatlyase 
from Erwinia caratovora. (Lei et al, 1987) Downstream of the CH1 sequences, a myc- and His-tag are located followed by an 
amber stop codon and the gene for the pIII phage surface protein (gIII) and a terminator sequence. When using a supE strain 
with the amber stop codon, the fusion protein of Fab and pIII is expressed. The plasmid contains the ampicillin antibiotic 
resistance gene (Amp, β-lactamase) as selection marker for bacterial cells carrying the phagemid, Col E1 origin for bacterial 
replication of the phagemid, and a f1 phage origin for the synthesis of single-stranded DNA. (B)-(D) The pTT5 vector (National 
Research Council Canada) is a mammalian expression vector containing the following elements: The EBV oriP is the origin of 
replication in mammalian cells, again the ampicillin resistance gene (Amp, β-lactamase), the pMB1 ori as bacterial origin of 
replication, the pCMV stands for the cytomegalovirus immediate early promoter, AV TPL codes for the adenovirus tripartite 
leader, an synthetic intron including an enhancer element from the adeonivurs major late promoter enhancing protein 
expression (enh MLP). Downstream of the antibody sequences, the rabbit β-globin polyadenylation signal (pA) is located. 
(Zhang et al, 2009) The three vector encode the antibody light chain (VL-CL) (B), the antibody heavy chain (VH-CH1-hinge-
CH2-CH3) including SEED-AG sequences in the CH3 domain (C), and a scFv fused to the hinge-CH2-CH3 domains (D) while 
the CH3 includes the SEED-GA sequences. The vector maps were created with SnapGene Viewer ver. 2.6.2. 
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3.3. Enzymes and proteins 
Antarctic phosphatase, calf intestinal (CIP) New England Biolabs, Beverly, USA 
Benzonase Novagen, Nottingham, GB 
Bovine serum albumin (BSA), fraction V  Merck, Darmstadt, Germany 
BSA standard solution (2 mg/ml) Thermo Scientific, Schwerte, Germany 
Gibco® Trypsin-EDTA Life Technologies, Darmstadt, Germany 
Lysozyme Roche, Mannheim, Germany 
Phosphatase inhibitor set II (#P524625) Merck, Darmstadt, Germany (Calbiochem) 
Phusion DNA polymerase New England BioLabs, Ipswich, MA, USA 
Protease inhibitor set III (#P524525) Merck, Darmstadt, Germany (Calbiochem) 
Recombinant human c-MET ECD-strepII-His Merck, Darmstadt, Germany 
Recombinant human c-MET SEMA-PSI-FLAG-
His 
Merck, Darmstadt, Germany 
Recombinant human EGF (236-EG/CF) R&D Systems, Minneapolis, MN, USA 
Recombinant human EGFR (1-618)-His Merck, Darmstadt, Germany 
Recombinant human HGF (294-HGN/CF) R&D Systems, Minneapolis, MN, USA 
Recombinant sortase A Merck, Darmstadt, Germany 
T4 DNA ligase New England BioLabs, Ipswich, MA, USA 
Trypsin Sigma Aldrich, Steinheim, Germany 
 
3.3.1. Antibodies 
Reference antibodies 
cetuximab (Erbitux®, C225) Merck, Darmstadt, Germany 
matuzumab (C425) Merck, Darmstadt, Germany 
oa 5D5v2 g1 hinge IgG1 Fc (Knobs-into-holes) Merck, Darmstadt, Germany 
LY2875358 (LA480_vC8H241 IgG1) Merck, Darmstadt, Germany 
hu224G11 IgG1 Merck, Darmstadt, Germany 
DN30 IgG1 Merck, Darmstadt, Germany 
oa anti-hen egg lysozyme (HEL) SEED  Merck, Darmstadt, Germany 
 
Anti-c-MET reference antibodies, including humanized oa 5D5 (MetMAb, onartuzumab), LY2875358 
(LA480_vC8H241, emibetuzumab), hu224G11 (ABT-700), and DN30 IgG were reproduced based on VH 
and VL sequences derived from publicly available information (Patents no. US 6,214,344B1 (2001), US 
8,398,974B2 (2013), US 8,329,173B2 (2012), EP 2500036B1 (2011)). (Liu et al., 2014; Merchant et al., 
2013). Sequences were cloned in mammalian expression vectors (pTT5) containing constant IgG1 light 
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and heavy chain fragments except oa 5D5 applying knob-into-hole technology. (Ridgway et al., 1996) All 
reference antibodies were produced in HEK293E cells using standard transfection and purification 
procedure (cf. chapters 4.4.1, 4.3.3 and 4.3.4) and were kindly provided by Merck, Darmstadt, Germany. 
Hence, the evaluated anti-c-MET reference antibodies were not derived from the respective laboratories 
of the original publications. 
 
Primary antibodies for Western Blot 
Rabbit anti-actin (20-30) pAb (A5060) Sigma-Aldrich, Steinheim, Germany 
Mouse anti-pIII antibody MoBiTec, Göttingen, Germany 
Rabbit anti-c-MET pAb (M3007-13A) Biomol, Hamburg, Germany 
Rabbit anti-cofilin mAb, clone D3F9 (#5175) Cell Signaling Technologies, Cambridge GB 
Rabbit anti-EGFR mAb, clone D38B1 Cell Signaling Technologies, Cambridge GB 
Rabbit anti-GAPDH mAb, clone 14C10 
(#2118) 
Cell Signaling Technologies, Cambridge GB 
Rabbit anti-p44/42 MAPK (Erk1/2) mAb, 
clone 137F5(#9101) 
Cell Signaling Technologies, Cambridge GB 
Rabbit anti-phospho p44/42 MAPK (Erk1/2) 
(T202/Y204) XP® mAb, clone D13.14.4E 
(#4370) 
Cell Signaling Technologies, Cambridge GB 
Rabbit anti-phospho-Akt (S473) mAb, clone 
D9E (#4060) 
Cell Signaling Technologies, Cambridge GB 
Rabbit anti-phospho-cMET mAb 
(Y1234/Y1235), clone D26 (#3077) 
Cell Signaling Technologies, Cambridge GB 
Rabbit anti-phospho-EGFR mAb (Y1173), 
clone E124 (ab32578) 
Abcam, Cambridge,GB 
Rabbit anti-Akt Ab (#9272) Cell Signaling Technologies, Cambridge GB 
 
Secondary antibodies for Western Blot 
Goat anti-mouse IgG (H+L) peroxidase (HRP) 
conjugate 
Jackson ImmunoResearch, Suffolk, GB 
Alexa Fluor® 680 goat anti-rabbit IgG (H+L), 
A21076 
Life Technologies, Darmstadt, Germany 
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Detection antibodies for flow cytometry 
Anti-Alexa Fluor® 488 rabbit IgG 
(Quenching) 
Life Technologies, Darmstadt, Germany 
Goat anti-human Fc-specific Fab2 PE conjugate Jackson ImmunoResearch, Suffolk, GB 
Goat anti-human IgG, Fc specific, FITC 
conjugate  
Jackson ImmunoResearch, Suffolk, GB 
 
Antibodies for receptor quantification 
Mouse anti-EGFR mAb (ab187287) Abcam, Cambridge, GB 
Mouse anti-c-MET mAb (MAB3582) R&D Systems, Minneapolis, MN, USA 
Goat anti-mouse Fc F(ab‘)2 FITC conjugate Jackson ImmunoResearch, Suffolk, GB 
 
Antibodies for ELISA 
Anti-His6 peroxidase (HRP) conjugate Roche, Mannheim, Germany 
Mouse anti-myc Merck, Darmstadt, Germany 
Goat anti-HGF mAb, clone AF 294-NA R&D Systems, Minneapolis, MN, USA 
Goat anti-mouse IgG (H+L) peroxidase (HRP) 
conjugate 
Jackson ImmunoResearch, Suffolk, GB 
Goat anti-human IgG, Fcγ fragment specific 
peroxidase (HRP) conjugate  
Jackson ImmunoResearch, Suffolk, GB 
Rabbit anti-goat IgG (H+L) peroxidase (HRP) 
conjugate  
Jackson ImmunoResearch, Suffolk, GB 
Streptavidin-peroxidase (HRP) conjugate Merck, Darmstadt, Germany 
 
Capture and detection antibodies for MSD assay 
Cannot be listed due to patent issues. 
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3.4. Oligonucleotides 
Oligonucleotides were obtained from Eurofins MWG Operon, Ebersberg, Germany. 
 
Primers for error prone PCR of c-MET binders B10 and F06: 
PelB_VH_f1 GCCTACGGCAGCCGCTGG 
CH1_VH_r1 GCACCAGCGGTGGCACCG 
PelB_VL_f1 CTGTTGCCAACCGCTGCG 
CL_VL_r1 CGCTGCTAGGCGGAAAC 
 
Primers for site-directed mutagenesis PCR of hu225 scFv variants: 
hu225_S58R_f CGAGTGGATTGGAGTGATATGGAGAGGTGGAAACACAGAC 
hu225_S58R_r GTCTGTGTTTCCACCTCTCCATATCACTCCAATCCACTCG 
hu225_N108Y_f CTTACTACTGTCAACAAAATTATAACTGGCCAACCACGTTTGGCC 
hu225_N108Y_r GGCCAAACGTGGTTGGCCAGTTATAATTTTGTTGACAGTAGTAAG 
hu225_T109D_f GCAAGAGCCCTCGACTACTATGATTACGAGTTTGCTTACTGG 
hu225_T109D_r CCAGTAAGCAAACTCGTAATCATAGTAGTCGAGGGCTCTTGC 
hu225_N109E-T112N_f GTCAACAAAATAATGAGTGGCCAAACACGTTTGGCCAAGG 
hu225_N109E-T112N_r CCTTGGCCAAACGTGTTTGGCCACTCATTATTTTGTTGAC 
 
Primers for sequencing: 
pDFall_VL-f GGAATTGTGAGCGGATAAC 
pDFall_VH_r CAGACAACCCAGTGCTGCG 
pTT5_UP CTGCGCTAAGATTGTCAGT 
pTT5_RP CCATATGTCCTTCCGAGTG 
 
3.5. Chemicals 
1-StepTM Ultra TMB-ELISA substrate solution Thermo Scientific, Schwerte, Germany 
Agar-agar Merck, Darmstadt, Germany 
Agarose Life Technologies, Darmstadt, Germany 
Ampicillin, sodium salt Life Technologies, Darmstadt, Germany 
Biocytin Life Technologies, Darmstadt, Germany 
Blocking solution for fluorescent Western Blot Biomol, Hamburg, Germany 
Calcium chloride (CaCl2) Merck, Darmstadt, Germany 
Coomassie InstantBlueTM Expedeon Ltd, San Diego, CA, USA 
Coomassie Plus - Bradford AssayTM Reagent Thermo Scientific, Schwerte, Germany 
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Desocyribonucleotide triphosphates (dNTPs) Novagen, Nottingham, GB 
Disodium hydrogen phosphate (Na2HPO4*2H2O) Merck, Darmstadt, Germany 
Eagle Minimal Essential Medium (MEM) Sigma-Aldrich, Steinheim, Germany 
EDTA (ethylenediaminetetraacetic acid) Sigma Aldrich, Steinheim, Germany 
EZ-Link-NHS-Biotin Life Technologies, Darmstadt, Germany 
Expi293TM expression medium Life Technologies, Darmstadt, Germany 
Gel filtration standards Bio-Rad, Munich, Germany 
Gel loading dye (6x) Novagen, Nottingham, GB 
GelRedTM VWR International, Darmstadt, Germany 
Gibco® Dulbecco’s modified eagle medium 
(DMEM) 
Life Technologies, Darmstadt, Germany 
Giboco® DMEM/F-12 (1:1) Life Technologies, Darmstadt, Germany 
Gibco® Dulbecco’s PBS (DPBS, w/o CaCl2, 
MgCl2); phosphate buffered saline 
Life Technologies, Darmstadt, Germany 
Gibco® Fetal calf serum (FCS) Life Technologies, Darmstadt, Germany 
Gibco® L-glutamine Life Technologies, Darmstadt, Germany 
Gibco® sodium pyruvate Life Technologies, Darmstadt, Germany 
Giboc® RPMI 1640 medium Life Technologies, Darmstadt, Germany 
Glucose Sigma-Aldrich, Steinheim, Germany 
Guava instrument cleaning fluid (ICF) Merck, Darmstadt, Germany 
Glycine Merck, Darmstadt, Germany 
Hydrogen chloride (HCl) Merck, Darmstadt, Germany 
Isopropyl-β,D-thiogalactopyranosid (IPTG) Merck, Darmstadt, Germany (Calbiochem) 
Insulin Sigma-Aldrich, Steinheim, Germany 
Kanamycin sulfate Merck, Darmstadt, Germany 
Keratinocyte growth medium PromoCell, Heidelberg, Germany 
Methanol Merck, Darmstadt, Germany 
Monomethyl auristatin E (MMAE) with valine-
citrulline (vc) linker and triple-glycine moiety 
Merck, Darmstadt, Germany 
MSD® Blocker A (R93BA-4) Meso Scale Discovery, Gaithersburg, MD, USA 
MSD® Read Buffer T (4x, R92TC-3) Meso Scale Discovery, Gaithersburg, MD, USA 
MSD® Tris Lysis Buffer (R60TX-3) Meso Scale Discovery, Gaithersburg, MD, USA 
MSD® Tris Wash Buffer (10x, R61TX-2) Meso Scale Discovery, Gaithersburg, MD, USA 
NuPAGE® LDS sample buffer (4x) Life Technologies, Darmstadt, Germany 
NuPAGE® MES SDS running buffer Life Technologies, Darmstadt, Germany 
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NuPAGE® sample reducing agent Life Technologies, Darmstadt, Germany 
NuPAGE® Tris-acetate running buffer Life Technologies, Darmstadt, Germany 
Formaldehyde 37% Merck, Darmstadt, Germany 
Peptone Merck, Darmstadt, Germany 
Perfect DNATM markers, 0.1 – 12 kbp Merck, Darmstadt, Germany 
Phusion HF buffer (5x) New England Biolabs, Ipswich, MA, USA 
Polyethylene glycol 8000 Sigma-Aldrich, Steinheim, Germany 
Polyethylenimine, linear (PEI) Polysciences Europe, Eppelheim, Germany 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
Potassium di-hydrogen phosphate (KH2PO4) Merck, Darmstadt, Germany 
Precision Plus ProteinTM standards Bio-Rad, Munich, Germany 
ProCHO5 medium Lonza, Basel, Switzerland 
Propidium iodide (PI) Life Technologies, Darmstadt, Germany 
Protein standard HiMarkTM pre-stained Life Technologies, Darmstadt, Germany 
Restriction enzyme buffers CutSmart or NEB1-4 New England Biolabs, Ipswich, MA, USA 
RIPA cell lysis buffer (10x, #9806) Cell Signaling Technologies, Cambridge GB 
Sucrose Merck, Darmstadt, Germany 
S.O.C. medium Life Technologies, Darmstadt, Germany 
See Blue® Plus 2 prestained protein standard Life Technologies, Darmstadt, Germany 
Skim milk powder Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium hydroxide solution (NaOH), 2N Merck, Darmstadt, Germany 
Sodium perchlorate monohydrate (NaClO4*H2O) Merck, Darmstadt, Germany 
Sulfo-NHS-LC-Biotin Thermo Scientific, Schwerte, Germany 
Sulforic acid (H2SO4) Bernd Kraft, Duisburg, Germany 
SYPRO Orange Life Technologies, Darmstadt, Germany 
T4 DNA Ligation Buffer (10x) New England BioLabs, Ipswich, MA, USA 
TAE buffer Life Technologies, Darmstadt, Germany 
Tetracycline VWR International, Darmstadt, Germany 
Tris(hydrocymethyl)aminomethane (Tris) Carl Roth, Karlsruhe, Germany 
Tris-hydrochloride (Tris-HCl) Sigma-Aldrich, Steinheim, Germany 
Tween®20 Merck, Darmstadt, Germany 
Ultra low IgG FCS Life Technologies, Darmstadt, Germany 
Yeast extract Becton Dickinson, Heidelberg, Germany 
 
 3. Materials  31 
3.6. Cell culture media 
A431, A549, U87MG DMEM, 10% (v/v) FCS 
KP-4 DMEM/F-12 (1:1), 10% (v/v) FCS  
MDA-MB-468, , HepG2, MKN45, NCI-H1975 RPMI 1640, 10% (v/v) FCS, 2 mM L-glutamine, 
1 mM sodium pyruvate 
HCC-827, NCI-H441, NCI-H596 RPMI 1640, 10% (v/v) FCS, 2 mM L-glutamine, 
1 mM sodium pyruvate, 2.5 g/l glucose 
T47D RPMI 1640, 10% (v/v) FCS, 2 mM L-glutamine, 
1 mM sodium pyruvate 
10 µg/ml insulin 
EBC-1 MEM Eagle, 10% (v/v) FCS, 2 mM L-glutamine 
SK-MEL2 MEM Eagle, 10% (v/v) FCS, 2 mM L-glutamine, 
1 mM Na-pyruvate, NEAA 
CHO-S ProCHO5, 4 mM L-glutamine 
Expi293FTM Expi293TM expression medium 
NHEK.f-c. Keratinocyte growth medium (Promega) 
ADCC assay medium RPMI 1640, 4% (v/v) low IgG FCS (heat 
inactivated at 56°C for 30 min) 
 
3.7. Solutions, media and buffer 
Phosphate buffered saline (1xPBS) 140 mM NaCl, 3 mM KCl,  
8 mM Na2HPO4 x 2H2O, 2 mM KH2PO4, pH 7.4 
Potassium phosphate buffer 125.4 g/l K2HPO, 23.1 g/l KH2PO4, pH 7.4 
LB medium 10 g/l peptone, 5 g/l yeast extract, 
10 g/l NaCl 
LB-A medium LB, 0.1 mg/l ampicillin 
LB-A agar LB-A, 15 g/l agar-agar,  
2xTY medium 16 g/l peptone, 10 g/l yeast extract, 
5 g/l NaCl, pH 7.0 
2xTY-GA medium 2xTY, 20 g/l glucose, 0.1 mg/l ampicllin 
2xTY-GA agar 2xTY-GA, 15 g/l agar-agar 
5xTY medium 10 g/L peptone, 50 g/l yeast extract, pH 7.0 
Phage dilution buffer 10 mM Tris, 20 mM NaCl, 2 mM EDTA 
Polyethylenelgycol (PEG)/NaCl 200 g/l PEG6000, 2.5M NaCl ad dH2O 
Wash solution/PBS-T 0.05% (v/v) Tween® 20 in 1xPBS pH 7.4 
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Panning block buffer PBS-T, 2% (w/v) BSA, 2% (w/v) milk powder 
Blocking solution for peroxidase Western Blot 5% skim milk powder in PBS-T 
Blocking solution for fluorescent Western Blot 1:1 Blocking solution for fluoresecent Western 
Blotting:1xPBS 
Wash solution for fluorescent Western Blot 0.02 % Tween®20 in blocking solution for 
fluorescent Western Blot 
FACS binding buffer 1% (w/v) BSA in DPBS 
ProSepA binding buffer A 1.5 M glycine/NaOH, 3 M NaCl pH 9.0 
ProSepA elution buffer B2 0.2 M glycine/HCL pH 2.5 
ProSepA neutralization buffer C 1 M Tris/HCl pH 9.0 
Protein A chromatography binding buffer PBS, pH 6.8 – pH 7.0 or  
10 mM Na2HPO4, 10 mM NaH2PO4, 500 mM 
NaCl, pH 7.0 
Protein A chromatography elution buffer 0.1 M sodium citrate, pH 3.0 or  
50 mM acetic acid, pH 3.0  
Protein A chromatography neutralization 
buffer 
3 M Tris/HCl, pH 8.5 or 1 M Tris/HCl, pH 9.0 
Analytical size exclusion chromatography 
(SEC) mobile phase 
PBS, pH 7.4 or 0.05 M sodium phosphate 
(NaH2PO4, Na2HPO4), 0.4 M sodium 
perchlorate, pH 6.35 
Preparative SEC mobile phase PBS, pH 7.4 
Sortase reaction buffer 50 mM Tris, 150 mM NaCl, pH 7.5 
Kinetics buffer (KB) for BLI 0.1% (w/v) BSA, 0.02% (v/v) Tween®20 in 
PBS 
Low pH buffer (internalization assay for 
confocal microscopy) 
50 mM glycine, 150 mM NaCl, pH 2.7 
adjusted with HCl 
 
3.8. Kits and laboratory materials 
ADCC reporter bioassay kit Promega, Mannheim, Germany 
AirPoreTM Tape Sheets, breathable sealing foil Qiagen, Hilden, Germany 
Amicon® Ultra-15 and 0.5 ml centrifugal filter 
units 
Merck, Darmstadt, Germany 
Cell culture flasks T75, T175 Greiner Bio-One, Kremsmuenster, Austria 
Cell culture flat and round bottom NucleonTM 
delta surface 96 well plates 
Thermo Scientific, Schwerte, Germany 
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Cell culture 24 well plates Costar® Thermo Scientific, Schwerte, Germany 
CellTiter-Glo® luminescent cell viability assay 
kit 
Promega, Mannheim, Germany 
Gene Pulser ® electroporation cuvette, 0.1 cm Bio-Rad, Munich, Germany 
ExpiFectamineTM 293 transfection kit Life Technologies, Darmstadt, Germany 
Falcon® tumbes, 15 ml and 50 ml VWR International, Darmstadt, Germany 
FortéBio tips (AHC, streptavidin, ProteinA) Pall ForteBio LLC, Menlo Park, CA, USA 
GeneMorph II random mutagenesis kit Agilent Technologies, Waldbronn, Germany 
Gel and PCR clean-up kit NucleoSpin® Macherey-Nagel, Dueren, Germany 
HiLoad Superdex 200 pg 26/60 columns GE Healthcare, Munich, Germany 
HiTrap MabSelect SuRe columns, 5 ml GE Healthcare, Munich, Germany 
Human serum Merck medical office, Darmstadt, Germany 
iBlot® dry blotting nitrocellulose regular 
transfer stack (#B3010-01) 
Life Technologies, Darmstadt, Germany 
JETSTAR Plasmid Purification Kit (Midi and 
Maxi column) 
Genomed, Loehne, Germany 
Limulus amebocyte lysate Endosafe®-PTSTM 
cartriges, PTS2001F, FDA-licensed,  
1-0.01 EU/ml  
Charles River Laboratories, Wilmington, MA, 
USA  
Keratinocyte detachment kit PromoCell, Heidelberg, Germany 
MaxiSorp®f flat-bottom 96 well micotiter 
plates 
Sigma-Aldrich, Steinheim, Germany 
Menzel glass coverslips Menzel Glaser, Braunschweig, Germany 
Mini-Sub® Cell GT cell gel chambers Bio-Rad, Munich, Germany 
Montage PROSEP-A spin columns (#P36486) Merck, Darmstadt, Germany 
Mouse serum (+ 0.09% soridum azide) Bio-Rad, Munich, Germany (AbD Serotec) 
NuPAGE® 3-8% Tris-Acetate gels Life Technologies, Darmstadt, Germany 
NuPAGE® 4-12% Bis-Tris gels Life Technologies, Darmstadt, Germany 
Phospho (S473)/total Akt assay whole cell 
lysate kit (K15100D) 
Meso Scale Discovery, Gaithersburg, MD, USA 
Phospho (T202/Y204;T185/Y187)/total 
ERK1/2 assay whole cell lysate kit (K15107D) 
Meso Scale Discovery, Gaithersburg, MD, USA 
PKH2 green fluorescent cell linker kit for cell 
membrane labeling 
Sigma-Aldrich, Steinheim, Germany 
Polypropylene microtiter plates, black Greiner Bio-one, Frickenhausen, Germany 
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Polypropylene microtiter plates, clear Greiner Bio-one, Frickenhausen, Germany 
Polystyrene round bottom 96 well microtiter 
plates 
Greiner Bio-one, Frickenhausen, Germany 
ProLong Diamond Antifade Mountant with 
DAPI (4’,6-diamidino-2-phenylindole) 
Life Technologies, Darmstadt, Germany 
Pur-A-LyzerTM maxi dialysis kit 35100 Sigma-Aldrich, Steinheim, Germany 
Qiaprep® Spin Miniprep kit Qiagen, Hilden, Germany 
Quick Ligation Kit New England BioLabs, Ipswich, MA, USA 
QFIKIT (Dako, K0078) Agilent Technologies, Waldbronn, Germany 
QuikChange II site-directed mutagenesis kit Agilent Technologies, Waldbronn, Germany 
Steriflip® filter device 0.22 µm Merck, Darmstadt, Germany 
SteritopTM bottle top filter 0.22 µm Merck, Darmstadt, Germany 
Tissue culture 24 well plates Greiner Bio-one, Frickenhausen, Germany 
TMB peroxidase substrate solution Vector Laboratories, Burlingame, CA, USA 
TSKgel SuperSW3000 column Tosoh Bioscience, Darmstadt, Germany 
Ultrafree® Centrifugal filter units Merck, Darmstadt, Germany 
Zeba Spin desalting PD-10 columns Life Technologies, Darmstadt, Germany 
 
3.9. Equipment 
Analytical balance New Classic MF MS3002S Mettler Toledo, Giessen, Germany 
Cell counter Vi-CELL® XR Beckmann Coulter, Brea, CA, USA 
Chromatography systems ÄKTAxpress and 
ÄTKAexplorer 100 
GE Healthcare, Munich, Germany 
Confocal fluorescence microscope Leica TCS 
SPS, 100x objective  
Leica Microsystems, Wetzlar, Germany 
Electrophoresis chambers Bio-Rad, Munich, Germany 
Electroporation system Gene Pulser XcellTM Bio-Rad, Munich, Germany 
Endosafe®-PTSTM reader, PTS100  Charles River, Wilmington, MA, USA  
Flow cytometer Guava easyCyte HT 2L Merck, Darmstadt, Germany 
Fluoresence reader Odyssey® CLx LI-COR Biosciences, Bad Homburg, Germany 
FortéBio Octet RED Pall ForteBio LLC, Menlo Park, CA, USA 
Gel imaging system GBOX Syngene, Cambridge, GB 
HeraSafe® Clean Bench Thermo Scientific, Schwerte, Germany 
Hot plate magnetic stirrer IKA® RCT basic Sigma-Aldrich, Steinheim, Germany 
HPLC Agilent 1200, ChemStation LC 3D Agilent Technologies, FFM, Germany 
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iBlot® dry blotting system Life Technologies, Darmstadt, Germany 
Incubation shaker Minitron Infros HT, Bottmingen, Switzerland 
Incubator Heracell 150 Thermo Scientific, Schwerte, Germany 
Megafuge 1.0R, rotor BS4402/A Thermo Scientific, Schwerte, Germany 
Microplate washer, ELx405TM BioTeK, Bad Friedrichshall, Germany 
Microtiter plate reader BioTeK SynergyTM 4 BioTeK, Bad Friedrichshall, Germany 
Microtiter plate reader SpectraMax® 
Paradigm® 
Molecular Devices, Wals, Austria 
MSD® plate reader Sector Imager 6000, 
Model 1200 
Meso Scale Discovery, Gaithersburg, MD, USA 
pH meter 744 Metrohm, Filderstadt, Germany 
Power supply EC 250-90 Thermo Scientific, Schwerte, Germany 
PowerPacTM basic power supply  Bio-Rad, Munich, Germany 
Real-Time PCR system StepOnePlus Life Technologies, Darmstadt, Germany 
Spectrophotometer Nanodrop ND-1000 Peqlab, Erlangen, Germany 
Spectrophotometer Ultrospex 3000 GE Healthcare, Munich, Germany 
Table centrifuge 5415D Eppendorf, Hamburg, Germany 
Tetrad® 2 Peltier Thermal Cycler (PCR) Bio-Rad, Munich, Germany 
ThermoMixer® Eppendorf, Hamburg, Germany 
Utlracentrifuge Beckmann OptimaTM LE-80K, 
SW41 TI rotor 
Global Medical Instrumentation, Ramsey, MN, 
USA 
XCell SureLockTM gel electrophoresis device Life Technologies, Darmstadt, Germany 
 
Further equipment comprised common laboratory instrumentation. 
 
3.10. Software 
ÄKTA UNICORN software ver. 5.11 (Build 407) GE Healthcare, Munich, Germany 
Endosafe®-PTSTM data logging utility ver. 1.0  Charles River Laboratories, Wilmington, MA, 
USA  
FortéBio octet data acquisition ver. 8.0 Pall ForteBio LLC, Menlo Park, CA, USA 
FortéBio octet data analysis ver. 8.0 Pall ForteBio LLC, Menlo Park, CA, USA 
Gen5TM microplate reader software ver. 1.11.5 BioTeK Instruments, Bad Friedrichshall, 
Germany 
GraphPad Prism ver. V5.0.4 GraphPad Software, La Jolla, CA, USA 
GuavaSoft ver 2.7 Merck, Darmstadt, Germany 
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HPLC software ChemStation Agilent Technologies, FFM, Germany 
Image StudioTM software ver. 2.1 LI-COR Biosciences, Bad Homburg, Germany 
Lasergene ver. 12.3.1 DNA Star Inc., Wisconsin, WI, USA 
Microsoft Office 2013 Microsoft Corp., Redmond, WA, USA 
MSD Software Assay Explorer ver. 3.3 Meso Scale Discovery, Gaithersburg, MD, USA 
ParadigmTM software SoftMaxPro ver. 6.3 Molecular Devices, Wals, Austria 
Protein Thermal ShiftTM software ver. 1.0 Life Technologies, Darmstadt, Germany 
PyMOL ver. 1.3r1 Schrodinger LLC, San Diego, CA, USA 
Reference Manager ver. 12 Thomson Reuters, FFM, Germany 
SnapGene® Viewer ver. 2.6.2 GSL Biotech LLC, Chicago, IL, USA 
Vi-CELL® XR ver. 2.04 Beckmann Coulter, Brea, CA, USA 
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4. Methods 
 
4.1. Molecular biological methods 
4.1.1. Determination of DNA concentration 
The nucleic acid concentration in aqueous solutions was measured by a UV spectrophotometer Nanodrop 
ND1000 (cf. chapter 3.9) applying 1.5 µl of sample. The underlying physical principals are the law of 
Lambert-Beer and the absorption of aromatic nucleobases within the DNA at the wavelength 260 nm. 
The ratios A260/A280 and A260/A230 can be used as a quality criteria for the purity of the DNA and should 
be around 1.8 and 2.0-2.2, respectively. 
 
4.1.2. Polymerase chain reaction 
DNA can be exponentially and specifically amplified by the polymerase chain reaction (PCR) employing 
DNA flanking, complementary oligonucleotides or primers. (Mullis et al, 1986). For DNA fragment 
amplification prior to cloning, 10 ng of plasmid DNA were mixed with 10 µl Phusion HF buffer, 0.2 µM 
forward and reverse primer, 200 µM dNTPs, 0.5 µl 2 U/µl Phusion® High-Fidelity DNA polymerase, and 
dH2O in a final volume of 50 µl. After initial denaturation at 95°C for 60 sec, 30 cycles of amplification 
were performed for each 10 sec at 95°C for denaturation, 30 sec at 55°C for annealing, and 30 sec at 
72°C for extension followed by a final extension for 10 min at 72°C. The annealing temperature was 
adjusted to the melting temperatures of the used primer pair calculated by Seqbuilder (Lasergene). 
In order to introduce nucleotide changes, QuikChangeII site-directed mutagenesis kit (Chapter 3.8) was 
applied according to the manufacturer’s instructions. Briefly, PCR mixtures were prepared as described 
above except 5 µl reaction buffer and 1 µl PfuUltra HF DNA polymerase (2.5 U/µl) were used. After 
initial denaturation at 95°C for 30 sec, 12 to 18 cycles of amplification were used for each 30 sec at 95°C 
for denaturation, 1 min at 55°C for annealing, and 1 min/kb of plasmid length at 68°C for extension. 
After subsequent incubation for 2 min on ice, parental DNA was digested with 1 µl DpnI restriction 
enzyme. Then, DNA was subjected to transformation in supercompetent E. coli XLI blue cells. 
For the randomization of variable regions of heavy and light chain, error prone PCR was conducted 
applying the GeneMorph II Random Mutagenesis Kit (Chapter 3.8) containing a DNA polymerase which 
is prone to base pair exchanges (16 mutations in 1000 bp). Briefly, 0.2 ng DNA template were added to 
5 µl reaction buffer, 200 µM dNTPs, 0.2 µM forward and reverse primer, 1 µl Mutazyme II DNA 
polymerase (2.5 U/µl) and dH2O in a final volume of 50 µl. After initial denaturation at 95°C for 2 min, 
30 cycles of amplification were used for each 30 sec at 95°C for denaturation, 30 sec at 60°C for 
annealing, and 1 min at 72°C for extension. 
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4.1.3. Purification of DNA 
DNA fragments were purified after PCR amplification or from agarose gel bands excised with a clean 
scalpel using the Gel and PCR clean-up kit NucleoSpin® (chapter 3.9) according to the manufacturer’s 
instructions. DNA was eluted in 10-50 µl elution buffer from the kit or dH2O. DNA concentration was 
photometrically determined (cf. chapter 4.1.1). 
 
4.1.4. Enzymatic digestion and ligation of DNA 
Type II restriction endonucleases can be used as molecular scissors for DNA fragmentation at defined 
sequences. For preparative digest, 5 µg DNA were digested with two restriction enzymes (each 1-2 µl) 
in corresponding restriction buffer for 2-3 h at the temperature optimum of the respective enzymes in a 
volume of 30 µl. After digestion, thermal inactivation of enzymes was carried out (in general 20 min at 
65-80°C) and p.r.n. plasmid DNA was dephosphorylated by addition of 1 µl calf intestinal Antarctic 
phosphatase (CIP) for 1 h at 37°C. Antarctic phosphatase removes 5’-phosphate groups in linear, double 
strand DNA and prevents religation of plasmid DNA and the reaction was inactivated by heat (10 min, 
65°C). 
For ligation, three fold molar excess of insert were mixed with dephosphorylated and linearized DNA 
vector (50 ng for conventional ligation, 1 µg for library cloning) in ligation buffer in presence of 1 µl T4-
DNA ligase in final volume of 20 or 100 µl for library generation overnight at 16°C. After ligation, DNA 
was purified in Amicon® centrifugal tubes and ligation mixture was subjected to transformation in 
E. coli. 
 
4.1.5. Gel electrophoresis and gel extraction 
With the help of agarose gel electrophoreses, linear DNA fragments can be separated in an electric field 
based on their length. In general, 1-2% (w/v) agarose gels were prepared in TAE buffer (chapter 3.5) 
supplemented with GelRedTM solution (1:10,000). DNA premixed with 6x loading dye were loaded on 
gels along with 10 µl Perfect DNATM marker (0.1-12 kbp) for determination of size and quantity of 
separated DNA fragments and gels were run for 45 min at 100 V. DNA bands were visualized by UV light 
using the gel imaging system GBOX (chapter 3.9).  
 
4.1.6. DNA sequencing 
Isolated plasmid DNA (15 µl with 50-100 ng/µl) or alternatively transformed E. coli glycerol stocks in 96 
well plates were transferred to Eurofins MWG Operon (Ebersberg, Germany) and sequenced using 
primers listed in chapter 3.4. 
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4.2. Microbiological methods 
4.2.1. Transformation in E. coli and plasmid preparation 
Transformation of E. coli XL1 blue MRF’ cells with plasmid DNA was carried out by electroporation or 
heat shock. For library generation, 20 µl purified ligation mix was added to 30 µl electrocompetent E. coli 
cells in 0.1 cm electroporation cuvettes. After incubation on ice for 1 min, electroporation was conducted 
with an electric pulse of 1.7 kV for ~5 msec. Transformed cells were immediately transferred to 1 ml 
pre-warmed S.O.C. medium (chapter 3.5) and incubated at 37°C and 600 rpm for 1 h. Afterwards, cells 
were plated on 25 x 25 cm agar plates with 2xTY-GA selective agar and incubated overnight at 37°C. 
For plasmid amplification (after ligation etc.), 5 µl plasmid DNA were incubated with 50 µl chemically 
competent E. coli One shot TOP10 (or alternatively 50 µl supercompetent E. coli XL1 blue cells for site-
directed mutagenesis), which were thawed on ice, for 30 min. Heat-shock was performed for 30 sec at 
42°C followed by incubation on ice for 1-2 min. Then, transformed cells were shaken in 250 µl S.O.C. 
medium for 1 h at 225 rpm and 37°C followed by plating on LB-A selective agar and incubation overnight 
at 37°C. For plasmid re-transformation, only 1 µl plasmid DNA was applied and incubation times were 
shortened to 10 min on ice and 30 min at 225 rpm and 37°C, respectively. 
 
From single E. coli colonies, overnight E. coli cultures were inoculated in LB-medium. Plasmid DNA was 
isolated from 2 ml E. coli cultures using the Qiaprep® Spin Miniprep kit or from 100-200 ml E. coli 
cultures applying the JetStar plasmid preparation kits (Midi and Maxi, respectively) according to the 
manufacturer’s information. DNA elution was carried out with 50-300 µl dH2O depending on the size of 
the E. coli culture. 
 
4.2.2. Sub-library generation for affinity maturation 
For in vitro affinity maturation, three sub-libraries based on randomization of VH and –VL sequences of 
the anti-c-MET binder F06 were generated. F06 was derived from panning of HAL7/8 libraries (Hust et 
al, 2011) against c-MET and was kindly provided by Merck, Darmstadt, Germany. 
The first two sub-libraries were generated by error-prone PCR of the F06-VH and –VL sequences using 
the primers PelB_VH_f1, CH1_VH_r1, PelB_VL_f1, and CL_VL_r1 (chapter 4.1.2). After PCR, amplified 
DNA fragments were cloned into the pDF-Fab-F06 vector with restriction enzymes (NcoI/SalI for VH and 
BssHII/AvrII for VL) followed by ligation and transformation in E. coli (cf. methods in chapters 4.1 
and 4.2). For the third sub-library, a parsimonious mutagenesis approach was applied for the CDR-H3 
of F06. The coding mixtures for each amino acid of the CDR-H3 was calculated so that the parental 
amino acid remains to a probability of 60-70% and that the generation of stop codons, methionines, and 
cysteins are avoided. Based on the calculated codon mixture, the sub-library was generated by GeneArt® 
(Life Technologies, Darmstadt, Germany) by gene synthesis. The parsimonious sub-library was cloned 
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with restriction enzymes NcoI/SalI into the pDF-Fab-F06 vector (chapter 3.2) followed by ligation and 
transformation in E. coli (cf. methods in chapters 4.1 and 4.2). 
 
4.2.3. Library packaging and Fab phage production 
In order to package a library, 30 ml of 2xTY-GA were inoculated with 50-200 µl E. coli transformed with 
library antigen fragment phagemid vectors (OD600nm<0.1) and were grown to OD600nm ~0.5 at 37°C with 
250 rpm on a shaker. Then, 5 ml E. coli culture (~2.5x109 cells) were infected with 500 µl helperphage 
M13K07 (ratio 1:20) followed by 30 min incubation without shaking and then 30 min with 350 rpm 
shaking at 37°C. Due to the packaging signal coded by the phagemid and the envelope proteins coded 
by the phage genome, bacteriophages can be produced and secreted from E. coli cells. Subsequently, 
cells were centrifuged (3220xg, 10 min) in order to remove glucose which represses lac promoter 
(cf. chapter 3.2) and therefore expression of Fab-pIII fusion protein. Cells were resuspended in 30 ml 
2xTY supplemented with 0.1 mg/l ampicillin and 0.03 mg/l kanamycin to produce Fab-phage overnight 
at 250 rpm and 30°C. Bacteria were centrifuged (3220xg, 4°C, 10 min) and bacteriophages were 
precipitated from the supernatant by addition of 1/5 volume PEG/NaCl (cf. chapter 3.7) for 1 h on ice 
followed by centrifugation. The phage pellet was resuspended in 500 µl phage dilution buffer 
(cf. chapter 3.7). In order to remove potential cell debris, phage solution was centrifuged once again 
(16,100xg, 10 min, RT) and packaged antibody phage library was stored at 4°C. 
 
For phage titration, 50 ml 2xTY supplemented with 12.5 mg/l tetracycline were inoculated with E. coli 
XL1 blue MRF’ overnight culture at 37°C and 250 rpm until reaching OD600nm ~0.5. A serial dilution of 
the phage suspension was prepared in PBS (10-2 to 10-10 phages/ml). Afterwards, 50 µl E. coli culture 
was mixed with 10 µl of the respective dilution, incubated for 30 min at 37°C and plated on 2xTY-GA 
agar plates. After incubation at 37°C overnight, colony forming units (cfu) were counted and phage titer 
(cfu/ml) was calculated according to the dilution. 
 
4.2.4. Selection of phage display libraries 
The antibody selection was carried out in MaxiSorp® microtiter plates with immobilized c-MET ECD 
protein (Merck, Darmstadt, Germany). In the first panning round, 2 µg/well and in the following two 
rounds 1 µg/well c-MET were immobilized overnight on plates in 150 µl PBS at 4°C. After three times 
washing with PBS-T (300 µl) with a microplate washer ELx405TM, the microtiter plate antigen-coated 
surface was blocked with 300 µl panning block buffer at RT for 1 h. In parallel, the Fab-antibody-
fragment-phage library (first panning round: 2x1011, second and third panning rounds: 5x1010 phages) 
was pre-incubated for 1 h in an empty well in 150 µl panning block in order to remove anti-plastic, anti-
BSA, and anti-milk powder binders. Afterwards, the amplified Fab-antibody-fragment-phage library 
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(cf. chapter 4.2.3) was incubated on the surface-bound antigen at RT in a humidified chamber for 2 h. 
Starting in the second round, a 50 fold excess of soluble c-MET was added in the last hour of the antigen 
incubation in order to remove anti-c-MET binders with fast off-rates. Subsequently, stringent washing 
was applied (first panning round: 10x, round 2: 20x, round 3: 30x) to remove the vast excess of 
nonbinding antibody phages. Phages were eluted with 200 µl trypsin (10 µg/ml) at 37°C for 15 min. The 
phage titer after the selection was carried out as described in chapter 4.2.3. Subsequently, 20 ml of E. coli 
culture with OD600nm ~0.5 was infected with phage eluate and incubated for 30 min without shaking 
and 30 min at 250 rpm at 37°C. After centrifugation (3220xg, 10 min), the cell pellet was resuspended 
and plated on 2xTY-GA agar plates overnight. The next day, agar plates were floated-off with 5 ml 2xTY-
GA and either glycerol stocks were prepared (800 µl bacteria solution + 200 µl 80% (v/v) glycerol, 
storage at -80°C) or phages were amplified from phagemid carrying bacteria according to chapter 4.2.3 
and a new selection round was started.  
 
4.2.5. Production of soluble Fab-fragments in microtiter plates 
From the selective agar plates of the respective round, single colonies were picked with sterile tips and 
inoculated in 96 well polypropylene microtiter plates with 150 µl TY-GA. The plates were sealed with 
breathable sealing film and incubated overnight at 37°C, 800 rpm, and 70% humidity. For soluble Fab-
fragment production, 10 µl of each single culture was added to 180 µl 2xTY-GA in a new polypropylene 
microtiter plate and incubated for 2 h at 37°C, 800 rpm, and 70% humidity. To the residual culture, 
100 µl/well 50% glycerol were added and stored at -80°C. After 2 h, the new culture was centrifuged 
(3220xg, 4°C, 10 min) and resuspended in 200 µl 5xTY medium supplemented with 1x potassium 
phosphate buffer, 50 mM saccharose, 0.1 mg/l ampicillin, and 100 µM isopropyl-β,D-
thiogalactopyranosid (IPTG). The production of soluble Fabs was carried out overnight at 30°C, 800 rpm, 
and 70% humidity. After centrifugation (3220xg, 4°C, 10 min), soluble Fab-antibody fragment-
containing supernatants were subjected to further analysis. 
 
4.3. Biochemical methods 
4.3.1. Determination of protein concentration 
Protein concentration were photometrically determined either by absorption at 280 nm (A280) according 
to the law of Lambert-Beer’s, by Bradford assay using the Coomassie Plus - Bradford AssayTM reagent 
(Bradford, 1976) or applying the UV spectrophotometer Nanodrop ND1000 (cf. chapter 3.9) while the 
concentration was calculated to the respective molecular weight (in kDa) and molar extinction 
coefficient (M-1 cm-1; Protean Software, Lasergene DNASTAR, chapter 3.10) of the protein. For the 
Bradford assay, a serial dilution of BSA (0.1-1 mg/ml) served as a reference protein standard curve. The 
sample was diluted (1:2 to 1:10 depending on the concentration). 5 µl of each sample or standard 
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dilution were added to a microtiter plate well together with 150 µl Bradford reagent. After shaking and 
incubation for 10 min in the dark, adsorption at 595 nm was performed. Comparison of samples with 
the calibration curve was used for calculation of the protein concentration. 
 
4.3.2. Protein biotinylation 
Biotinylation was performed with the EZ-LinkTM Sulfo-NHS (N-Hydroxysuccinimide)-Biotinylation Kit 
(chapter 3.8) according to the manufacturer’s instructions incubating 50-200 µg protein with a 50-fold 
molar excess of EZ-LinkTM Sulfo-NHS reagent in 200-700 µl PBS. Residual reagent was removed by 
ZebaTM Desalt Spin columns (chapter 3.8). 
 
4.3.3. Protein A affinity chromatography 
For purification of antibodies from supernatants of small-scale productions (25 ml, chapter 4.4.2) 
purification was carried out with PROSEP® A centrifugal Protein A columns (chapter 3.8) according to 
manufacturer’s instructions using recommended buffers binding buffer A, elution buffer B2 and 
neutralization buffer C (chapter 3.7) as well as centrifugation (150xg, 5-20 min per step). Briefly, 
PROSEP® A columns were equilibrated with binding buffer A and supernatants mixed in a ratio of 
1:1 (v/v) with binding buffer A were applied on the columns followed by two washing steps à 10 ml 
binding buffer A. Elution was carried out with 10 ml elution buffer B2 in tubes containing 1.3 ml 
neutralization buffer C. Eluates were concentrated with Amicon® Ultra-15 centrifugal filter device with 
10,000 molecular weight cut-off (MWCO; 3000xg, ~10 min) and subsequently dialyzed to PBS pH 7.4 
using Pur-A-LyzerTM Dialysis Kit (both chapter 3.8). 
 
For purification of antibodies from supernatants of large scale productions (200 ml, chapter 4.4.2) 
affinity chromatography using 5 ml HiTrap MabSelect SuRe (chapter 3.8) on an ÄKTAxplorer 100 or 
ÄKTAxpress system (chapter 3.9) was applied using binding, elution and neutralization buffer described 
in chapter 3.7. Briefly, the column was equilibrated with 5 column volumes (CV) of binding buffer at 
2.5 ml/min. Subsequently, supernatants were applied (2.5 ml/min) with active air sensor and washed 
with 10 CV of binding buffer. Elution was carried out with 5 CV elution buffer. 1 ml fractions were collected 
in 96 deep well plates (chapter 3.8) with 200 µl neutralization buffer. Fractions from the protein peak 
were pooled, concentrated with Amicon® Ultra-15 centrifugal filter device with 10,000 MWCO (3000xg, 
~10 min) and subjected to size exclusion chromatography (SEC, chapter 4.3.4). 
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4.3.4. Size exclusion chromatography 
4.3.4.1. Preparative size exclusion chromatography 
To separate desired antibody monomer from high molecular weight protein aggregates and in case of 
bsAbs also from GA-GA-SEED homodimers, preparative size exclusion chromatography (SEC) was 
performed using the HiLoad 26/60 Superdex 200 pg (cf. chapter 3.8) with PBS pH 7.4 or other desired 
buffer as mobile phase. Columns were equilibrated with 2 CV buffer at 2.5 ml/min, before 2 ml 
concentrated protein was loaded with a sample loop. 1 ml fractions were collected and selected fractions 
were pooled. Antibodies were again concentrated with Amicon® Ultra-15 centrifugal filter device 
(10 kDa MWCO) resulting final concentrations of 1-2 mg/ml protein. Protein concentrations and purity 
were determined by A280 spectroscopy, gel electrophoreses and analytical SEC (chapters 4.3.2, 4.3.5, 
4.3.6 and 4.3.8.1). Endotoxin levels were assessed by Limulus amebocyte lysate (LAL) Endosafe® PTS 
cartridges and Endosafe® PTS reader (chapter 3.8, 3.9 and 3.10) according to the manufacturer’s 
instructions. 
 
4.3.4.2. Analytical size exclusion chromatography 
For evaluation of protein purity, molecular size and presence of high molecular weight protein 
aggregates or SEED-homodimers for bsAbs, analytical size exclusion high performance liquid 
chromatography (SE-HPLC) was performed using TSK Super SW3000 column (Tosoh, chapter 3.8) and 
the HPLC Agilent 1200 (ChemStation LC 3D, chapter 3.9 and 3.10). Briefly, columns were equilibrated 
with mobile phase buffer (chapter 3.7) at 0.35 ml/min until obtaining stable baseline (~45 min). As 
molecular weight standard reference proteins from the gel filtration standard (Bio-Rad, chapter 3.8) 
were prepared and applied according to the manufacturer’s instructions (diluted 1:20 in PBS). Protein 
samples were diluted to a final concentration of 0.5 mg/ml in PBS. The injection volume was 15 µl per 
run and the following sequence was injected: mobile phase, gel filtration standard, duplicates of protein 
samples, gel filtration standard, mobile phase. Chromatograms recorded at 280 nm (or alternatively 214 
and 254 nm) were analyzed by the ChemStation software (chapter 3.10) by integration of peaks. 
 
4.3.5. SDS-PAGE 
In order to determine protein purity or analyze cell lysates, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was conducted for protein separation by molecular weight in an electric 
field according to Laemmli. (Laemmli, 1970) SDS (or lithium dodecyl sulfate, LDS) thereby serves as 
anionic detergent which attaches to proteins resulting in a total negative net charge. For this, protein 
samples or cell lysates were mixed with 4 x LDS sample buffer and 10 x sample reducing agent (when 
reduction of disulfide bonds was aimed), followed by incubation for 10 min at 70°C for protein 
denaturation. Samples were subjected to either NuPAGE® Bis-Tris gels (4-12%) or Tris-Acetate gels (3-
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8%) using the appropriate volume according to the size of the wells which were installed in gel 
electrophoresis chambers with MES (2-(N-morpholino)ethanesulfonic acid) or Tris-Acetate SDS running 
buffer, respectively (chapter 3.8). As protein standard for antibody samples, the See Blue® Plus 2 
prestained protein standard and for cell lysates or the HiMarkTM pre-stained protein standard were used 
(chapter 3.8). Bis-Tris gels were run for 30 min at 200 V and Tris-Acetate gels for 1 h at 150 V. Next, 
gels were subjected to coomassie staining (chapter 4.3.6.) or Western blotting (chapter 4.3.7.). 
 
4.3.6. Coomassie staining 
Coomassie staining was performed for direct visualization of proteins separated by SDS-PAGE using 
Coomassie InstantBlueTM (chapter 3.5). Gels were incubated for 10-30 min and destained in dH2O 
according to the manufacturer’s instructions. 
 
4.3.7. Western blotting 
Western blotting for protein visualization mediated by detection antibodies conjugated to either enzymes 
(e.g. HRP, horse reddish peroxidase) or fluorescent dyes was carried out with the dry blotting system 
iBlot according to the manufacturer’s instructions (chapters 3.8 and 3.9). Briefly, proteins from SDS-
PAGE gels were transferred to polyvinylidene difluoride (PVDF) membranes (program 3, 7 min, 20 V) 
and proteins were detected with antibodies listed in chapter 3.3.1. 
 
4.3.7.1. Peroxidase-labeled secondary antibodies 
After transfer of proteins to PVDF membrane, membranes were blocked in blocking solution 
(chapter 3.7, 5% skim milk powder in PBS-T) for 1 h at RT. Then, membranes were incubated with 
primary antibodies in PBS-T for 1 h at RT. After washing three times with PBS-T, membranes were 
incubated with peroxidase-labeled secondary antibody for 1 h at RT. After washing, antibody binding 
was revealed by addition of peroxidase substrate, 3,3’,5,5’-tetramethylbenzidine (TMB) within the TMB 
substrate kit (chapter 3.8) following the manufacturer’s instructions. 
 
4.3.7.2. Fluorescently labeled secondary antibodies 
For fluorescent western blotting, PVDF membranes were blocked in 1:1 dilution of Fluorescent Western 
Blot Solution in PBS (chapter 3.7) for 1 h at RT. Afterwards, membranes were cut if necessary and 
incubated with primary antibodies in 1:1 dilution of Fluorescent Western Blot Solution in PBS 
(chapter 3.7) supplemented with 0.2% Tween®20 overnight at 4°C. After washing three times with 1:1 
dilution of Fluorescent Western Blot Solution in PBS (chapter 3.7) supplemented with 0.05% Tween®20, 
detection was carried out with AlexaFluor 680 labeled secondary antibody (usually goat-anti-rabbit IgG, 
chapter 3.3.1) diluted 1:10,000 in washing buffer. After additional washing and drying of membranes, 
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fluorescent bands were visualized using the Fluorescence reader Odyssey® CLx and corresponding 
software Image StudioTM software (chapters 3.9 and 3.10). 
 
4.3.8. Enzyme-linked immunosorbent assay 
Determination of specific protein-protein interactions was determined by enzyme-linked immunosorbent 
assay (ELISA) in 96 well MaxiSorp® polystyrene microtiter plates (Engvall et al, 1971). All steps were 
carried out at room temperature in a volume of 100 µl with exception of blocking and washing which 
were conducted in 300 µl 2% BSA in PBS-T overnight at 4°C and 300 µl PBS-T, respectively. Washing 
was performed with a microplate washer ELx405TM (chapter 3.9). The peroxidase was detected by 
addition of 100 µl 1 step Ultra TMB ELISA substrate solution and the reaction was terminated with 
100 µl 2 N sulfuric acid. Absorbance was measured at 450 nm using the ParadigmTM microtiter plate 
reader and respective software (chapter 3.9 and 3.10). 
 
4.3.8.1 Binding of soluble Fab-fragments to c-MET 
For the determination of soluble Fab-antibody fragments binding to c-MET, ELISA was performed with 
100 ng immobilized c-MET ECD in microtiter plates which was carried out overnight at 4°C. After three 
times washing, plates were blocked at RT for 1 h. After a subsequent washing step, Fab-antibody 
fragments were added diluted in the ratio 1:2 in 100 µl 2% BSA in PBS-T. After removal of Fabs by 
washing, the detection was carried out with mouse anti-myc (IgG9E10, 1:1000) and peroxidase labeled 
goat anti-mouse IgG (H+L, 1:5000). A non-related Fab-fragment binding hen egg lysozyme (HEL) 
served as a negative control. 
 
4.3.8.2 HGF competition ELISA 
Competition of recombinant human HGF with antibody binding to recombinant human c-MET ECD was 
detected by ELISA using HGF in solid phase. For this, 1.25 pmol HGF were immobilized on 96 well 
MaxiSorp® plates overnight at 4°C. After blocking plates with 2% BSA in PBS-T, 1.13 pmol biotinylated 
c-MET ECD pre-incubated with serial dilutions of antibodies (0.2-200 nM) were added to plates. Binding 
was revealed using HRP-conjugated streptavidin followed by addition of 1 step Ultra TMB ELISA 
substrate solution and sulfuric acid. Resulting absorbance for c-MET ECD binding to HGF without 
addition of anti-c-MET directed antibody was defined as 100% HGF binding. Anti-HEL SEED was used 
as an unrelated isotype control antibody. Data were plotted as % HGF binding against the logarithm of 
the antibody concentration and fitted to a sigmoidal dose-response curve with variable slope (4PL) using 
GraphPad Prism 5 (chapter 3.10). 
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4.3.8.3 Serum stability ELISA 
For determination of long-term stability of bsAbs in human or mouse serum, bridging ELISA was applied. 
Prior to the main assay, antibodies were titrated for determining the linear range for the concentration 
dependent reduction in ELISA signal in order to prevent signal saturation for the assay antibody 
concentration. 100 ng human recombinant EGFR ECD were immobilized on MaxiSorp® plates overnight 
at 4°C. After blocking, bsAbs were incubated in plates (B10v5x225-H and CSx225-H 1:60 dilution, 
B10v5x225-M and CS06x225-M 1:6 dilution) at RT for 1 h. After washing, 100 ng biotinylated human 
recombinant c-MET ECD were added and were detected with streptavidin-HRP conjugate (1:200 diluted, 
chapter 3.3.1). 
 
Cetuximab samples were subjected to plates with immobilized EGFR ECD (100 ng) and detected with 
HRP-conjugated goat-anti-human IgG, Fcγ specific (1:5000 diluted, chapter 3.3.1). For the verification 
for immobilized EGFR-ECD, HRP-conjugated anti-His6 antibody was applied (1:500 diluted, 
chapter 3.3.1). The zero time point control served for each antibody as 100% control and based on this, 
reduction in protein functionality was determined. 
 
4.3.8.4 Electrochemiluminescence ELISA (MSD-assay) 
MSD assays (Meso Scale Discover) or electrochemiluminescence (ECL) ELISAs were performed to detect 
phosphorylated and total levels of c-MET, EGFR, and AKT of cell lysates which were treated with 
antibodies and/or stimulated prior to lysis (cf. chapter 4.4.4). 
 
High bind 96-well plates including electrodes (L11XB-3) were coated with capture anti-total c-MET (Cell 
Signaling Technologies) or anti-total EGFR antibodies followed by blocking with 3% Block A (R93Ba-4) 
in PBS supplemented with 0.05% Tween®20. After washing three times with PBS-T, cell lysates were 
added (25 µl/well, 1h at RT) and detection was carried out with anti-phospho-c-MET, anti-phospho-
tyrosine and by the supplier recommended detection reagents. The measurement was performed in Read 
Buffer T (R92TC-1) with the SECTOR® Imager 6000 (Meso Scale Discovery). 
 
For quantification of phospho-AKT levels, the Phospho(Ser473)/Total AKT Assay Whole Cell Lyate Kit 
(Meso Scale Discovery, K15100D) was used according to the manufacturer’s instruction. Dose response 
curves were plotted as the logarithm of antibody concentration versus ECL signal. IC50 values were 
calculated by a 3PL fitting model using GraphPad Prism 5 (cf. chapter 3.10). Data from at least two 
experiments were used to calculate mean IC50 ± standard deviation (s.d.). 
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4.3.9. Sortase A mediated toxin conjugation 
Sortase mediated site-directed conjugation of valine-citrulline (vc)-monomethyl auristatin E (MMAE, 
chapter 3.5) to antibody Fc was performed as described elsewhere. (Chen et al, 2011; Dickgiesser et al, 
2015) Briefly, antibodies carrying the enzyme recognition site (LPETG) C-terminally on both heavy 
chains were generated, transfected and purified by affinity chromatography. Then, one equivalent of 
antibody was incubated with 11 equivalents of substrate-vc-MMAE conjugate in the presence of 5 µM 
sortase and 5 mM CaCl2 in sortase reaction buffer (50 mM Tris, 150 mM NaCl, pH 7.5) for 30 min at 
22 °C. The reaction was stopped with 10 mM EDTA as calcium ion chelator. The resulting ADC was 
purified by SEC as described before. 
 
4.4. Cell biological methods 
4.4.1. Cultivation of mammalian cells 
All mammalian cell lines (chapter 3.1) were cultivated in tissue culture flasks of appropriate sizes 
(chapter 3.8, T75-T175 or alternatively Erlenmeyer flask) using the recommended media formulations 
(chapter 3.6) under sterile conditions at 37°C, 5% CO2 under humidified atmosphere. Cells were certified 
mycoplasma-free and never exceeded passage 20.  
 
Adherent cells were detached by trypsin-EDTA (chapter 3.3) for 2-3 min at 37°C after washing with 
DPBS to remove residual serum components. For primary keratinocytes, the recommended DetachKit 
was used (chapter 3.6 and 3.8). Cell number and viability of detached adherent cells or unprocessed 
suspension cells were measured by the cell counting device Vi-CELL® XR (chapter 3.9) by calculating 
the average of 20 images of trypan blue treated cells. Alternatively, standard cell counting using 
Neubauer cell chamber was applied. After cell pelleting (250xg, 10 min, RT), supernatants were 
discarded and cells were diluted in pre-warmed medium yielding appropriate cell numbers (dependent 
on cell line). Cell lines were testified mycoplasma free and cell culture conditions were standardized 
since cell handling is known to influence receptor cell surface expression. (Panke et al, 2013) 
 
4.4.2. Transfection of mammalian cells and antibody expression 
Antibodies were expressed by transient co-transfection of antibody chains in Expi293FTM cells 
(chapter 3.1) using the corresponding transfection kit and media (chapter 3.6 and 3.8) according to the 
manufacturer’s instruction. Briefly, Expi293FTM cells were cultivated in 200 ml in Erlenmeyer flasks at 
37°C, 5% CO2 and 180 rpm orbital shaking. For passaging, cells were counted and pelleted (250xg, 
10 min) and added to fresh medium resulting in final cell number of 0.5 x 106 viable cells per ml. On 
day of transfection, cells were seeded with a final density of 2.5 x 106 viable cells per ml in Expi293FTM 
medium. 
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For small scale expression, 25 µg DNA (plasmid ratio: 1:1 HC:LC for mAbs or 3:2:1 for HC-AG:LC:scFv-
GA for bsAbs) and 81 µl ExpiFectamineTM293 were preincubated each in 1.25 ml OptiMEM® 
(chapter 3.8) and subsequently mixed. After 20-30 min incubation, the DNA-transfection mix was added 
to 21 ml cells. 16-18 h post transfection, enhancers were added. Supernatants were harvested 5 days 
post transfection by centrifugation (1500xg, 10 min) and sterile filtration through 0.22 µm Steriflip 
devices. For mid scale expression, the transfection volume was adjusted to 200 ml and the transfection 
mix was scaled to 200 µg DNA and 540 µl ExpiFectamineTM293. The overall procedure was analog to 
the description above. Supernatants were harvested by centrifugation (4000xg, 20 min, 4°C) and sterile 
filtration using Stericup devices. 
 
4.4.3. Flow cytometry 
Flow cytometric analysis was carried out at a Guava easyCyte HT cytometer (chapter 3.9) using 
corresponding software Guava ExpressPro (chapter 3.10). Adherent human cell lines were detached at 
70-80% confluency with trypsin-EDTA and suspension cells were directly subjected to assays. Cells were 
counted with the Vi-CELL® XR (chapter 3.9). All washing and sample incubation steps were carried out 
in FACS binding buffer (chapter 3.7) on ice for each 1 h except stated otherwise. Cells were pelleted at 
250xg (4°C, 10 min). Incubation steps were performed in volume of 100 µl, washing with 300 µl. 
 
4.4.3.1 Cellular binding 
For the determination of antibody binding to cellular targets by flow cytometry, 1x105 vc/well were 
incubated with serial dilutions of bsAbs (0.02-200 nM). After washing with FACS binding buffer 
(3 times), antibody binding was detected via FITC conjugated goat anti-human Fcγ specific pAb. 
Addition of propidium iodide enabled dead cell staining. 5,000 events were detected per sample. For 
geometric mean fluorescence intensity (MFI) values, background autofluorescence values of cells treated 
with medium only were subtracted. Means of triplicate normalized MFI values were plotted versus 
logarithm of mAb concentration and fitted by a 3PL model using GraphPad Prism 5 (chapter 3.10).  
 
4.4.3.2 Receptor cell surface quantification 
Receptor surface expression levels on selected cell lines were determined using the QFIKIT (Dako). 
Briefly, five populations of calibration beads presenting different numbers of mouse mAb molecules on 
their surfaces were used as a calibration standard. 1.5x105  viable cells per well were labeled with 
primary mouse anti-EGFR (ab187287) or mouse anti-c-MET antibodies (MAB3582) at saturating doses 
(5 µg/ml). After washing with FACS buffer (3x 300 µl), beads and cells were stained with 10 µg/ml 
secondary goat anti-mouse Fc (Fab’)2 FITC conjugate and were subjected to flow cytometry 
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measurement. Beads and cells were measured on the same day using the same settings. Based on a 
calibration line for fluorescence of beads versus bead surface density, antigen cell surface densities for 
c-MET and EGFR were calculated. 
 
4.4.3.3 Selectivity 
The selectivity of bsAbs was assessed by analyzing binding of antibodies to a cell mixture composed of a 
tumor model cell line (e.g. EBC-1) with high expression in both EGFR and c-MET in presence of an 
excess of an epithelial model cell line (e.g. T47D) with low EGFR expression and no c-MET expression. 
In order to discriminate the two cell lines during flow cytometry, tumor model cells were stained with 
the PKH2 green fluorescent cell linker kit (chapter 3.8) according to the manufacturer’s instructions 
using 2x107 cells with 4 µl dye. Unstained epithelial model cells and stained tumor model cells were 
mixed in a ratio of 1:30, 1.3x105 viable cells per well were added in 96 well round bottom plates and 
incubated with either 3 or 30 nM antibody. After washing, binding of antibodies was detected with PE-
conjugated goat anti-human Fc-specific Fab2. The samples were subjected to flow cytometric analysis 
with 30,000 counts collected per sample. The membrane dye PKH2 was detected in the green channel, 
antibody binding in the PE-channel (yellow). Due to crosstalk between green and yellow channel, green 
emission was compensated in the yellow channel. 
 
4.4.3.4 Internalization 
Internalization was either determined by flow cytometry using an anti-Alexa Fluor 488 quenching 
antibody (Gostring et al, 2010) or confocal fluorescence microscopy (chapter 4.5.3). For flow cytometry, 
1x105 viable cells were incubated with 100 nM bsAbs followed by detection with AlexaFluor 488 
conjugated anti-human Fcγ specific pAb. After washing, cells were incubated at either 37°C allowing 
internalization or at 4°C preventing internalization for 1 h. Afterwards, residual surface binding of bsAb 
was quenched by anti-AlexaFluor 488 IgG or not quenched. Afterwards, cells were fixated with 4% (w/v) 
formaldehyde and subjected to flow cytometric analysis. Internalization was calculated as following:  
 
𝑟𝑒𝑙. 𝑖𝑛𝑡𝑒𝑟𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 [%] =
(37 °𝐶 𝑤𝑖𝑡ℎ 𝑞𝑢𝑒𝑛𝑐ℎ) − (4 °𝐶 𝑤𝑖𝑡ℎ 𝑞𝑢𝑒𝑛𝑐ℎ)
(37 °𝐶 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑞𝑢𝑒𝑛𝑐ℎ) 
𝑥100 
 
4.4.4. Phosphorylation assay 
4.4.4.1. Western blot analysis 
For fluorescent Western blot analysis of antibody treated and/or stimulated cell lysates, cells were seeded 
into tissue culture 24-well plates on day 1 with 1-3x105 viable cells per well in the respective medium of 
the cell line. The next day, cells were starved for 16-18 h with medium lacking FCS. On day 3, cells were 
treated with antibodies (300 nM in 200 µl) for 1-4 h at 37°C, followed by stimulation with 100 ng/ml 
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EGF or HGF for 10 min at 37°C. Then plates were transferred to ice, medium was aspirated and cells 
were lysed with 50 µl ice-cold RIPA buffer supplemented with protease (1:1000) and phosphatase 
inhibitors (1:100) as well as benzonase (1:1000) per well(chapters 3.3 and 3.8). Protein amounts of cell 
lysates were quantified by Bradford assay (chapter 4.3.1) and subjected to SDS-PAGE and Western blot 
analysis (chapters 4.3.5 and 4.3.7). 
 
4.4.4.2. Electrochemiluminescence ELISA analysis 
Phosphorylation levels were determined by c-MET or EGFR capture electrochemiluminescence (ECL) 
ELISA (MSD assay). Briefly, cells were plated in Nunc-Immuno 96-microwell tissue culture plates 
(chapter 3.8) with 12,500 viable cells per well (A549, MDA-MB-468) or 30,000 viable cells per well 
(MKN45, NCI-H596, NCI-H441, A431, and NHEK.f-c.) one day before treatment using recommended 
cell media formulations (chapter 3.1 and 3.6). On the day of treatment, cells were starved with medium 
lacking FCS for 1 h and serial dilution of antibodies (0 – 167 nM in 80 µl starvation medium) were added 
for 1 h at 37°C, 5% CO2. Upon stimulation with either 100 ng/ml HGF and/or EGF (both R&D Systems) 
for 5 min at 37°C, cells were lysed with 40 µl/well ice-cold lysis buffer (MSD, chapter 3.8) supplemented 
with protease and phosphatase inhibitors and subjected to ECL ELISA assay analysis (MSD assay) 
(cf. chapter 4.3.8.4). 
 
4.4.5. Antibody dependent cellular cytotoxicity 
Antibody dependent cellular cytotoxicity (ADCC) assays were performed using the ADCC Reporter 
Bioassay Core Kit (Promega, chapter 3.8) according to the manufacturer’s instruction. Briefly, target cells 
(e.g. A431 or EBC-1 cells) were detached and seeded into the inner wells of opaque white tissue culture 
treated 96 well plates with 12,500 viable cells per well in ADCC buffer (chapter 3.7) and allowed to 
attach overnight in a humidified chamber at 37°C, 5% CO2. The next day, cells were treated with 5 to 
0.0016 nM of mAbs diluted in ADCC buffer and 75,000 recombinant Jurkat cells (chapter 3.1) per well 
as effector cells were added. After 6 h of incubation, 75 µl per well Bio Glo Luciferase substrate 
equilibrated at RT were added and incubated for 10 min at RT avoiding light. Luminescence was 
measured at a Synergy 4 plate reader with a read time of 0.5 seconds per well (sensitivity: 170, chapter 
3.9 and 3.10) using the Gen5 software. Background luminescence in only medium wells was subtracted. 
Mean relative luminescence units (in triplicates) were plotted against the logarithm of antibody 
concentration and dose response curves were fitted using 3PL model by GraphPad Prism 5 (chapter 
3.10). 
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4.4.6. Cytotoxicity or cell viability assay 
Cell viability was quantified using the ATP-based luminescence CellTiter-Glo® assay (chapter 3.8) and 
was performed according to the manufacturer’s instructions. Briefly, cells were detached and seeded in 
the inner wells of opaque white tissue culture treated 96 well plates. The seeding cell number ranged 
from 8,000 to 15,000 viable cells per well depending on the cell line in 80 µl cell line specific medium. 
Cells were allowed to attach at least 3 h in a humidified chamber at 37°C, 5% CO2 before ADC treatment 
(ranging from 50 to 0.01 nM final) in duplicates in cell line specific medium. After 72 h, viability of cells 
was detected by adding 100 µl per well of CellTiter-Glo® reagent with subsequent mixing on a plate 
shaker for 2 min at 350 rpm and 10 min incubation in the dark at RT. Luminescence was measured at a 
Synergy 4 plate reader (chapter 3.9 and 3.10) with a read time of 0.5 seconds per well (sensitivity: 170). 
Background luminescence in wells with only medium plus the CellTiter-Glo® reagent was subtracted. 
Data were plotted as percentage of untreated cell viability versus the logarithm of antibody concentration 
and fitted with 3PL model using GraphPad Prism 5 (chapter 3.10). Data from at least three independent 
experiments with duplicates were used to calculate mean IC50 ± standard deviation (s.d.). 
 
4.5. Biophysical methods 
4.5.1. Biolayer interferometry 
Biosensor experiments using biolayer interferometry were performed on an Octet Red96 platform using 
Octet Data Acquisition and Analysis software (cf. chapter 3.9 and 3.10) at 30°C using 1000 rpm orbital 
sensor agitation in a volume of 200 µl in black 96-well microplates. The physical principal of biolayer 
interferometry is based on the optical detection of changes within the layer thickness on biosensor tips 
by association and dissociation of molecules resulting in a shift in the interference pattern of reflected 
light. White light is thereby directed through the biosensor and is reflected once by a reference layer 
within the biosensor tip and secondly by the tip surface. (Rich & Myszka, 2007) 
 
4.5.1.1. Antibody quantification 
For determining the concentration of produced Fab-fragments and antibodies, anti-human Fab-CH1 and 
protein A biosensor tips (chapter 3.8) were used, respectively. Biosensors were equilibrated in the 
medium or buffer, in which the Fab-fragment or mAb is present, for 10 min at RT. Then, association of 
Fab-fragments or mAbs is evaluated for 300 sec at 1000 rpm. Based on standard curves of Fab-fragments 
or mAbs of known concentration in the respective medium, the concentration can be calculated. For this, 
binding rates were calculated with the analysis software based on five parameter fitting (5PL 
unweighted) and using either the initial slope after 120 sec or the “R equilibrium” after 300 sec. 
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4.5.1.2. Determination of kinetic parameters 
Anti-human IgG Fc capture biosensor tips were equilibrated 30 sec in DPBS. Then, 5 µg/ml antibodies 
diluted in DPBS were immobilized on biosensor tips for 120 sec, a baseline was recorded for 60 sec in 
kinetics buffer (KB) followed by stepwise association and dissociation of the analyte (serial dilution in 
KB) for 600 sec and 1200 sec, respectively. Buffer controls were subtracted as background and binding 
parameters were calculated assuming a 1:1 Langmuir binding model performing global fitting algorithm 
provided by the Octet data analysis software. 
 
4.5.1.3. Simultaneous binding 
For evaluating simultaneous binding, 5 µg/ml biotinylated c-MET ECD were captured on streptavidin 
biosensor tips for 40 sec. Then, biosensors were first blocked with 1% milk powder, 1% BSA, 
0.1% Tween®20 and 10 µg/ml biocytin for 60 sec and then stepwise subjected to 50 nM bsAbs and 
50 nM EGFR-ECD for 300 sec each. As controls, the non-related isotype control anti-hen egg lysozyme 
(anti-HEL) or buffer controls were implemented to exclude unspecific binding. 
 
4.5.1.4. Epitope binning 
An epitope binning experiment was carried out analyzing competing binding of antibodies to c-MET 
ECD. (Estep et al, 2013) For this, binding of generated antibodies to c-MET ECD was compared to 
reproduced reference antibodies from the literature (oa 5D5, LY2875358, hu224G11, DN30). Anti-
human Fc biosensor tips were equilibrated 30 sec in DPBS followed by capture of 25 nM bivalent mAbs 
or 50 nM monovalent one-armed antibodies in DPBS for 200 sec. Then, biosensors were quenched with 
400 nM of a non-related control antibody (anti-HEL SEED, diluted in DPBS) to minimize subsequent 
binding of secondary antibodies to biosensor tips. After performing a baseline in KB for 60 sec, human 
c-MET-ECD was subjected to immobilized primary antibodies for 600 sec. Afterwards, interactions of 
secondary anti-c-MET antibodies to c-MET-ECD bound to immobilized primary antibodies was analyzed 
for 600 sec. Binding of secondary antibody was analyzed visually by distinguishing simultaneous binding 
by a higher binding rate [nm] compared to a non-related isotype control (anti-HEL SEED). 
 
4.5.2. Determination of thermal stability 
4.5.2.1. Thermal shift assay 
Thermal stability of antibodies was measured using a StepOnePlus Real-Time PCR System 
(cf. chapter 3.9) according to the manufacturer’s instruction. The method is described as differential 
scanning fluorimetry (DSF, thermal shift assay). (Lo et al, 2004) Briefly, 1 µM of protein was mixed with 
a 20 fold excess of SYPRO Orange in PBS pH 7.4. Melting curves were recorded from 25°C to 99°C with 
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an increment of 1°C/60 sec. Data were analyzed with the Protein Thermal ShiftTM Software (Life 
Technologies) by calculating the maximum of the second derivative curve. 
 
4.5.2.2. Long-term stability in serum 
For assessment of long-term stability of bsAbs and mAbs in human and mouse serum, antibodies were 
incubated in triplicates at 5 µg/ml concentration in 50 µl aliquots at 37°C with 750 rpm shaking. Human 
sera were obtained from the Merck medical office (from female and male blood samples, Darmstadt, 
Germany) subsequently supplemented with 0.09% sodium azide or from AbD Serotec (Bio-Rad, chapter 
3.8) for mouse serum. The zero time point sample were immediately frozen at -80°C after antibody 
dilution, the other samples were frozen every 3-4 days up to 24 days. Frozen samples were subjected to 
bridging ELISA (chapter 4.3.8.3). 
 
4.5.3. Confocal microscopy 
For fluorescence microscopy, 3x105 viable cells were grown on glass coverslips (chapter 3.8) placed in 
6-well plates. Two days later, cells were placed on ice and treated with 100 nM bsAbs or mAbs followed 
by detection with Alexa Fluor 488 conjugated anti human Fc Fab-fragment. After washing with 1% BSA 
in PBS, cells were incubated in respective medium at either 37°C allowing internalization or 4°C 
preventing internalization for 1 h. By addition of ice-cold low pH buffer (chapter 3.7), residual bsAbs on 
the cell surface were removed. Finally, cells were fixed with 4% (w/v) formaldehyde and mounted on 
object slides with ProLong Diamond Antifade Mountant supplemented with DAPI (4’,6-diamidino-2-
phenylindole; chapter 3.8). Analysis was carried out with a Leica TCS SPS confocal microscope equipped 
with a 100x objective (chapter 3.9). 
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5. Results 
 
5.1. Quality control of target proteins and characterization of cellular target expression 
Both for selection and biophysical analysis of antibodies, high protein quality plays a pivotal role. In 
respect two membrane bound target, cellular receptor densities can influence binding, selectivity and 
pharmacodynamics of both mAbs and bsAbs. (Jarantow et al., 2015)  
 
Protein purity of recombinant EGFR and c-MET extracellular domains (ECDs) had been determined by 
analytical SE-HPLC and gel electrophoresis under reduced and non-reduced conditions (Figure 7). As 
expected, band sizes of 69 kDa for EGFR-ECD, 66 kDa for c-MET SEMA domain, and 104 kDa for c-MET 
ECD wt and N375S could be observed under non-reduced conditions. Since c-MET is a disulfide-linked 
heterodimer which is processed from a single precursor-protein by furin cleavage within the SEMA-
domain, protein reduction resulted in two protein chains: the SEMA α-chain (~45 kDa) and the SEMA 
β-chain for the total SEMA domain or the c-MET ECD β-chain for c-MET ECD. The protein purity based 
on SDS-PAGE analysis was assessed as sufficient for all following assays. 
 
 
Figure 7: SDS-PAGE of EGFR ECD, c-MET SEMA domain, ECD wt, and N375S. 
Protein purity was accessed by gel electrophoresis and coomassie staining of non-reduced and reduced recombinant human 
protein samples. For EGFR, the ECD (1-618) with His-tag was used in the following experiments (MW: 69 kDa). For c-MET, 
three different recombinant human proteins were evaluated: the SEMA-PSI domain (1-562) with FLAG and His-tag 
(MW: 66 kDa) and the c-MET ECD (1-932) with strepII- and His-tag wild type and with SNP N375S (both 104 kDa). c-MET is 
a disulfide-linked heterodimer and the disulfide bridge is located within the SEMA domain. Under reduced conditions, this 
results in two visible bands of which one is the SEMA α-chain (~45 kDa) and the second band is the SEMA β-chain (lane 2) or 
the ECD β-chain (lane 3+4). M = protein marker. 
 
For later functional analysis of the generated mAbs and evaluation of the tumor selectivity of bsAbs, 
receptor surface expression levels of several cancer cell lines from various indications (chapter 3.1) and 
additionally of primary keratinocytes (NHEK.f-c.) were determined via flow cytometry (chapter 4.4.3). 
Within the QFKIT (chapter 3.8), five bead populations decorated with distinct numbers of mouse mAb 
molecules served as a standard. Concurrently, cell lines were incubated with either mouse anti-EGFR or 
mouse anti-c-MET antibodies with subsequent detection via anti-mouse FITC conjugates. Based on the 
calibration curve, EGFR and c-MET surface levels were calculated and summarized in Table 2 (parts of 
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this data was kindly provided by Merck, Darmstadt). The presented data confirmed high receptor levels 
of EGFR on A431 and MDA-MB-468 cells, while high c-MET densities were assessed on EBC-1 and 
MKN45 cells (both c-MET amplified), and moderate EGFR levels were measured on primary 
keratinocytes in accordance with previously published data. (Hyatt & Ceresa, 2008; Jarantow et al., 
2015) Taken together, several c-MET and EGFR double positive cancer cell lines could be confirmed. 
 
Table 2: c-MET and EGFR quantification on cancer cell lines. 
c-MET and EGFR cell surface expression levels on several cancer cell lines as well as primary keratinocytes (NHEK.f-c.) were 
measured via flow cytometry employing the QFIKIT. Values are indicated as mean of antigens per cell from triplicates based on 
the calibration curve which was measured by five bead populations with distinct molecules per bead. Standard deviations (s.d.) 
are given in percent. Additionally, cell line origin, dependence on HGF, and KRAS mutational status are listed. Legend: ACA = 
adenocarcinoma, CA = carcinoma, n.a. = not accessible. 
 
Cell line Origin HGF dependence 
c-MET density  
[x 103 ± s.d %] 
EGFR density  
[x 103 ± s.d %] 
KRAS 
mutation 
A431 epidermoid CA n.a. 14.7 ± 0.2 661.0 ± 1.4  
A549 lung ACA yes 18.0 ± 0.6 39.3 ± 0.6 G12S 
EBC-1 lung SCC no 261.6 ± 1.1 62.2 ± 1.1  
HepG2 
hepatocellular 
CA 
n.a. 
11.1 ± 1.4 1.3 ± 4.7 
 
KP-4 pancreatic CA yes 7.7 ± 0.5 50.8 ± 0.9  
MDA-MB-
468 
breast ACA 
n.a. 
14.2 ± 1.0 1825.5 ± 0.1 
 
MKN45 gastric ACA no 171.7 ± 1.0 45.4 ± 0.3  
NCI-H1975 lung ACA yes 35.5 ± 0.7 37.8 ± 0.7  
NCI-H441 lung ACA yes 52.2 ± 0.8 46.6 ± 3.7 G12V 
NCI-H596 lung ACA yes 6.7 ± 1.0 148.5 ± 1.4  
NHEK.f-c. keratinocytes n.a. 7.1 ± 8.9 128.7 ± 8.7  
T47D breast ACA n.a. 0.0 13.2 ± 0.9  
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5.2. Selection and characterization of c-MET binders 
To evaluate the influence of kinetic variants in c-MET x EGFR bsAbs on the tumor selectivity, a broad 
panel of c-MET binders with distinct affinities was generated by affinity maturation. Two low affinity 
anti-c-MET binders, B10 and F06, isolated by phage display (Hust et al, 2007; Hust et al., 2011) as well 
as one affinity matured anti-c-MET binder, B10v5, isolated by yeast surface display  (Benatuil et al, 2010; 
Rakestraw et al, 2009), were kindly provided by Merck, Darmstadt, Germany. For the affinity maturation 
of Fab-fragment F06, sub-libraries were generated by (1) randomization of variable heavy chain of 
parental clone F06 by error prone PCR (epPCR, theoretical diversity 2.4x106) and (2) parsimonious 
mutagenesis of the CDR-H3 (theoretical diversity 4.1x106, cf. Appendix Table 12). Due to fast 
dissociation rate of F06, an off-rate screening strategy was applied using stringent washing conditions 
(10 or 20 times washing with panning buffer), and competition with an excess of soluble c-MET ECD 
during panning (cf. chapter 4.2.4). After two rounds of panning, 96 clones were analyzed by Sanger 
sequencing for each approach and unique clones (in terms of identical amino acid sequence) were 
analyzed by ELISA (cf. Appendix Table 12 and data not shown). Binding of E. coli expressed soluble 
Fab-fragment F06v1 from sub-library 1 to c-MET ECD was confirmed by ELISA and displayed an 
improved affinity with slower off-rate confirmed by biolayer interferometry (BLI). Fab-fragment F06v1 
contained four mutations in the VH region (Figure 8). 
 
 
Figure 8: Sequence alignment of affinity matured variants to the parental VH sequence of Fab-fragment F06. 
Sequence analysis revealed four mutations of variant F06v1 compared to parental Fab-fragment F06 within the VH region. This 
clone was derived from the epPCR sub-library approach. Combinatory analysis of mutations indicated that only two mutations 
were responsible for affinity increase from equilibrium dissociation constant values KD = 15 nM to KD = 1.2 nM. Rational 
combination with an additional mutation, which was abundant in the epPCR sequence analysis and is located in the CDR-H1, 
further slightly increased affinity to c-MET (KD = 0.94 nM). 
 
To identify responsible amino acids for the improved affinity, combinatory mutation variants were 
generated by site directed mutagenesis and affinities of resulting E. coli expressed soluble Fab-fragments 
were evaluated by BLI using anti-Fab-antibody fragment biosensors. The data indicated that two 
mutations were sufficient for increased affinity and the corresponding variant was denoted as Fab-
fragment F06v2. Interestingly, only one mutation was located in the CDR-H3 (D104Y) resulting in a 
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patch of seven subsequent tyrosine residues. Nevertheless, the presence of multiple tyrosines did not 
affect the specificity of the Fab-fragment for its target, c-MET (data not shown). This specific CDR-H3 
mutation was also derived in the parsimonious-sub-library approach with high prevalence (cf. Appendix, 
Figure 32). Further rational combination with an abundant mutation derived from the epPCR-sub-
library approach, which was located in CDR-H1 (Y32N) (cf. Appendix, Figure 33), slightly further 
improved affinity to c-MET. The resulting anti-c-MET Fab-antibody fragment, denoted as CS06, was 
selected for further analysis together with B10, F06, and B10v5 as c-MET binding moiety in the bsAbs 
c-MET x EGFR approach. All four binders were reformatted in mammalian expression pTT5 vectors 
containing IgG1-Fc sequences including the SEED-AG sequences in the CH3 region. (Muda et al., 2011) 
After expression as monovalent anti-c-MET Fab-SEEDS by transient transfection in Expi293FTM cells, 
kinetic parameters including the equilibrium dissociation constant (KD) were determined again by BLI 
using anti-human Fc biosensors (AHC). Calculated KD-value of anti-c-MET monovalent antibodies B10 
to B10v5 was improved by the factor 30 (KD = 12 nM and KD = 0.4 nM, respectively) and of F06 to CS06 
by the factor 21 (KD = 4.2 nM and KD = 0.2 nM, respectively, Figure 9). 
 
 
Figure 9: Comparison of parental and affinity maturated c-MET binders by kinetic analysis via BLI.  
Transiently produced monovalent anti-c-MET Fab-SEED antibodies were captured on anti-human Fc (AHC) biosensor. 
Association and dissociation of c-MET ECD to mAbs were monitored for 600 sec and 1200 sec, respectively. Affinity maturation 
of Fab-antibody fragment B10 by light chain shuffling and of Fab-fragment F06 by epPCR yielded in clone B10v5 with a 30-fold 
improved affinity (KD = 12 nM to KD = 0.4 nM) and clone CS06 with improved affinity by factor 21 (KD = 4.2 nM to 
KD = 0.2 nM), respectively. 
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5.2.1. HGF competition by ELISA 
The ability of antibodies to compete with ligand binding to respective RTKs can give a hint on the mode 
of action. Preliminary experiments indicated that both parental anti-c-MET binders compete with HGF 
binding to c-MET ECD in ELISA (communication with Merck, Darmstadt, Germany). In order to evaluate 
the competition of HGF binding to c-MET by anti-c-MET binders, 1 pmol/well immobilized HGF was 
incubated with an equimolar amount of biotinylated c-MET ECD which was pre-incubated with 
increasing concentrations of antibodies. c-MET binding to HGF was revealed with streptavidin-HRP 
conjugate and standard ELISA procedure (cf. chapter 4.3.8). Besides B10v5, CS06, B10 and F06, 
reproduced reference anti-c-MET antibodies LY2875358, oa5D5, and hu224G11 (all kindly provided by 
Merck, Darmstadt, Germany) were able to compete HGF binding to c-MET (Figure 10). c-MET incubated 
without antibody was used as positive control for 100% HGF binding and a non-related isotype control 
(anti-HEL SEED) was unable to compete with c-MET binding to HGF. IC50 values for all anti-c-MET 
antibodies ranged from 3 nM (hu224G11) to 10 nM (LY2875358). At high concentration (> 100 nM), 
all anti-c-MET binders achieved 100% blockade of HGF binding except LY2875358 which only yielded 
in 80% HGF displacement confirming previously presented data. (Liu et al., 2014) 
 
 
Figure 10: Anti-c-MET binders compete with HGF binding to c-MET ECD. 
Serial dilutions of antibodies were pre-incubated with 1 pmol biotinylated human c-MET ECD and subjected to microtiter plates 
with immobilized HGF (1 pmol). Biotinylated c-MET without antibody was defined as 100% HGF binding. Anti-HEL SEED was 
used as a non-related isotype control. Absorbance values were calculated as % HGF binding and plotted to logarithm of antibody 
concentration. Sigmoid curves were fitted using four parameter fitting (4PL) with variable slope using GraphPad Prism 5. 
 
5.2.2. Epitope binning 
For the parental c-MET antibodies, it was known that the epitope of mAb B10 was located within the 
c-MET SEMA domain whereas anti-c-MET binder F06 in contrast demonstrated binding to the stalk 
domain (communication with Merck, Darmstadt, Germany). To evaluate whether the affinity matured 
anti-c-MET binders B10v5 and CS06 still recognize the same epitope, a binning experiment was 
performed employing BLI. (Estep et al., 2013). Moreover, epitope bins of reproduced reference 
antibodies from the literature (Prat et al., 2014) (LY2875358 by Eli Lilly, hu224G11 by Pierre 
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Fabre/AbbVie, one-armed (oa) 5D5 by Roche/Genentech, and DN30 by Comoglio and co-workers, all 
kindly provided by Merck, Darmstadt, Germany) were used for further characterization. Antibodies 
competing for the same or an overlapping epitope on the antigen’s surface were classified as the same 
epitope bin. Briefly, the first antibody was immobilized on anti-human Fc (AHC) biosensor tips followed 
by quenching with an unrelated-isotype control (anti-HEL). Afterwards, c-MET and subsequently the 
second antibody were step-wise associated (Appendix, Figure 34). The assay was evaluated by 
alignment of the c-MET association step. Even though the biosensor tips were quenched, residual binding 
was observed for an anti-HEL mAb as a non-related isotype control when applied as second antibody 
which is exemplarily depicted in Figure 11A. However, residual binding could be clearly distinguished 
to simultaneous binding of second antibody to c-MET together with the first antibody. 
 
 
Figure 11: Schematic summary of epitope binning of anti-c-MET binders. 
(A) Exemplary graph for the analysis of the epitope binning experiment by BLI. Briefly, the first antibody (here: LY2875358) 
was immobilized on AHC biosensors. After quenching with anti-HEL, c-MET ECD and subsequently the second antibodies were 
associated. For analysis, the step of the c-MET ECD association was aligned and association of the second antibody in 
comparison to a non-related mAb control (anti-HEL) was visually evaluated as binding/no competition or no 
binding/competition. In Table 3, a summary can be found. (B) Schematic representation of antibody epitope bins located in 
the c-MET ECD based on results of the presented epitope binning experiment and data adapted from Basilico et al. and Prat et 
al.. (Basilico et al., 2014; Prat et al., 2014) A detailed description of the c-MET structure can be found in Figure 4. 
 
 5. Results  60 
The results are summarized in Table 3 and Figure 11B. B10, B10v5 and LY2875358 built up one epitope 
bin. For LY2875358 binding to SEMA blades 2 and 3 was described (Liu et al., 2014). The oa 5D5 bound 
to a distinct epitope which is located on blade 4, 5 and 6 of the SEMA β-propeller domain demonstrated 
by co-crystallization by Merchant and colleagues. (Merchant et al., 2013) The next epitope bin is 
composed of F06, CS06 and hu224G11 although there are some inconclusive results related to 
competitiveness with oa5D5. (Basilico et al., 2014; Prat et al., 2014) Since F06, CS06 and hu224G11 
(patent US2012/8,329,173 B2) were not able to bind the c-MET SEMA domain, their epitope must be 
located within the stalk domain. Basilico and co-workers engineered MET fragment proteins lacking 
distinct domains. (Basilico et al., 2014) The data indicated that the epitope of hu224G11 can be 
narrowed down to the first two IPT domains. Nevertheless, Basilico et al. also observed interference of 
hu224G11 and oa 5D5 binding to c-MET probably because of sterical hindrance due to close spatial 
proximity of SEMA and IPT regions. The anti-c-MET antibody DN30 is known for its different mode of 
action by inducing receptor ectodomain shedding. (Petrelli et al, 2006) In accordance with data by 
Basilico et al., the presented results indicate that DN30 covers a distinct epitope bin which is located 
within the juxtamembrane region in IPT4. (Basilico et al., 2008) 
 
Table 3: Epitope binning of c-MET binders. 
The epitope binning of c-MET antibodies was measured by BLI and visually analyzed. Briefly, competition of a primary antibody 
immobilized on AHC biosensors and associated with c-MET ECD was analyzed by association of a second antibody. Residual 
binding of antibodies to AHC sensors was monitored by a non-related mAb control (anti-HEL). Binding and no-binding was 
determined in comparison to anti-HEL binding as second antibody (cf. Figure 11).  
Legend: + binding/no competition (green); +/- unclear results (yellow); - no binding/competition (red) 
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B10 - n.d. n.d. + n.d. + n.d. +/- 
B10v5 - - - + + + + +/- 
LY2875358 n.d. - - n.d. + + + n.d. 
F06 + n.d. n.d. - n.d. - n.d. +/- 
CS06 + + + - - - +/- + 
hu224G11 + n.d. n.d. - n.d. - n.d. + 
oa 5D5 + + + - - + - +/- 
DN30 + n.d. n.d. + n.d. +/- n.d. - 
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5.2.3. Binding of SNP variant 
The single nucleotide polymorphism (SNP) N375S within the c-MET SEMA domain was described in 
tumor tissues from NSCLC patients of East Asian, African-American and Caucasian ethnicities. 
(Krishnaswamy et al, 2009; Shieh et al, 2013) In the Taiwanese population, around 13-14% are 
heterozygous and 0.5 to 1.1% are homozygous for this SNP variant. (Shieh et al., 2013) Even though 
the N375S was not associated with NSCLC occurrence or prognosis, the mutation could affect structural 
alterations of c-MET and result in changed HGF binding behavior ultimately influencing antibody 
binding. (Shieh et al., 2013) To evaluate interference of this SNP variant with anti-c-MET mAbs binding, 
c-MET was mutated to N375S (Figure 12A) and expressed by transient transfection. Kinetic parameters 
of immobilized anti-c-MET mAbs (AHC biosensors) to c-MET wild type (wt) or c-MET SNP N375S were 
monitored (Figure 12B). Taken together, all analyzed c-MET mAbs demonstrated similar binding to 
c-MET wt and c-MET SNP N375S (Table 4) and the mutation N375S did not interfere with binding of 
the generated mAbs to c-MET. 
 
Figure 12: Schematic representation of c-MET N375S (A) and binding by anti-c-MET antibodies (B). 
(A) Schematic illustration of the location of the SNP mutation N375S within the β-chain of the SEMA domain. (B) Kinetic 
analysis for binding c-MET wild type (wt) and SNP N375S (concentrations 25 to 1.56 nM) to immobilized c-MET mAbs on 
biosensors was conducted. No binding of 25 nM EGFR (grey) as a non-related negative control was observed. For selected 
concentrations, curve fitting (1:1, Langmuir; red lines) was performed. 
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Table 4: Binding of c-MET SNP variant (N375S) by anti-c-MET antibodies. 
Kinetic analysis of anti-c-MET mAbs binding to c-MET ECD wt and N375S were performed by BLI. The mAbs were immobilized 
on AHC biosensors and various concentrations of respective c-MET were associated and dissociated. Affinities (equilibrium 
dissociation constant, KD) as well as association and dissociation rates (ka and kd) were determined via Langmuir 1:1 fitting. 
  
c-MET c-MET SNP variant (N375S)  
KD [M] ka [M-1s-1] kd [s-1] KD [M] ka [M-1s-1] kd [s-1] 
oa CS06 1.7E-10 1.5E+06 2.6E-04 1.4E-10 2.1E+06 3.0E-04 
oa B10v5 3.4E-10 5.1E+05 1.7E-04 3.0E-10 5.8E+05 1.8E-04 
oa F06 4.2E-09 2.5E+06  1.1E-02 1.4E-09 5.4E+06 7.4E-03 
oa B10 1.6E-08 7.3E+04 1.2E-03 3.2E-08 5.1E+04 1.6E-03 
oa 5D5 2.7E-10 4.3E+05 1.2E-04 2.1E-10 5.3E+05 1.1E-04 
LY2875358 4.0E-10 1.8E+05 7.0E-05 6.1E-10 2.1E+05 1.3E-04 
 
 
5.3. Selection and characterization of EGFR binders 
The inhibition of EGFR by small molecules and mAbs is associated with severe toxicities in the skin. 
(Lacouture, 2006; Melosky et al., 2009) Thus, affinity attenuated variants of anti-EGFR antibodies in 
combination with the bispecific format could increase tumor selectivity and diminish adverse events in 
normal tissue. Affinity variants of humanized cetuximab (C225) (Muda et al., 2011) were generated by 
in silico screening and kindly provided by Merck, Darmstadt, Germany. Briefly, based on the crystal 
structure of the C225-Fab-fragment in complex of EGFR ECD (Li et al., 2005), residues in proximity to 
the binding interface were mutated by computational design in order to find the lowest energy rotamer 
via the Rosetta energy function. To this end, a triple mutant with increased affinity was found, 
designated as 225-H while H stands for high affinity. For attenuated variants in contrast, it was aimed 
for weak repulsive forces. From this approach, two clones were selected named 225-M for medium and 
–L for low affinity. The in silico mutations were then introduced into C225-Fab-fragment and the kinetic 
parameters of the resulting Fab-fragment clones were analyzed (kindly performed by Merck, Darmstadt, 
Germany). In course of this work, the mutations were transferred to vectors containing humanized C225 
(hu225) scFv with the SEED-GA-chain (Muda et al., 2011) for analysis in bispecific combinations 
together with c-MET binders. An alignment of the scFv sequences of the three variants in comparison to 
hu225 are illustrated in Figure 13. The three monovalent, one-armed anti-EGFR 225 scFv-SEEDs were 
expressed in Expi293FTM cells by transient transfection and kinetic parameters were analyzed by BLI 
with EGFR-ECD (Figure 14A). Additionally, humanized matuzumab (424) (Muda et al., 2011) was used 
for expression and analysis (Figure 14A) since 425 occupies a distinct epitope on domain III of EGFR 
(Figure 14B). 225-H had an affinity of 0.1 nM while for C225 an affinity to EGFR-ECD in the single digit 
nanomolar range is described (Li et al., 2005). 225-M and 225-L displayed KD values of 4 nM and ~1 µM, 
respectively. For 425, an affinity of 14 nM was determined. 
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Figure 13: Multiple sequence alignment of humanized C225 scFv kinetic variants. 
Both 225-L and 225-M contain a single mutation within the CDR-L-3 and CDR-H2, respectively. 225-H is composed of a 
combination of three individual mutations from an in silico screening (kindly provided by Merck, Darmstadt, Germany). 
 
 
 
Figure 14: Kinetic analyses of EGFR binders (A) and epitopes of cetuximab and matuzumab on EGFR domain III (B). 
(A) Association and dissociation of EGFR-ECD to immobilized anti-EGFR scFV-SEEDs by BLI. Fitting was performed assuming 
1:1 Langmuir binding model. Equilibrium dissociation constants (KD) are depicted next to graphs. (B) Binding epitopes of 
cetuximab (C225) and matuzumab (425) on EGFR domain III. Note that only cetuximab binding overlaps with EGF binding. 
This sphere structure is adapted from Schmitz and Ferguson. (Schmitz & Ferguson, 2009)  
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5.4. Characterization of bispecific c-MET x EGFR antibodies 
5.4.1. Manufacturing and purification 
The aim of the present study was to evaluate the influence of kinetic variants on the tumor selectivity of 
bsAbs targeting two ubiquitously expressed cancer targets, c-MET and EGFR. Based on the 
aforementioned broad panel of anti-c-MET and anti-EGFR binders with fast and slower off-rates 
targeting distinct epitopes, bispecific Fab-scFv-SEED antibodies were produced by transient transfection 
(Figure 15A). The scFv-technology was applied for correct light chain pairing. (Muda et al., 2011) 
Briefly, VH and VL sequences have been subcloned into pTT5 mammalian expression containing cognate 
constant domains (CH1-CH2-SEED-AG and CL, respectively) for anti-c-MET binders (chapters 5.2 and 
5.3). Kinetic hu225 variants in the scFv-CH2-SEED-GA format were generated by introduction of 
described mutations via site-directed mutagenesis PCR. Thereby, a glycine-serine-linker was chosen as 
peptide linker. As control antibodies, monovalent anti-c-MET Fab-SEEDs or monovalent anti-EGFR scFv-
SEEDs were expressed (Figure 15B and C). For expression of monovalent antibodies, pTT5 vectors 
containing CH2-SEED-AG or CH2-SEED-GA sequences were applied. 
 
Figure 15: Schematic presentation of anti-c-MET and anti-EGFR bsAb (A) and corresponding monovalent, one-armed 
control SEEDs (B-C). 
(A) Based on four anti-c-MET binders (B10, F06, B10v5, and CS06) and four anti-EGFR binders (225-L, 225-M, 225-H, and 
425), bispecific SEED antibodies were generated, while the c-MET binding arm was composed of a Fab-fragment and the EGFR 
binding arm was present in a scFv format with a glycine-serine linker. B10 and F06 are the parental c-MET antibodies derived 
by phage display. B10v5 and CS06 represent binders from the affinity maturation. As EGFR directed antibodies, humanized 
cetuximab (C225) and matuzumab (425) were selected. (Muda et al., 2011) (B) Scheme for monovalent, one-armed anti-
c-MET Fab-SEED antibodies. (C) Presentation of monovalent, one-armed anti-EGFR scFv-SEED antibodies.  
 
5.4.1.1 Small-scale production 
The resulting sixteen different bsAbs with the corresponding eight monovalent mAbs were first expressed 
at small scale, then purified via protein A affinity chromatography spin columns, and analyzed by gel 
electrophoresis (Appendix, Figure 35 and Figure 36) and size exclusion-high-performance liquid 
chromatography (SE-HPLC, Table 5). Expression yields of bsAbs ranged from 20 to 196 mg/l after 
purification. The bsAbs containing the 225-M variant displayed slightly poorer yields. For monovalent 
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control mAbs, anti-c-MET Fab-SEEDs had slightly higher yields (192-256 mg/l) with exception of Fab-
F06-SEED than cetuximab based scFv-SEEDs (8-36 mg/l). Regarding monomer proportion, F06 and 
CS06 containing bsAbs displayed higher purity compared to B10 and B10v5 containing bsAbs. This is 
also true for the monovalent anti-c-MET Fab SEEDs. When comparing the influence of the anti-EGFR 
scFv in bsAbs on monomer percentage, 425 had a slight negative effect (for B10x425, CS06x425, and 
oa 425) when compared to 225 variants. However, bsAbs were only expressed one to two times at small 
scale for initial experiments. 
 
Table 5: Expression yields of small scale production and monomer proportion. 
Antibody yield after expression by transient transfection in Expi293FTM cells and purification via protein A affinity 
chromatography (calculated as mg/25ml and mg/l). Percentages of monomers were determined by analytical size exclusion 
high-performance liquid chromatography (SE-HPLC). n.d. = not determined. 
 
Antibody 
Yield 
[mg/25 ml] 
Yield 
[mg/l] 
Monomer [%] 
B10x225-L 1.6 64 77 
B10x225-M 1.5 60 63 
B10x225-H 3.9 156 68 
B10x425 2.1 84 47 
F06x225-L 1.6 64 67 
F06x225-M 1.1 44 74 
F06x225-H 2.3 92 79 
F06x425 4.9 196 80 
B10v5x225-L 3.6 144 69 
B10v5x225-M 0.8 32 71 
B10v5x225-H 1.5 60 74 
B10v5x425 2.7 108 77 
CS06x225-L 1.1 44 84 
CS06x225-M 0.6 24 85 
CS06x225-H 1.4 56 89 
CS06x425 0.5 20 81 
oa 225-L 0.9 36 n.d. 
oa225-M 0.2 8 63 
oa 225-H 0.5 20 59 
oa 425 2.2 88 45 
oa F06 0.8 32 93 
oa B10 4.8 192 70 
oa CS06 5.9 236 84 
oa B10v5 6.4 256 77 
 
5.4.1.2 Mid-scale production 
Based on initial results, the number of bsAbs was narrowed down to four constructs for mid-scale 
production and subsequent preparative SEC purification: B10v5x225-M, B10v5x225-H, CS06x225-M, 
and CS06x225-H. Corresponding monovalent control mAbs were also expressed. Final yields and 
monomer content before and after preparative SEC (Appendix, Figure 37) are summarized in Table 6. 
In general, the up-scale of the expression volume did not translate into higher yields. However, the 
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percentage of monomers was slightly increased when compared to small scale production. Again, mAbs 
containing the 225-M scFv tend to display lower yields and lower monomer percentage compared to 
mAbs with 225-H. Taken together, both yields and monomer contents after preparative SEC were 
suitable for functional characterization of bsAbs. 
 
Table 6: Yields and purity of bsAbs and monovalent mAbs after up-scale production. 
Antibody yields were photometrically (A280) determined after expression of bsAbs by transient transfection in 200 ml 
Expi293FTM  cells and purification via protein A affinity chromatography and preparative SEC (units: mg/200ml and mg/l). 
Percentages of monomers were calculated by analytical size exclusion high-performance liquid chromatography (SE-HPLC). 
 
Antibody Yield 
[mg/200 ml] 
Yield  
[mg/l] 
Monomer [%] 
before SEC 
Monomer [%] 
after SEC 
B10v5x225-M 5.1 25.5 80.9 98.0 
B10v5x225-H 20.5 102.5 80.5 95.6 
CS06x225-M 3.8 19.0 88.0 100.0 
CS06x225-H 9.6 48.0 90.1 100.0 
oa B10v5 29.6 148.0 95.6 100.0 
oa CS06 10.1 50.5 87.4 98.5 
oa 225-M 2.6 13.0 83.8 100.0 
oa 225-H 9.4 47.0 96.5 100.0 
 
 
5.4.2. Kinetic analysis of bispecific antibodies 
Kinetic parameters of bsAbs and monovalent mAbs were analyzed by biolayer interferometry (BLI) to 
assess the influence of the reformatting in the bispecific format. Note that the detection limit of this 
biophysical method for kinetic measurements is considered as 100 pM. (Estep et al., 2013) Briefly, mAbs 
were immobilized on anti-human Fc (AHC) biosensor tips and association as well as dissociation of 
c-MET or EGFR were monitored. Exemplary graphs of monovalent mAbs were shown in chapters 5.2 
and 5.3 (cf. Figure 9 and Figure 14, respectively). The kinetic parameters are summarized in Table 7 
and illustrated in iso-affinity plots (Figure 16). The data confirms that reformatting of anti-c-MET and 
anti-EGFR binders into the bispecific format did not alter kinetic profiles for functional binding of 
respective soluble receptor. B10v5, 225-M, and 225-H resulted in nearly identical kinetic parameters 
when comparing monovalent mAbs to bsAbs. For CS06, only CS06x225-H slightly differed from oa CS06 
and CS06x225-M but within the instrumental error margin (factor 2). 
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Table 7: Kinetic parameters for bsAbs and monovalent control mAbs determined by BLI. 
Affinities displayed as equilibrium dissociation constant (KD) as well as association (ka) and dissociation rates (kd) were 
determined by BLI. The mAbs were immobilized on AHC biosensors followed by association and dissociation of c-MET or EGFR. 
For each measurement, six analyte concentrations were measured ranging from 50 nM to 0.8 nM. Note that C225 (cetuximab) 
is a bivalent, chimeric IgG and 225 variants (H and M) are based on humanized cetuximab. 
 
Antibody Analyte KD [M] ka [M-1s-1] kd [s-1] 
oa B10 c-MET 1.2E-08 1.0E+05 1.2E-03 
oa B10v5 c-MET 3.8E-10 4.0E+05 1.6E-04 
B10v5x225-M c-MET 3.7E-10 4.0E+05 1.5E-04 
B10v5x225-H c-MET 3.6E-10 4.0E+05 1.5E-04 
oa F06 c-MET 4.2E-09 2.5E+06  1.1E-02 
oa CS06 c-MET 1.9E-10 1.1E+06 2.1E-04 
CS06x225-M c-MET 2.1E-10 1.1E+06 2.2E-04 
CS06x225-H c-MET 1.2E-10 3.3E+06  3.9E-04 
oa 225-L EGFR 1.1E-06 9.4E+04 1.0E-01  
oa 225-M EGFR 4.4E-09  3.7E+06 1.6E-02  
B10v5x225-M EGFR 4.7E-09 3.6E+06 1.7E-02 
CS06x225-M EGFR 3.9E-09 4.6E+06 1.8E-02 
oa 225-H EGFR 1.4E-10 3.6E+06 4.9E-04 
B10v5x225-H EGFR 1.5E-10  3.5E+06 5.3E-04 
CS06x225-H EGFR 1.2E-10 3.3E+06 3.9E-04 
C225 EGFR 1.2E-09 6.1E+05 7.4E-04 
oa 425 EGFR 1.4E-08 8.3E+05 1.2E-02  
 
 
Figure 16: Iso-affinity plots of bsAbs in comparison to monovalent or bivalent reference mAbs. 
Logarithm of association rate was plotted against logarithm of dissociation rate for bsAbs and mAbs to c-MET (A) or EGFR (B). 
Dotted diagonals represent iso-affinities. That means that the combination of ka and kd values results in the same KD. The units 
of kd and ka are s-1 and M-1s-1, respectively. 
 
 
5.4.3. Simultaneous binding 
To verify that simultaneous binding of both antigens to bsAbs is not sterically impaired, a bridging 
experimental setup was selected for BLI. In brief, biotinylated c-MET was captured on streptavidin 
biosensors which were subsequently quenched with biocytin and milk powder to prevent unspecific 
binding to biosensor tips. Then, bsAbs were associated followed by addition of EGFR. Exemplary graphs 
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for the last two association steps are depicted in Figure 17. Due to the smaller size of EGFR ECD (69 kDa) 
compared to the bispecific antibody (~125 kDa), the shift for the association of EGFR ECD is half the 
size of the shift for the association of bsAb: In Figure 17A, addition of B10v5x225-H to biosensor tips 
results in shift of 0.4 nm and EGFR subsequently in 0.2 nm. For CS06x225-H the shift is 0.2 nm and 
followed by EGFR with a shift of 0.1 nm (Figure 17B). That means that after association of bsAbs an 
equimolar amount of EGFR is associated. The second shift in interference pattern only represented EGFR 
association since the buffer control did not show any dissociation of bsAb. Addition of an unrelated 
isotype mAb (anti-HEL) and EGFR indicated no unspecific binding to streptavidin biosensors. As a 
consequence, the bsAbs are 100% functional and simultaneous binding of both antigens is sterically 
possible. 
 
Figure 17: Simultaneous binding of c-MET and EGFR by bsAbs demonstrated via BLI. 
Biotinylated c-MET was immobilized on streptavidin biosensors. Then, association of bsAbs B10v5x225-H (A) and CS06x225-H 
(B) followed by EGFR was monitored. For both association steps an interference pattern shift could be observed indicating 
simultaneous binding of both antigens by bsAbs. Controls with a non-related isotype antibody (anti-HEL) and EGFR indicated 
no unspecific binding to streptavidin biosensors. (C) Schematic representation of experimental set-up. 
 
 
5.4.4. Analysis of antibody stability 
5.4.4.1 Thermal shift assay 
Muda et al. already analyzed the biophysical and biochemical properties of the SEED format and 
demonstrated suitability of this technology for therapeutic approaches. (Muda et al., 2011) In order to 
evaluate the influence of binder combinations in the SEED format on bsAb stability, a differential 
scanning fluorimetry (DSF), which is also known as thermal shift assay (TSA), was performed. 
Accelerated thermal stability of proteins might also be an indicator for long-term stability during storage. 
During thermal denaturation of proteins, hydrophobic patches are exposed allowing attachment of a 
polarity-sensitive fluorescent dye, e.g. SYPRO orange. (Lo et al., 2004) In summary, all evaluated mAbs 
had a melting temperature (Tm) above 60°C (Table 8) which is considered as critical Tm for therapeutic 
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antibodies. (King et al, 2011) Immunoglobulins have slightly higher stability compared to artificial SEED 
molecules. (Muda et al., 2011) The Tm difference (∆Tm) of cetuximab (67.3°C) and CS06x225-H (62.2°C) 
accounted thereby 5.1°C. The raw data is summarized in the Appendix Figure 38. 
 
Table 8: Thermal stability of bsAbs in comparison to monovalent mAbs and cetuximab. 
Melting temperatures (Tm) of mAbs was measured by thermal shift assay using 1 µM protein with a 20 fold excess of the 
fluorescent dye SYPRO orange. Raw data are summarized in Figure 38 (Appendix). Means and standard deviations were 
calculated based on Tm of triplicates. oa = one-armed. 
 
Antibody Tm [°C] 
cetuximab 67.3 ± 0.172 
oa B10 65.7 ± 0.001 
oa C225-Fab 65.7 ± 0.001 
oa 225-M 65.2 ± 0.174 
oa CS06 64.9 ± 0.001 
oa F06 64.8 ± 0.172 
CS06x225-M 64.8 ± 0.126 
B10v5x225-M 64.5 ± 0.001 
oa B10v5 64.0 ± 0.172 
B10v5x225-H 62.8 ± 0.174 
oa 225-H 62.7 ± 0.001 
CS06x225-H 62.2 ± 0.172 
 
 
5.4.4.1 Long-term stability in human and mouse serum 
The bsAbs as well as cetuximab were incubated in human or mouse serum at 37°C for 24 days. Every 
two to three days, aliquots were immediately frozen and stored at -80°C. The concentration of bsAbs and 
cetuximab was normalized to 5 µg/ml. The stability of every sample to each time point was determined 
in triplicates by functional bridging ELISA using 100 ng immobilized EGFR and biotinylated c-MET as 
well as streptavidin-HRP conjugate for detection. Sera were not heat-inactivated before the experiment 
because no influence was shown (personal communication Merck, Darmstadt, Germany). Before the 
assay, mAb assay concentration were titrated in order to determine the linear range of the detection 
signal and to avoid signal saturation for each mAb individually. Cetuximab was detected with an anti-
human Fc-HRP conjugate. ELISA signals of aliquots from time point t=0 were considered as reference 
value for 100% functionality for each mAb. As depicted in Figure 18, calculated percent decrease in 
bsAb or cetuximab functionality was plotted against the time. Overall, the stability of mAbs in human 
and mouse serum demonstrated similar tendencies. After 24 days, the functionality of cetuximab was 
reduced to ~95%. For bsAbs with the 225-H variant, functionality was reduced to 85% on day 10 to 14 
and further dropped to 71-76% on day 24. 225-M containing bsAbs, already lost ~20% functionality on 
day 1 and decreased to 53-57% (for mouse serum) and 68-80% (for human serum) on day 24. Taken 
together, B10v5x225-M and CS06x225-M tended to be less stable in serum at 37°C compared to 225-H 
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bsAbs. Cetuximab IgG displayed the highest stability after 24 days again demonstrating higher stability 
of immunoglobulins in comparison to artificial SEED molecules. Given a standard half-life of IgGs of 20 
days (Brekke & Sandlie, 2003), all four bsAbs displayed suitable thermal stability in serum. 
 
Figure 18: Long-term stability of bsAbs in comparison to cetuximab in human (A) and mouse serum (B). 
100 ng EGFR were coated in microtiter plates. Cetuximab and bsAbs were incubated in human (A) and mouse (B) serum at 
37°C for 0 to 24 days as triplicates. Aliquots (t=0) which were immediately frozen at -80°C after antibody dilution in serum 
(5 µg/ml) served as 100% reference value for functionality of each mAb and reduction in functionality of later time points were 
calculated based on this value. BsAbs were detected with biotinylated c-MET ECD and streptavidin-HRP conjugate. Cetuximab 
binding was revealed by anti-human Fc antibody-HRP conjugate using standard ELISA detection methods. 
 
5.4.5. Cellular binding 
As described before, bsAbs displayed the desired kinetic characteristics with affinities ranging from two 
digit nanomolar to the sub-nanomolar affinities for their cognate targets (with exception of 225-L with 
1.1 µM affinity for soluble EGFR). The next step was to analyze whether binding of soluble protein can 
be translated into functional binding of cellular presented target protein. Therefore, binding of 100 nM 
bsAbs on several cancer cell lines was performed by flow cytometry (chapter 4.4.3). Cancer cell lines 
were chosen based on different receptor expression levels of c-MET and EGFR which were determined 
by receptor quantification using normalized cell numbers (chapter 5.1). An unrelated isotype control 
mAb (anti-HEL), unstained cells or cells only treated with secondary FITC-conjugated antibody served 
as controls to reveal the amount of cellular autofluorescence. Exemplary histograms for relative 
fluorescence intensities are depicted in Figure 19. BsAbs exhibited strong cellular binding to c-MET or 
EGFR overexpressing cell lines, e.g. c-MET amplified EBC-1 cells (Figure 19A) and EGFR overexpressing 
A431 cells (Figure 19C) comparable to respective monospecific reference binders oa CS06, oa B10v5 or 
cetuximab, respectively. For cell lines with nearly equal c-MET and EGFR expression, e.g. A549 and NCI-
H441 (chapter 5.1), bsAbs tended to bind stronger compared to corresponding anti-c-MET mAbs and 
anti-EGFR reference binders indicating cooperative and simultaneous engagement of both antigens on 
the cellular surface (Figure 19B, Figure 20).  
 5. Results  71 
 
Figure 19: Cellular binding of bsAbs and reference mAbs to several cancer cell lines. 
Cell lines were incubated with 100 nM mAb and binding was revealed with anti-human Fc antibody-FITC conjugate via flow 
cytometry (5,000 counts). (A) Both bsAbs and monovalent anti-c-MET antibodies displayed stronger binding to c-MET amplified 
EBC-1 cells with medium EGFR surface expression compared to cetuximab. (B) A549 cells present similar EGFR and c-MET 
levels on their surface and binding of bsAbs to A549 cells is slightly increased compared to monovalent anti-c-MET and anti-
EGFR mAbs. (C) For the EGFR overexpressing cell line A431 binding of bsAbs was comparable to cetuximab. (D) EGFR negative 
cell line SK-MEL2 did not show cetuximab binding, but anti-c-MET mAb and bsAbs displayed binding. (E) Due to slightly higher 
c-MET than EGFR expression of HepG2, bsAbs and anti-c-MET mAbs demonstrated stronger binding than cetuximab. (F) 
Binding to c-MET negative T47D cells by bsAbs and cetuximab could be observed, while no binding of oa B10v5 and oa CS06 
was observable. Note that for T47D only 30 nM mAbs and 20,000 counts were used. 
 
 
Figure 20: Cellular binding to NCI-H441 cells indicated simultaneous binding of bsAbs. 
NCI-H441 cells displayed similar EGFR and c-MET receptor surface expression levels. Cells were incubated with varying 
concentrations of antibodies (0.02-200 nM) and binding was revealed with anti-human Fc-FITC conjugate and flow cytometry. 
MFI values were plotted against the logarithm of antibody concentration. Means of duplicates and standard deviations were 
calculated. As a result, bsAbs bound stronger to NCI-H441 cells compared to monovalent anti-c-MET mAbs, oa B10v5 and oa 
CS06, as well as monovalent anti-EGFR mAb oa 225-H. No unspecific binding was observed with an unrelated isotype control 
(anti-HEL). EC50 values ranged from 0.3 to 1.1 nM for cellular binding of all mAbs. The experiment was confirmed in two 
independent experiments. 
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Table 9: Cellular binding of bsAbs to tumor cell lines with different expression levels in c-MET and EGFR. 
Binding of bsAbs and corresponding reference binders was analyzed via flow cytometry on several cancer cell lines. Mean 
fluorescence intensity (MFI) values were calculated by subtraction of fluorescence intensity of isotype control. In the table, MFI 
values for cells incubated with 100 nM mAb were summarized. Strong binding of bsAbs could be observed for cell lines with 
high c-MET and/or high EGFR expression (EBC-1, MKN45, A431). Medium to low binding was detected on A549 and HepG2 
cells displaying low c-MET and EGFR surface expression levels. For A549 cells, slightly stronger binding could be observed for 
bsAbs in comparison to monovalent mAbs. CHO-S cells served as a non-human cell line control. Antibodies which were tested 
for not being cross-reactive to mouse c-MET or EGFR, e.g. cetuximab, F06, and CS06, demonstrated no unspecific binding to 
CHO-S cells. However, rodent-cross-reactive oa B10 and oa B10v5 as well as bsAbs containing one of those two binders 
demonstrated slight binding to CHO-S cells. 
Color code: green = high MFI values / high binding, yellow = medium MFI values, red = low MFI values / no binding 
Legend: MFI = mean fluorescence intensity, n.d. = not determined, +++ = high expression (>105 receptors per cell), ++ = 
medium expression (103 receptors per cell < x <105 receptors per cell), + = low expression (>103 receptors per cell), - = no 
expression. Quantification of receptor densities was described in chapter 5.1. 
 
 EBC-1 MKN45 A431 A549 HepG2 CHO-S 
mAb 
c-MET+++ 
EGFR++ 
c-MET+++ 
EGFR++ 
c-MET+ 
EGFR+++ 
c-MET+ 
EGFR+ 
c-MET+    
EGFR+ 
c-MET -     
EGFR - 
B10x225-L 1.1E+03 1.2E+03 9.3E+02 1.8E+02 7.2E+01 3.0E+00 
B10x225-M 1.2E+03 1.8E+03 1.5E+03 5.6E+02 7.1E+01 2.3E+01 
B10x225-H 1.1E+03 1.3E+03 2.0E+03 4.5E+02 8.7E+01 3.3E+01 
B10x425 1.2E+03 1.3E+03 1.1E+03 2.6E+02 8.8E+01 5.0E+00 
F06x225-L 9.3E+02 1.2E+03 1.2E+03 2.1E+02 8.5E+01 1.5E+01 
F06x225-M 9.0E+02 1.2E+03 1.9E+03 n.d. 6.1E+01 1.0E+00 
F06x225-H 8.8E+02 1.2E+03 3.2E+03 2.9E+02 7.4E+01 2.0E+00 
F06x425 7.1E+02 1.2E+03 1.3E+03 2.6E+02 6.3E+01 9.0E+00 
B10v5x225-L 8.4E+02 1.2E+03 8.3E+02 2.4E+02 4.3E+02 1.2E+02 
B10v5x225-M 1.1E+03 1.3E+03 1.3E+03 3.7E+02 7.7E+02 2.7E+02 
B10v5x225-H 1.1E+03 1.3E+03 1.7E+03 3.3E+02 3.3E+02 8.3E+01 
B10v5x425 1.0E+03 1.3E+03 1.4E+03 3.2E+02 3.3E+02 9.8E+01 
CS06x225-L 1.2E+03 1.5E+03 8.7E+02 2.0E+02 2.3E+02 7.0E+00 
CS06x225-M 1.2E+03 1.5E+03 1.2E+03 2.6E+02 3.1E+02 3.0E+01 
CS06x225-H 1.1E+03 1.5E+03 1.8E+03 2.8E+02 1.8E+02 4.0E+00 
CS06x425 9.8E+02 1.4E+03 1.3E+03 2.6E+02 1.4E+02 1.0E+00 
oa 225-L 1.4E+02 7.4E+01 9.9E+02 8.1E+01 1.1E+01 3.0E+00 
oa225-M 2.7E+02 1.4E+02 1.1E+03 1.3E+02 2.4E+01 8.0E+00 
oa 225-H 6.3E+02 1.9E+02 1.7E+03 1.7E+02 3.7E+01 1.0E+00 
oa 425 2.4E+02 1.8E+02 8.6E+02 1.6E+02 4.3E+01 6.0E+00 
oa F06 1.1E+03 9.1E+02 3.1E+01 8.1E+01 1.5E+01 0.0E+00 
oa B10 1.3E+03 1.3E+03 9.4E+01 1.2E+02 5.6E+01 3.4E+01 
oa CS06 1.3E+03 1.5E+03 1.8E+01 1.4E+02 2.7E+02 1.0E+00 
oa B10v5 1.3E+03 1.5E+03 3.0E+01 1.5E+02 3.8E+02 7.7E+01 
 
For EGFR-negative SK-MEL2 cells, bsAbs, oa CS06 and oa B10v5 displayed binding while there was no 
binding detectable for EGFR-specific antibody cetuximab (Figure 19D). Vice versa, cetuximab and bsAbs 
bound to c-MET-negative T47D cells, while oa CS06 and oa B10v5 omitted binding (Figure 19F). Slight 
EGFR expression in HepG2 cells correlated with slight binding of cetuximab (Figure 19E). Data also 
indicated affinity dependent binding (Table 9). Affinity matured anti-c-MET binders (CS06 and B10v5) 
alone or in the bsAb format demonstrated higher MFI values compared to corresponding parental binders 
(F06 and B10). The same tendencies could be observed for the anti-EGFR binding moieties 225-L, 225-M, 
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225-H and 425: The higher the affinity of the binder, the stronger the cellular binding. In general, 
binding behavior of bsAbs could be correlated with the higher expressed target on the surface of cells. 
The CHO-S cell line with non-human origin was selected as negative cell line. For cetuximab, oa F06, oa 
CS06 as well as F06 or CS06 containing bsAbs, no unspecific binding to CHO-S was detectable (Table 
9). B10 and B10v5 containing monovalent mAbs and bsAbs indicated binding to CHO-S cells. This could 
be a result of cross-species-reactivity of B10 and B10v5 to rodent c-MET. Additionally, oa B10v5 did not 
bind to c-MET negative T47D cells excluding unspecific binding of the antibody. Taken together, bsAbs 
strongly bound to c-MET and EGFR overexpressing cell lines in an affinity dependent manner and with 
high specificity. 
 
5.4.6. Pharmacodynamics 
After confirming the capability of bsAbs to bind cellular bound target protein, functional analyses were 
conducted for bsAbs. The focus was laid on the proximal and distal receptor signaling including 
phosphorylation of c-MET, EGFR, AKT, and MAPK (chapter 2.3.3, Figure 4). For cetuximab and 
matuzumab, inhibition of EGFR phosphorylation were previously described by direct competition with 
ligand binding (Ferguson et al., 2003) and prevention of conformational rearrangements for receptor 
activation (Schmiedel et al., 2008), respectively. The presented study analyzed how kinetic variants and 
monovalency of the anti-EGFR and anti-c-MET binders in the bispecific format affect potency and efficacy 
for the inhibition of EGFR as well as c-MET signaling. For the analysis of the sixteen bsAbs produced by 
small scale production without further purification by preparative SEC, initial Western Blot experiments 
were conducted in HGF-dependent A549 cells and c-MET amplified EBC-1 cells. Briefly, cells were 
treated with 300 nM antibodies for 4 h before ligand stimulation and detection was carried out with 
antibodies directed against total and phosphorylated c-MET and EGFR as well as actin as a loading 
control (Appendix, Figure 39). BsAbs containing 225-M and 225-H efficiently inhibited EGFR 
phosphorylation comparable to cetuximab in A549 cells. In contrast, bsAbs with 225-L and 425 could 
not prevent EGFR phosphorylation completely. BsAbs with CS06 and F06 displayed highly efficient 
inhibition of c-MET phosphorylation in A549 cells while B10 and B10v5 containing bsAbs demonstrated 
medium efficiency for c-MET inactivation (Appendix, Figure 39). In c-MET amplified EBC-1 cells, which 
are not dependent on HGF stimulation, all bsAbs were not able to reduce c-MET phosphorylation. Only 
the reproduced anti-c-MET mAb DN-30 inducing ECD shedding resulted in a decreased total c-MET and 
phosphorylated MET signal. (Petrelli et al., 2006) However, a slight reduction in total c-MET signal 
intensities was observed under treatment with B10 or B10v5 containing bsAbs indicating c-MET 
degradation (Appendix, Figure 39). 
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For further functional analysis, the number of evaluated bsAbs was narrowed down to four based on 
their ability to inhibit phosphorylation of the respective receptor: B10v5x225-M, B10v5x225-H, 
CS06x225-M and CS06x225-H. In order to remove aggregates and/or homodimers which could interfere 
with cellular assays (Joubert et al, 2012), preparative SEC purification was conducted. Additionally, 
distal signaling including phosphorylation of AKT and MAPKP as well as potential synergistic effects 
mediated by bsAbs in comparison to the combination of monovalent mAbs were further analyzed (Figure 
21). Data presented in Figure 21A indicated that CS06x225-H inhibited c-MET phosphorylation in A549 
cells with higher efficiency compared to B10v5x225-H and reproduced LY2875358.  
 
Figure 21: Simultaneous inhibition of EGFR and c-MET phosphorylation by bsAbs affected downstream signaling. 
(A) After starvation, A549 cells were pre-incubated with 300 nM bsAbs and reference binders for three hours followed by 
stimulation with 100 ng/ml HGF and EGF and cell lysis. Cell lysates were subjected to SDS-PAGE and Western blotting. Signals 
were detected with antibodies directed against c-MET; phospho-c-MET (p-c-MET), EGFR, phospho-EGFR (p-EGFR), AKT, 
phospho-AKT (p-AKT), MAPK, phospho-MAPK (p-MAPK) and GAPDH as loading control. Treatment with bsAbs resulted in 
inhibition of c-MET and EGFR phosphorylation similar to respective reference antibodies (LY2875358 and cetuximab). 
Additionally, phosphorylation of AKT was prevented. (B) Serum starved A549 cells were treated with 500 nM mAbs or mAbs 
combinations for 1 h before stimulation with 100 ng/ml HGF and EGF. Cell lysates were subjected to MSD-assay analyzing AKT 
phosphorylation. p=phosphorylated 
 
Furthermore, the two latter mAbs induced slight c-MET activation in absence of ligand stimulation 
potentially indicating partial agonism which was described for LY2875358. (Liu et al., 2014) Cetuximab 
and the unrelated isotype control, anti-HEL, did not affect c-MET phosphorylation in comparison to HGF-
stimulated A549 cells. No significant changes for total c-MET and total EGFR levels were observable 
during 3 h treatment with 300 nM mAbs. The bsAbs containing the 225-H variant reduced EGFR 
phosphorylation similar to cetuximab while the anti-c-MET mAb LY2875358 as well as anti-HEL did not 
affect phospho-EGFR levels. While no significant changes were detectable for phospho-MAPK, bsAbs 
efficiently reduced AKT phosphorylation in contrast to cetuximab and LY2875358 which partly induced 
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AKT phosphorylation under non-stimulated conditions. To note, there were no observable increase in 
AKT phosphorylation in untreated cells or cells incubated with anti-HEL without stimulation. 
 
To further analyze AKT, EGFR and c-MET phosphorylation in a concentration dependent manner and to 
be able to compare IC50 values, electrochemiluminescence ELISA assays (MSD-assays) were conducted 
(Figure 21B, Figure 22-23). Treatment with 500 nM of mAbs or mAb combination revealed nearly 
complete reduction of AKT stimulation to levels of non-stimulated cells by CS06x225-H similar to the 
combination of cetuximab with reproduced oa 5D5. There is a slight increase in phospho-AKT level for 
the combination oa CS06 and oa 225-H. For the monovalent c-MET antibodies oa 5D5 and oa CS06, a 
reduction of AKT-phosphorylation of 24% and 42%, respectively, was detected when compared to 
stimulated A549 cells. Cetuximab in contrast slightly increased levels of phospho-AKT during stimulation 
with EGF and HGF similarly reported by Castoldi and colleagues. (Castoldi et al., 2013)  
 
 
Figure 22: Inhibition of c-MET phosphorylation by bsAbs. 
A549 (A), NCI-H596 (B), primary keratinocytes (NHEK.f-c., C), A431 (D) and MDA-MB-468 cells (E) were serum starved and 
treated with varying concentrations of bsAbs and reference anti-c-MET mAbs or anti-HEL mAb for 1 h followed by stimulation 
with 100 ng/ml HGF for 5 min and detection of phosphorylated c-MET by electrochemiluminescence (ECL) ELISA (MSD-assay). 
As controls, cells were stimulated or maintained non-stimulated without the incubation of antibodies. MSD signals were plotted 
against the logarithm of the antibody concentration and sigmoidal curve fitting was performed. CS06x225-M and –H inhibited 
c-MET phosphorylation more potently compared to oa 5D5 and LY2875358 in all five cell lines. 
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Figure 23: Inhibition of EGFR phosphorylation by bsAbs. 
A549 (A), NCI-H596 (B), primary keratinocytes (NHEK.f-c., C), A431 (D) and MDA-MB-468 cells (E) were serum starved. 
Afterwards, serial diluted bsAbs and reference anti-EGFR mAbs (cetuximab and oa 225-H) or alternatively anti-HEL were 
incubated for 1 h followed by stimulation with 100 ng/ml EGF for 5 min and detection of phosphorylated EGFR by 
electrochemiluminescence (ECL) ELISA (MSD-assay). As controls, cells were stimulated or maintained non-stimulated without 
the incubation with antibodies. MSD signals were plotted against the logarithm of the antibody concentration and sigmoidal 
curve fitting was performed. Inhibition of EGFR phosphorylation was dependent on the valence and affinity of the EGFR binder. 
Cetuximab (C225) displayed a higher potency and efficacy compared to oa 225-H and oa 225-M both in monospecific and 
bispecific format. 
 
Table 10: IC50 values for the inhibition of c-MET and EGFR phosphorylation by bsAbs. 
Based on three parameter curve fitting of MSD-signals plotted against the logarithm of antibody concentration, IC50 values were 
calculated with GraphPad Prism 5. The number of independent experiments with duplicates was indicated (n). n.d. = not 
determined; s.d. = standard deviation.  
 
Antibody Receptor 
A549 NHEK.f-c. 
 IC50 [nM] ± s.d. n  IC50 [nM] ± s.d. n 
CS06x225-H 
phospho-c-MET    0.3 ± 0.2 4    0.1 1 
phospho-EGFR    0.8 1    0.8 1 
B10v5x225-H 
phospho-c-MET    0.3 ± 0.2 2    0.2 1 
phospho-EGFR    1.1 ± 0.4 2    1.7 ± 0.3 2 
oa 5D5 phospho-c-MET    0.8 ± 0.5 4    0.7 1 
LY2875358 phospho-c-MET    1.0 ± 0.9 2    n.d. - 
cetuximab phospho-EGFR    0.4 ± 0.1 3    0.3 ± 0.2 2 
 
Regarding inhibition of c-MET phosphorylation, CS06x225-H and CS06x225-M displayed higher potency 
compared to oa 5D5 in primary keratinocytes, HGF-dependent A549 and NCI-H596 cells as well as in 
EGFR overexpressing A431 and MDA-MB-468 (Figure 22). B10v5x225-H and B10v5x225-M had a 
similar efficacy in inhibiting c-MET phosphorylation to LY2875358, but reduced efficacy compared to 
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CS06 bsAbs and oa 5D5 confirming the results by Western Blot. The corresponding IC50 values for A549 
and NHEK cells are summarized in Table 10. 
 
 
Figure 24: Potential synergistic effect of CS06x225-H (A) and B10v5x225-H induced c-MET degradation similar to 
LY2875358 (B). 
(A) A549 cells were treated with varying concentrations of mAb or mAb combination for 1 h and subsequently stimulated with 
100 ng/ml HGF. Cell lysates were subjected to MSD-assay detecting phosphorylated c-MET levels in duplicates. CS06x225-H 
displayed higher potency in inhibiting c-MET compared to the combination of monovalent oa CS06 and oa 225-H. Two 
independent experiments were performed in duplicates. (B) Overnight treatment of c-MET amplified MKN45 cells by 10, 100 
and 1000 nM mAbs. Degradation was calculated based on untreated cells serving as 100% c-MET levels. While anti-HEL mAb 
resulted in detrimental degradation, both LY2875358 and B10v5x225-H yielded in nearly 50% degradation. This is a 
representative graph of two independent experiments with duplicates. 
 
In the matter of c-MET inhibition, there were no significant differences between IC50 values for A549 
and primary keratinocytes. The inhibition of EGFR phosphorylation was dependent on the affinity and 
the valence of the antibody (Figure 23). The highest potency for EGFR inhibition in A549 cells was 
detected for cetuximab (IC50 = 0.4 nM), followed by 225-H bsAbs (IC50 value in the range of 1 nM, Table 
10) and 225-M bsAbs (IC50 > 25 nM, Figure 23). In summary, anti-EGFR potencies were independent 
of EGFR expression levels on several cell lines (chapter 5.1, Table 2). In contrast to c-MET, there was 
no synergistic effect detectable for the inhibition of EGFR phosphorylation mediated by bsAbs. For c-MET 
in contrast, a potential synergistic effect of c-MET and EGFR directed bsAb compared to monovalent oa 
CS06 or the combination of oa CS06 and oa 225-H could be observed, resulting in an increased potency 
by more than one log level (Figure 24A). Since B10v5 and the reproduced c-MET degrading antibody 
LY2875358 (Liu et al., 2014) target an overlapping epitope on the c-MET SEMA domain, this potential 
mode of action was further analyzed by MSD assays. For this, the incubation time was increased from 
4 h to 18 h as well as the antibody concentration was elevated up to 1 µM. To this end, B10v5x225-H 
resulted in similar c-MET degradation compared to LY2875358 at 100 nM and 1 µM after overnight 
treatment in c-MET amplified MKN45 cells up to 50%, (Figure 24B) in comparison to background 
degradation by a non-related isotype control antibody, anti-HEL, of 13%. 
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Figure 25: Analysis of potential c-MET agonism of bsAbs. 
(A) A549 cells were incubated with varying concentrations of mAbs without stimulation with HGF or EGF and cell lysates were 
analyzed by MSD-assay for phosphorylated c-MET. B10v5 containing bsAbs displayed similar partial agonism compared to 
LY2875358. Non-stimulated and HGF-stimulated A549 cells served as controls. (B) MKN45 cells were treated with 100 nM 
mAbs for 1 h and were either stimulated with 100 ng/ml HGF or remained unstimulated. Cell lysates were again subjected to 
MSD-assay to quantify phosphorylated c-MET. There was no significant difference between stimulated or non-stimulated 
samples. (C)+(D) A431 cells were treated with varying concentrations of mAbs for 1 h and cell lysates were analyzed for 
phosphorylated c-MET (C) or phosphorylated EGFR (D) by MSD-assay without respective ligand stimulation. 
 
Next, potential agonism of bsAbs was further analyzed in comparison to reproduced LY2875358 in a 
concentration dependent manner employing different cell lines. Due to close spatial proximity and 
interaction of c-MET and EGFR, which has already been demonstrated by co-immunoprecipitation (Jo 
et al., 2000), bsAbs directed against c-MET and EGFR could theoretically induce agonistic receptor 
activation by heterodimerization. As depicted in Figure 25A, A549 cells incubated with LY2875358, 
B10v5x225-H and B10v5x225-M without HGF stimulation displayed an increase of c-MET 
phosphorylation by 35-48%. A549 cells stimulated with 100 ng/ml HGF thereby served as 100% control. 
In contrast, monovalent oa B10v5 did not increase c-MET phosphorylation. While no agonistic behavior 
was detectable in c-MET amplified MKN45 cells (Figure 25B), B10v5 containing bsAbs and LY2875358 
displayed comparable agonistic behavior in A431 cells (Figure 25C) to A549 cells. However, none of 
the tested bsAbs activated EGFR in an agonistic manner (Figure 25D). Additionally, the capability of 
bsAbs to induce ADCC was confirmed (cf. Appendix, Figure 40). 
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5.4.7. Selectivity 
Basal EGFR expression in normal tissue, in particular in keratinocytes, can give rise to off-tumor toxicities 
via inhibition of EGFR signaling by antagonistic mAbs, e.g. cetuximab. (Lacouture, 2006; Melosky et al., 
2009) This in turn can lead to severe clinical adverse events during anti-EGFR therapy and negatively 
influences patient’s compliance. To evaluate the impact of affinity variants in the bispecific format on 
tumor selectivity in comparison to cetuximab, a cell mixing experiment was conducted via flow 
cytometry based on results presented by Robinson and co-workers (Robinson et al., 2008). For this, a 
tumor model cell population with high c-MET and EGFR surface expression, e.g. EBC-1 cells, was stained 
with a green fluorescent membrane dye and mixed in a ratio 1:30 with a non-stained, normal tissue 
model cell population displaying basal EGFR expressing and being devoid of c-MET expression, e.g. 
T47D cells (chapter 5.1, Table 2). The membrane dye served thereby for distinction of the two cell 
populations during flow cytometry and the cell mixing ratio of 1:30 was selected based on data presented 
by Robinson and co-workers (Robinson et al., 2008). Subsequently, the cell mixture was incubated with 
3 or 30 nM mAbs and antibody binding was revealed with anti-human Fc PE-conjugates. For 
quantification, the in vitro selectivity was defined as the ratio of tumor to normal tissue model cellular 
binding, e.g. MFI of EBC-1 cells divided by MFI of T47D cells. Taken together, all bsAbs displayed higher 
selectivity compared to cetuximab (Figure 26A). Representative dot plots for green versus yellow 
relative fluorescence intensities are depicted in Figure 26B. In the upper quadrants represent mAb 
binding to EBC-1. While control cells only labeled with detection antibody displayed background 
fluorescence, there is a shift in fluorescence for cetuximab incubated EBC-1 cells. BsAbs thereby bound 
stronger to EBC-1 cells compared to cetuximab. The lower quadrants contain the unstained T47D cell 
population. Again, there is only background fluorescence for control cells. The low affinity variants 
B10v5x225-L and CS06x225-L displayed less binding to T47D cells compared to cetuximab and the high 
affinity hu225 variants in the bispecific format. 
 
Based on the calculated selectivity as the ratio of MFIs for binding to EBC-1 versus binding to T47D cells, 
B10v5x225-L displayed a 23-fold and B10v5x225-M still a 5-fold increased selectivity compared to 
cetuximab (cf. Figure 26A). BsAbs with CS06 as anti-c-MET binder even further increased the tumor 
selectivity. Selectivity measured in this way was proportional to higher off rates or lower affinities of the 
EGFR binding moiety. The selectivity assay was conducted also for other cell line combinations (cf. 
Appendix, Table 13). Similar results were obtained for MKN45 and A431 cells when mixed with T47D 
cells. When HepG2 with low EGFR expression and slightly higher c-MET expression were used as normal 
tissue model cell line, bsAbs displayed still 2-fold higher selectivity to EBC-1 cells. However, the cell 
combination consisting of the EGFR overexpressing cell line A431 and HepG2 cells, cetuximab displayed 
higher selectivity compared to bsAbs due to the slightly higher c-MET expression in HepG2 cells. 
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Figure 26: In vitro selectivity of bsAbs in comparison to cetuximab. 
EBC-1 cells served as tumor model cell line with high to moderate expression in c-MET and EGFR while T47D cells were used 
as normal tissue model mimicking basal EGFR expression and no c-MET expression in normal tissue. In order to distinguish 
both cell populations during the mixing experiment, EBC-1 cells were stained with a green fluorescent membrane dye, while 
T47D cells remained unstained. Cells were mixed in a ratio of 1:30 for tumor to normal model cells and subsequently incubated 
with 30 nM mAbs. Antibody binding was revealed with anti-human Fc PE-conjugates and detection was carried out via flow 
cytometry. For each cell population, MFIs were calculated and the ratio of the MFI of EBC-1 cells and the one of T47D was 
defined as in vitro selectivity (A). As a result, the lower the affinity of the EGFR binder, the higher the selectivity towards the 
tumor model cell line. Representative dot plots with green vs. yellow relative fluorescence intensity are depicted in (B). 
 
In summary, c-MET x EGFR bsAbs displayed higher selectivity towards tumor model cells in comparison 
to cetuximab when the normal model cell line displays basal EGFR expression and is negative for c-MET 
expression. The selectivity was thereby dependent on the affinity of the EGFR binding moiety. 
 
5.4.8. Internalization 
Cetuximab is known to induce EGFR internalization either by clathrin-dependent or independent 
mechanisms. (Gostring et al., 2010; Prewett et al, 1996) In general, ligand binding to EGFR, e.g. by EGF, 
induces vesicle budding from the surface and transport to endosomes from where the receptor becomes 
recycled back to the surface or alternatively becomes processed in late endosomes or multivesicular 
bodies and finally degraded in lysosomes. (Gostring et al., 2010) For the c-MET targeting antibody 
LY2875358, receptor degradation is described via internalization. (Liu et al., 2014)  
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Figure 27: Internalization of bsAbs measured by confocal microscopy (A) and flow cytometry (B). 
(A) For confocal microscopy, EBC-1 cells were plated on cover slides and incubated with 100 nM CS06x225-H and subsequently 
with anti-human Fc-AlexaFluor488 conjugate (green). This was followed by 1 h in cell specific medium at 37°C allowing 
internalization or at 4°C preventing internalization. Residual surface staining was removed by acidic washing. Detection was 
carried out by confocal microscopy. Cell nuclei were stained with DAPI (blue). Cells incubated at 37°C clearly indicated 
internalized antibody in vesicles. Scale bar = 100 µm. (B) Flow cytometric analysis of internalization was carried out by 
incubation of cells (NCI-H441 and MDA-MB-468) with 100 nM antibodies followed by addition of secondary antibody fragment 
anti-human Fc AlexaFluor488 conjugate. Afterwards, cells were either incubation for 1 h at 37°C allowing internalization or at 
4°C preventing internalization. Residual surface binding was quenched with an antibody directed against AlexaFluor488. 
Internalization in percent was calculated as described in chapter 4.4.3 by comparing MFI of cells incubated at 37°C and those 
at 4°C. Non-quenched cells served thereby as control for total fluorescence. For instance, bsAbs displayed similar internalization 
as cetuximab (red). 
 
A qualitative proof of internalization was evaluated for all bsAbs. Employing confocal microscopy and 
pH stripping of cell surface bound bsAbs, internalization of fluorescently labelled CS06x225-H as a 
representative could be detected in EBC-1 cells at 37°C whereas no internalization was observable at 4°C 
(Figure 27A). As an alternative, a flow cytometric assay was conducted applying an anti-Alexa 488 
quenching antibody for elimination of residual surface staining of non-internalized antibodies. (Gostring 
et al., 2010) Representative data for bsAbs incubated at either 4°C or 37°C with and without quenching 
antibody on NCI-H441 cells were depicted in the Appendix (Figure 41). The percent internalization was 
calculated by the difference of quenched samples at 37°C and 4°C and normalized by unquenched 
samples as indicated by the formula listed in chapter 4.4.3. The results for NCI-H441 and MDA-MB-468 
are presented in Figure 27B and qualitatively confirmed the bsAbs’ ability to induce internalization.  
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5.5. Characterization of bispecific antibody-drug conjugates (ADCs) 
Given the confirmed improved tumor selectivity by affinity attenuated variants in the bispecific format 
and the capability to induce strong internalization, the herein presented bsAbs fulfill the prerequisites 
for the potential application as ADCs targeting two ubiquitously expressed cancer targets. Via 
conjugation of a highly cytotoxic agent, the potency of the bispecific targeting could be increased while 
potentially retaining the tumor selectivity. 
 
5.5.1. ADC generation 
For the generation of ADCs, monomethyl auristatin E (MMAE, cf. chapter  2.2.4, Figure 3C) was 
conjugated to a genetically C-terminally introduced recognition sequence LPETGS to both SEED heavy 
chains (AG and GA) via the sortase A reaction (cf. chapter 3.7) (Dickgiesser et al., 2015) resulting in a 
drug-to-antibody-ratio (DAR) of 2. An exemplary reaction scheme was depicted in the introduction (cf. 
chapter 2.2.4, Figure 3B). The tubulin polymerization inhibitor MMAE, which is currently evaluated in 
various clinical studies as ADC payload (Leal et al, 2014; Mullard, 2013), has been selected due to its 
selectivity for fast dividing cells. Thus, a second layer of selectivity was added via the choice of the toxin. 
The vc-linker can be cleaved by lysosomal proteases (Ritchie et al., 2013) restricting the toxin release to 
the intracellular compartment. As reference constructs, cetuximab and anti-HEL-IgG were analogously 
conjugated with GGG-vc-MMAE via sortase A mediated conjugation (cf. chapter 2.2.4 Figure 3B; 
generated ADCs were kindly provided by Merck, Darmstadt, Germany). After conjugation and 
purification of ADCs, DAR=2 could be confirmed by MALDI-TOF-MS (Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry, kindly provided by Merck, Darmstadt, Germany) 
of bispecific ADCs in comparison to respective unconjugated bsAb carrying the sortase A recognition site 
(cf. Appendix, Figure 42). The theoretical increase of molecular weight for the linker-toxin conjugation 
amounts 1133 Da per chain. For both CS06x225-H and B10v5x225-H the molecular weight shift was 
slightly smaller with 1063 and 922 Da per chain, respectively, confirming the DAR of 2. Furthermore, 
kinetic characteristics and cellular binding did not alter after C-terminal MMAE-conjugation (data not 
shown). 
 
5.5.2. Cytotoxicity of bispecific ADCs 
In order to functionally evaluate the generated bispecific ADCs, varying concentrations of ADCs were 
incubated for 72 h on cancer cells with mutual c-MET and EGFR expression, on a hepatocellular 
carcinoma cell line (HepG2) as liver model as well as on primary keratinocytes (NHEK.f-c., normal 
human epidermal keratinocytes, chapter 3.1) as a normal skin model cell. This was followed by the 
determination of cell viability using the ATP-based luminescent assay CellTiter-Glo® (cf. chapter 4.4.6). 
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Figure 28: Cytotoxicity of bispecific ADCs on cancer cell lines, liver cells and primary keratinocytes. 
Bispecific ADCs generated by enzyme-mediated, site-directed conjugation of vc-MMAE to both heavy chains were incubated on 
EGFR overexpressing MDA-MB-468 (A) and A431 cells (B), on c-MET amplified EBC-1 (D) and MKN45 (E) cells, primary 
keratinocytes (NHEK, C) as epithelial cell model as well as the hepatocellular carcinoma cell line HepG2 (F) as liver cell model 
for 72 h. Viability of cells was detected with the CellTiter-Glo assay. While on either EGFR or c-MET overexpressing cells, high 
cytotoxicity could be detected for bispecific ADCs (IC50 values in the nanomolar to subnanomolar range), reduced toxicity could 
be observed in primary keratinocytes. In HepG2 cells, only slight reduced viability could be measured at high ADC 
concentrations and no IC50 values could be calculated. Shown are exemplary graphs from at least three independent 
experiments. 
 
In EGFR overexpressing MDA-MB-468 and A431 cells (Figure 28A and B, respectively), bispecific ADCs 
reduced viability about 80-90% with IC50 values in the nanomolar to subnanomolar range comparable 
to cetuximab-vc-MMAE. In keratinocytes in contrast, cytotoxicity was dependent on the affinity and 
valence of the anti-EGFR binder with bivalent cetuximab-vc-MMAE having the lowest IC50 value followed 
by B10v5/CS06x225-H-vc-MMAE and then by bispecific ADCs containing the binding moiety 225-M 
(Figure 28C). At the highest ADC concentration, a reduction of cell viability by 30-40% could be 
observed. In c-MET amplified EBC-1 and MKN45 cells (Figure 28D and E, respectively), bispecific ADCs 
demonstrated ~ 60% efficacy, whereas cetuximab-vc-MMAE only slightly reduced cell viability despite 
confirmed medium EGFR expression in both cell lines (cf. Table 2). The low affinity anti-c-MET binder 
B10 in the bispecific ADC format showed reduced potencies compared to the affinity maturated variants 
CS06 and B10v5. In another c-MET amplified cell line, HCC-827, however cetuximab-vc-MMAE and 
bispecific ADCs comparably reduced cell viability (Appendix, Figure 43C). In HepG2 cells, no or only 
low cytotoxic effects could be observed in the evaluated concentration range up to 50 nM ADC (Figure 
28F). In all tested cell lines, a non-related isotype control ADC, anti-HEL-vc-MMAE, did not indicate a 
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significant reduction in cell viability. For cells with low to medium c-MET and EGFR expression, e.g. 
A549, NCI-H1975, NCI-H596 and KP-4 cells (cf. Table 2), potency and efficacy in cell killing were similar 
and both deteriorated in comparison to EGFR and c-MET overexpressing cell lines (cf. Appendix, Figure 
43). In contrast, bispecific ADCs and cetuximab as ADC did not induce cytotoxicity in NCI-H441 cells 
(cf. Appendix, Figure 43F). 
 
 
Figure 29: Cytotoxicity of bsAbs and cetuximab on cancer cell lines, liver cells and primary keratinocytes. 
BsAbs without conjugated toxin were incubated in varying concentrations on cancer cell lines as well as normal tissue models 
for 72 h and cell viability was determined with the CellTiter-Glo® assay. Affinity and valence dependent reduction of cell 
viability could be observed in parts in MDA-MB-468 cells (A), A431 (B), and primary keratinocytes (C). No cytotoxic effects 
could be detected for c-MET amplified EBC-1 (D), MKN45 (E) and A549 cells (F). 
 
To evaluate the influence of the inhibition mode targeting EGFR and c-MET on cell viability, cytotoxicity 
assays were conducted with unconjugated bsAbs analogously (Figure 29). Expression levels of the 
higher prevalent target, EGFR or c-MET, could thereby be correlated to responsiveness of bispecific 
ADCs. While viability of high c-MET/EGFR expressing cell lines were potently reduced, lower expression 
levels led to weaker responses (Figure 29A, B, and F). Potency and efficacy in cell killing of cetuximab 
and bsAbs were similar in primary keratinocytes when compared to the corresponding ADCs (Figure 
29C and 28C). Since the cultured primary keratinocytes displayed slower cell division rates in 
comparison to the other analyzed cancer cell lines, the incubation time was elongated from 72 h to 6 
days. The efficacy in reducing cell viability was thereby increased from 30% to 90% (Figure 30), whereas 
potencies did not significantly alter and were again comparable for ADCs and respective mAbs without 
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toxin. Once more, efficacies were dependent on the valence and the affinity of the EGFR binder 
(cetuximab < 225-H < 225-M). 
 
 
Figure 30: Cytotoxicity of bispecific ADCs and bsAbs without toxin on primary keratinocytes. 
Due to the slower cell division rate of primary keratinocytes in comparison to other herein evaluated cancer cell lines, the 
incubation time of bispecific ADCs (left) or bsAbs (right) was increased to six days before determining the cell viability. As a 
result, the efficacy for cell killing was increased in comparison to 72 h incubation, whereas the potency did not change 
significantly. IC50 values were dependent on the valence and affinity of the anti-EGFR binding moiety. 
 
Taken together, bispecific c-MET x EGFR ADCs displayed comparable efficacies in EGFR overexpressing 
cell lines, superior potencies in c-MET amplified cell lines and reduced cytotoxicity in primary 
keratinocytes as normal tissue model in comparison to cetuximab-vc-MMAE while no strong cytotoxic 
effects were observable in the hepatocellular carcinoma cell line HepG2 cells as a liver cell model. 
 
5.5.3. In vitro therapeutic index 
ADCs in general hold the potential to broaden the therapeutic window due to selective delivery of the 
cytotoxic compound to the tumor. (Muller & Milton, 2012; Panowski et al., 2014) Comparison of 
increased or similar potency in tumor cells and reduced toxicity in keratinocytes indicated a potentially 
broadened translational in vitro therapeutic window. To visualize and quantify a translational in vitro 
therapeutic index, graphs representing the six above analyzed cell lines for each molecule (Figure 31), 
comparison of calculated EC50 and IC50 values were conducted and minimum effective doses (MED, ED80) 
as well as maximum tolerated doses (MTD, TD20) values were determined on the bases of in vitro results 
presented within this study. Visual evaluation of Figure 31 indicated that the potency of bispecific ADCS 
was slightly reduced in comparison to cetuximab-vc-MMAE whereas both the potency and the efficacy 
were reduced by bispecific ADCs in comparison to cetuximab-ADC in primary keratinocytes. As a next 
step, quantification of a translational in vitro therapeutic index was envisioned. However, definitions 
and analysis of an in vitro therapeutic index can be rarely found in the literature because for most 
developed drugs in vivo studies have been conducted. Nevertheless, early safety assessment in the early 
drug development process is critical and animal experiments should be minimized due to ethical issues, 
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in particular when the targeting of tumor associated antigens with basal expression in normal tissue is 
aimed with an ADC approach. Usually either the difference or the ratio in dose-response curves was 
accounted for the calculation of the therapeutic window. (Muller & Milton, 2012; Panowski et al., 2014) 
Within this, either the half maximal inhibitory/effective concentrations in keratinocytes/cancer cells 
were applied or the maximal toxic dose (MTD) with the minimal effective dose (MED). For the latter we 
used TD20 and ED80 instead of the usually found TD10 and ED90 in literature because ADCs maximal 
resulted in around 90% cell killing in A431 and around 30-40% in keratinocytes (Table 11). 
 
 
Figure 31: Cytotoxicities grouped by ADC. 
Based on data presented in Figure 28, cell viability of the four ADCs based on the bsAbs B10v5x225-H (A), B10v5x225-M (B) 
and B10x225-M (C) as well as the mAb cetuximab (D) was plotted against the logarithm of ADC concentration for two EGFR 
overexpressing cell lines (A431, MDA-MB-468), two c-MET amplified cell lines (EBC-1, MKN45) and two normal tissue model 
cell lines (NHEK, HepG2). While in EGFR-overexpressing cells bispecific ADCs displayed similar potency when compared to 
cetuximab-vc-MMAE, bispecific ADCs had reduced toxicity in primary keratinocytes (NHEK.f-c.) dependent on the affinity of 
the EGFR binding moiety. 
 
In summary, the following two equations were used to calculate the therapeutic index (Equation 1 and 
2) and results were summarized in Table 11. Since for keratinocytes (NHEK.f-c.), the bispecific ADCs 
B10v5x225-M-vc-MMAE and B10x225-M-vc-MMAE (with medium affinity 225-M variant) did not reach 
a plateau at high ADC concentrations, the IC50 calculations for those two molecules were assumed to be 
a raw estimate only. Note, that equation 1 resulted in a stricter therapeutic window in comparison to 
equation 2. 
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Equation 1: 
𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐 𝑖𝑛𝑑𝑒𝑥 (1) =  
𝑇𝐷20
𝐸𝐷80
 
   TD20: toxic dose in keratinocytes (NHEK.f-c.) resulting in 20% reduced viability 
   ED80: effective dose in cancer cells, e.g. A431, resulting in 80% reduced viability 
 
Equation 2: 
𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐 𝑖𝑛𝑑𝑒𝑥 (2) =  𝐼𝐶50 − 𝐸𝐶50 
   IC50: half maximal inhibitory concentration in keratinocytes (NHEK.f-c.) 
   EC50: half maximal effective concentration in cancer cells, e.g. A431 
 
Table 11: Calculation of in vitro therapeutic window. 
Based on data presented in Figure 28, the effective dose resulting 80% cell killing (ED80) and the half maximal effective 
concentration (EC50) were calculated for the cancer cell line A431. For normal tissue model, the primary keratinocytes (NHEK.f-
c.), the toxic dose resulting in 20% cell killing (TD20) and the half maximal inhibitory concentration (IC50) were determined. 
Additionally, for both cell lines the percent cell killing at 50 nM ADC were listed. The number of independent experiments with 
duplicates was also indicated (n). Based on the equations 1 and 2, two translational in vitro therapeutic indices were calculated. 
As a result, the therapeutic window was increased by B10v5x225-M-vc-MMAE in comparison to cetuximab-vc-MMAE by the 
factor 5-6 or alternatively by 18-28, respectively. Asterisks (*) indicated estimated values as sigmoidal curves did not reached 
a plateau at high concentrations. 
 
Antibody 
A431 NHEK.f-c. 
Therapeutic 
window 
ED80 
[nM] 
EC50 
[nM] 
% cell 
killing at 
50 nM 
n 
TD20 
[nM] 
IC50 
[nM] 
% cell 
killing at 
50 nM 
n 
TD20/ 
ED80 
IC50-
EC50 
[nM] 
B10v5x225-
H-vc-MMAE 
2.1 ± 0.7 0.4 ± 0.1 93 ± 1.3 5 3.7 ± 1.1 5.9 ± 2.9 37 ± 12 5 2 5.6 
B10v5x225-
M-vc-MMAE 
4.4 ± 1.0 1.0 ± 0.3 91 ± 0.4 3 25 ± 8 >19* 30 ± 9 3 6 >28* 
B10x225-M-
vc-MMAE 
3.6 ± 0.9 0.7 ± 0.2 90 ± 0.5 3 19 ± 8 >20* 27 ± 11 3 5 >19* 
cetuximab-
vc-MMAE 
0.7 ± 0.3 0.1 ± 0.04 92  ± 1.4 5 0.8 ± 0.5 1.0 ± 0.5 34 ± 10 5 1 0.9 
 
Taken together, bispecificity and in consequence monovalency of the EGFR binding moiety in 
B10v5x225-H-vc-MMAE resulted in a two-fold increased therapeutic index in comparison to cetuximab-
vc-MMAE based on equation 1 or an at least six-fold increase from 0.9 nM to 5.6 nM according to 
equation 2. For bispecific ADCs composed of the medium affinity 255-M variant, only equation 2 
yielded in reliable results since sigmoidal response curves for NHEKs did not reach a plateau at higher 
concentrations and in consequence the calculation of IC50 values was inaccurate. Both B10v5x225-M and 
B10x225-M as an ADC conjugated with vc-MMAE increased the translational in vitro therapeutic window 
by the factor five to six. 
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6. Discussion 
 
6.1. EGFR and c-MET as cancer targets 
The involvement of EGFR and c-MET in the development and progression of cancer has been 
independently identified in the 1980s (Cooper et al., 1984; Downward et al., 1984) and both are 
associated with tumor aggressiveness and unfavorable survival outcomes. (Nicholson et al., 2001; Sierra 
& Tsao, 2011) (Nicholson et al., 2001; Sierra & Tsao, 2011) In the present study, the mutual 
overexpression of both RTKs has been confirmed in several cancer cell lines derived from different 
indications via quantification of cellular receptor surface levels (cf. Table 2). This included confirmation 
of high EGFR expression in A431 and MDA-MB-468 cells as well as elevated c-MET surface expression 
levels in c-MET amplified MKN45 and EBC-1 cells. Dual expression and redundant signaling of c-MET 
and EGFR via MAPK and AKT pathways have been described (Guo et al., 2008) leading to the 
propagation of pro-survival signals. Despite initial clinical successes, receptor interaction and crosstalk 
(Engelman et al., 2007; Jo et al., 2000) led therefore to the emergence of acquired resistance rendering 
monotherapies ineffective. One major resistance mechanism during EGFR inhibition by gefitinib involves 
the amplification of c-MET via activation of ErbB3 signaling. (Bean et al., 2007; Engelman et al., 2007) 
As a consequence, several combinatory treatment approaches are currently under clinical investigation 
including the dual application of anti-c-MET and anti-EGFR small molecule inhibitors and/or antibodies. 
(Prat et al., 2014; Sharma & Adjei, 2011; Sierra & Tsao, 2011; Yewale et al., 2013) Another factor 
influencing the efficacy of anti-c-MET antibodies are high HGF levels in the tumor microenvironment 
which can also counteract the efficacy of EGFR inhibition. (Straussman et al., 2012; Wang et al., 2009) 
Considering the interaction of both receptors, bispecific targeting of c-MET and EGFR could lead to 
synergistic effects and counteract c-MET mediated resistance mechanisms. Several pharmaceutical 
companies invested in the development of bsAbs directed against c-MET and EGFR and in parts entered 
clinical investigation. (Castoldi et al., 2012; Castoldi et al., 2013; Garber, 2014; Jarantow et al., 2015; 
Lee et al., 2016a; Lee et al., 2016b; Lewis et al., 2014; Spiess et al., 2013) However, clinical findings 
underscore the importance of tumor-selective targeting as inhibition of basally expressed EGFR in normal 
tissue can lead to severe skin toxicities negatively influencing patient compliance. (Lacouture, 2006; 
Melosky et al., 2009) Especially in combinatory treatment approaches, there is the risk of additive side 
effects for the combination of multiple single agents. Consequently, the right balance between high anti-
tumor efficacy and high tumor selectivity plays a pivotal role for a cancer drug’s safety profile. The 
combination of bsAbs with affinity-optimized binding moieties hold the potential to increase the 
selectivity to mutual overexpressing tumor cells via avidity while concurrently reducing binding to 
normal tissue. (Mazor et al., 2015b; Robinson et al., 2008) Thus, bsAbs with engineered affinities could 
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demonstrate high therapeutic benefit via dual inhibition of both RTKs on tumor cells which could also 
play a pivotal role in counteracting c-MET driven resistance mechanisms during anti-EGFR monotherapy. 
 
6.2. Characterization of single antibody binding moieties 
One part of this study comprised the generation of a broad panel of anti-c-MET variants with different 
affinities to their target by Fab-phage display and comprehensive functional characterization before the 
evaluation in the bispecific format. Randomization of the variable domain of the heavy chain resulted in 
increased affinity to soluble c-MET ECD with KD-values in the subnanomolar range in comparison to 
double digit affinity of the parental binder (cf. Figure 8 and 9). Epitope binning experiments revealed 
that affinity maturation of parental anti-c-MET binder F06 and B10 to CS06 and B10v5, respectively, did 
not alter the epitope or target specificity (cf. Figure 11 and Table 3). This experiment also indicated 
overlapping epitopes of B10/B10v5 with LY2875358 (Liu et al., 2014) on SEMA blade 2/3 and of 
F06/CS06 with h224G11 (Goetsch et al., 2010; Wang et al, 2016) within the IPT1 domain of the c-MET 
stalk. (Basilico et al., 2014; Prat et al., 2014) As assumed, the presence of the SNP N375S within the 
SEMA-β-chain did not influence binding of anti-c-MET antibodies to soluble mutated c-MET (cf. Figure 
12). Thus, this SNP variant did not constrain possible patient stratification strategy. Moreover, all 
evaluated anti-c-MET binders displayed competition with HGF binding to c-MET ECD (cf. Figure 10). 
Whether the displacement of HGF is based on direct competition of the HGF binding sites or mediated 
by sterical hindrance needs further analysis of their molecular features. Based on the literature, the low 
affinity binding site of HGF is located within the SEMA domain. The location of the high affinity binding 
epitope is controversially discussed: Basilico and colleagues hypothesizes binding to the IPT region 
(Basilico et al., 2008), while others assumed binding within the SEMA domain (Gherardi et al., 2003; 
Stamos et al., 2004). As a consequence, F06/CS06 either directly or sterically impair binding of HGF to 
c-MET ECD. 
 
It could be hypothesized that similar epitopes could correlate with comparable functionality and mode 
of action highlighting the importance of epitope binning studies. Pharmaceutical relevant characteristics 
of anti-c-MET binders include the ability to compete with HGF binding, murine cross-reactivity, agonism 
in the bivalent format as well as the mediation of receptor degradation. Both B10 and LY2875358 
displayed cross-reactivity to murine c-MET (Liu et al., 2014) whereas both F06 and h224G11 did not 
(Goetsch et al., 2010; Wang et al., 2016) (personal communication Merck, Darmstadt, Germany). 
Furthermore, B10v5 demonstrated partial agonistic activation of c-MET in the bispecific format in 
absecence of ligand stimulation comparable to LY2875358 (cf. Figure 25) in contrast to CS06 as bsAb 
and bivalent h224G11 (Goetsch et al., 2010; Wang et al., 2016). These results corroborate the notion 
that B10v5 and LY2875358 might have the same mode of action via the induction of receptor 
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degradation. Indeed, B10v5x225-H demonstrated c-MET degradation similarily to LY2875358 in the 
c-MET amplified cell line MKN45 (cf. Figure 24B). For c-MET monotherapy approaches, biparatopic 
approaches combining binders targeting distinct epitopes on the same target could also be considered in 
order to improve the efficacy of c-MET inhibition. This was elegantly evaluated by Basilico and co-
workers for combination of anti-SEMA binders with anti-IPT binders. (Basilico et al., 2014) However, 
the presented study focused on the evaluation and characterization of bsAbs directed against c-MET and 
EGFR. Thus, further analysis of monospecific and biparatopic anti-c-MET targeting approaches was not 
in the scope of this work. 
 
6.3. Manufacturability of bispecific c-MET x EGFR antibodies 
All evaluated bsAbs displayed suitable manufacturability (cf. Table 5 and 6) comparable to results 
presented by Muda et al. and Davis et al. fulfilling the requirements for therapeutic application. (Davis 
et al., 2010; Muda et al., 2011) Over >95% purity of correctly assembled bispecific heterodimer was 
achieved after preparative SEC purification for all four final bispecific constructs chosen for further 
evaluation (B10v5x225-M and -H as well as CS06x225-M and –H, cf. Table 6). In order to ensure 
cognate light chain pairing, the anti-EGFR binder was designed as scFv fragment. Some technologies for 
correct light chain pairing, e.g. common light or heavy chain (Fischer et al., 2015), Fab-interface 
engineering (Lewis et al., 2014), and the CrossMab technology (Schaefer et al., 2011b) may not be 
generically applicable to already existing binders or might be associated with extensive engineering 
efforts. Given the link of structure-function knowledge of c-MET and EGFR interaction and the 
complexity of this signaling system, an empirical approach combining several epitopes and off-rates was 
chosen over in silico predictions to develop an optimized c-MET x EGFR targeting bsAb. For this, the use 
of the herein presented modular toolbox approach employing scFv technology together with the SEED-
technology enabled facile screening of multiple binder combination expressed in the bispecific format. 
However, the use of scFv fragments can be associated with instability in comparison to Fab antibody 
fragments (Kramer et al, 2002) and may also require additional stability enhancing engineering (Lee et 
al., 2016b). The presented data indicated that kinetic features of binding moieties did not alter for mono- 
to bispecific formats as illustrated in Figure 16. High thermal stabilities, with melting temperatures of 
62-68°C and long-term stability at elevated temperatures in human and mouse serum (cf. Table 8 and 
Figure 18) assessed via dual target engagement ELISA, indicated suitable physicochemical properties 
for the developability of the presented bsAbs. 
 
One essential feature of bsAbs is the ability to simultaneously engage two antigens. Using BLI, association 
of all evaluated bsAbs to immobilized c-MET and subsequent binding of EGFR could be observed 
indicating that cooperative binding of both soluble antigens is sterically feasible. The reach of antibody 
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binding arms to membrane anchored target is geometrically restricted with ~9 nm (Sengers et al, 2016) 
and thus constrained on close proximity and lateral diffusion of antigens within the membrane. As 
described earlier, interaction of c-MET and EGFR on the cellular surface has been proposed so that the 
antibody binding arm range should be sufficient for those two target antigens. Next, binding of bsAbs 
was evaluated to cell lines with different receptor surface expression levels of c-MET and EGFR (cf. 
Figure 19 and Table 9). As a result, binding strength correlated with expression levels of the more 
abundant target as recently reported. (Jarantow et al., 2015) For monovalent reference binders, binding 
strength was proportional to the affinity. Furthermore, no unspecific binding was observed for 
monospecific control binders for either EGFR negative or c-MET negative cell lines, e.g. SK-MEL2 and 
T47D, respectively, proposing target-specific antigen recognition on cells. Binding of B10/v5 to rodent 
CHO cells could be ascribed to cross-reactivity to murine c-MET (personal communication, Merck, 
Darmstadt, Germany). In case of similar c-MET and EGFR surface expression levels, e.g. NCI-H441 cells 
(cf. Figure 20), increased binding of bsAbs could be detected in comparison to monospecific one-armed 
mAbs presumably indicating simultaneous engagement of both antigens on cellular surface. 
 
Thus, a proof of concept was demonstrated for the concept of highly specific and simultaneous target 
binding dependent on affinities and cellular receptor levels of c-MET and EGFR as envisioned by the 
introduced design. Differential binding pattern of bsAbs on double overexpressing cell lines in 
comparison to monovalent mAbs or low expressing cells thereby proposed potential for improved tumor 
specificity by bsAbs carrying affinity-optimized binding moieties.  
 
6.4. Bispecific c-MET x EGFR mAbs with increased tumor selectivity and high efficacy 
After confirming the affinity and receptor density dependent cellular binding of bsAbs, functional 
behavior was comprehensively analyzed. While anti-EGFR mAbs mainly act via ligand competition, the 
mode of action of anti c-MET mAbs can be either described by direct or indirect HGF competition or by 
the induction of receptor degradation. While onartuzumab (oa 5D5) and hu224G11 act via competition 
of HGF (Merchant et al., 2013; Wang et al., 2016), others, e.g. LY2875358 (emibetuzumab), SAIT301 
and DN30 (Liu et al., 2014; Oh et al., 2012; Pacchiana et al., 2010), induce c-MET degradation. 
Interestingly, receptor degradation can be achieved by different mechanisms: DN30 binds the 
juxtamembrane domain and induces receptor shedding via the metalloprotease ADAM. (Pacchiana et 
al., 2010) SAIT301 in contrast mediates c-MET degradation via LRR and immunoglobulin-like domain-
containing protein 1 (LRIG1). (Lee et al., 2014) LY2875358 in turn inhibits both HGF binding and 
concurrently induces receptor internalization and degradation by an unknown molecular mechanism. 
(Liu et al., 2014)  
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Initial Western blot studies presented herein demonstrated inhibition of c-MET phosphorylation by bsAbs 
carrying high affinity c-MET binding moieties with slightly higher efficiency in HGF dependent cells 
compared to parental monovalent one-armed SEEDs (cf. Figure 39). However, all four herein presented 
c-MET binders were not able to significantly reduce c-MET phosphorylation levels in constitutively 
activated, c-MET amplified cell lines in contrast to DN30. Due to distinct epitopes of F06/CS06 and 
B10/B10v5 and slightly higher efficacy of CS06 and B10v5, only the affinity matured c-MET binders 
were chosen for further development in the bispecific format. As for blockade of EGFR phosphorylation, 
225-H and 225-M displayed superiority over 225-L and 425 (cf. Figure 39). Hence, functional analysis 
was focused on 225-M and 225-H in combination with CS06 and B10v5 as bsAbs to balance anti-tumor 
efficacy and tumor selectivity. 
 
For quantitative analysis of receptor inhibition during ligand stimulation, ELISA-like MSD assays were 
conducted. As a result, both B10v5 and CS06 containing bsAb inhibited c-MET phosphorylation with 
higher potency compared to patent-based reproduced reference antibodies oa 5D5 and LY2875358, with 
IC50 values in the subnanomolar range (cf. Figure 22). Moreover, bsAb prevented c-MET activation with 
higher potency than respective monovalent one-armed anti-c-MET binders indicating a synergistic mode 
of action regarding c-MET inhibition in the bispecific format (cf. Figure 24A). Due to an overlapping 
epitope of B10v5 with LY2875358 (cf. Figure 11), bsAbs were analyzed for potential c-MET degradation 
during overnight treatment. Interestingly, B10v5x225-H induced c-MET degradation in c-MET amplified 
cell lines comparable to LY2875358 (cf. Figure 24B). Inhibition of EGFR phosphorylation by bsAbs was 
dependent on the affinity and valence of the EGFR binder (cf. Figure 23). Monovalency of the EGFR 
binding moiety due to the chosen bispecific design resulted in decreased potency of EGFR inactivation 
in comparison to bivalent cetuximab. However, the evaluated bsAbs also demonstrated increased 
inhibition of AKT downstream signaling, but not of MAPK phosphorylation, when compared to the 
combination of monospecific control mAbs (cf. Figure 21). Similarly to cetuximab, small molecule 
inhibitors, e.g. gefitinib, fail to prevent AKT phosphorylation in NSCLC cells. (Guo et al., 2008) This 
supports the hypothesis that double inhibition of both EGFR and c-MET signaling pathways by bsAbs can 
lead to efficient inhibition of downstream signaling, at least for AKT. In summary, bsAbs displayed 
superiority in inhibiting c-MET and AKT phosphorylation, but reduced potency for inhibition of EGFR 
phosphorylation in comparison to bivalent cetuximab. Potencies for inhibition of receptor 
phosphorylation thereby did not correlate with target cell densities as it had been reported by Jarantow 
and co-workers. (Jarantow et al., 2015) Thus, for efficient inhibition of EGFR phosphorylation, bivalent 
anti-EGFR mAbs might be required. 
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Some anti-c-MET mAbs are prone to mediate full or partial agonism, probably influenced by the 
antibody’s epitope. (Liu et al., 2014; Merchant et al., 2013) Due to the interaction of c-MET and EGFR 
(Jo et al., 2000), bsAbs could potentially induce agonism via receptor heterodimerization as well. The 
presented data indicated that B10v5 containing bsAbs partially activated c-MET phosphorylation in 
absence of ligand stimulation comparable to reproduced LY2875358 in contrast to monovalent B10v5 
or CS06 bsAbs or mAbs (cf. Figure 25). Due to the mode of action via c-MET internalization and 
degradation, LY2875358’s functionality presumably outweighs partial agonism, since this molecule is 
currently evaluated in clinical phase 2. (Liu et al., 2014) The same could be account for B10v5 containing 
bsAbs. Furthermore, a degradation mode of action is potentially independent of HGF dependence of the 
cell line and therefore also c-MET amplified cell lines could be targeted. The need for bivalency of the 
bispecific molecule for improved inhibition of c-MET phosphorylation and the partial agonism by 
B10v5x225-H indicated receptor interaction and simultaneous engagement of both targets. 
 
After characterizing the cellular functionality of bsAbs, the tumor selective binding was evaluated using 
a cell mixing experiment composed of a tumor model and an epithelial model cell line via flow cytometry. 
Skin related adverse events of EGFR inhibitors are probably mediated by EGFR inhibition in 
keratinocytes and are the main reason for treatment disruption by patients during EGFR therapy. 
(Lacouture, 2006) All bsAbs demonstrated increased binding to c-MET and EGFR overexpressing tumor 
model cell line while binding to an epithelial model cell line with basal EGFR expression was equal or 
even reduced compared to cetuximab. Thus, the selectivity defined as the ratio of tumor to epithelial 
model cell binding was improved by bispecificity as reported for other target combinations. (Mazor et 
al., 2015b; Robinson et al., 2008) In the presented study, the use of affinity attenuated EGFR binding 
moieties greatly improved tumor cell selectivity in vitro which could also result in decreased toxicities. 
Similar concepts have been recently experimentally evaluated for affinity-optimized CD4xCD70 bsAbs 
by Mazor et al. and subsequently mathematically modeled by Sengers et al.. (Mazor et al., 2015a; Sengers 
et al., 2016) In summary, increased tumor selectivity mediated by the application of affinity attenuated 
anti-EGFR binders can only be achieved at the cost of reduced efficacy for inhibiting EGFR 
phosphorylation. However, further experiments will be needed to evaluate if monovalency of the EGFR 
binding moiety in the bispecific format can reduce on-target off-tumor toxicity. Although no correlation 
between EGFR receptor density and potency of EGFR inhibition could be observed. Surface expression 
of c-MET and EGFR in normal tissue can be critical for a potential clinical development of such bsAbs 
since reduced EGFR-mediated toxicity could improve patient compliance. When compared the herein 
presented design to other bsAbs in clinical development targeting c-MET and EGFR, some approaches 
exploit tetravalent molecules carrying two EGFR binding moieties which could negatively influence the 
tumor selectivity in contrast to the presented heterodimeric bsAbs with monovalent EGFR targeting. 
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Further characterization of bsAbs included the confirmation of internalization and ADCC since both 
modes of action have been described for cetuximab (Kimura et al., 2007; Mendelsohn & Baselga, 2003) 
as depicted in Figure 27 and Figure 40. When aiming for applications without toxin conjugation, the 
induction of ADCC could be beneficial. With improved tumor selectivity and the capability to induce 
internalization, bsAbs fulfill the pre-requisites for the application as ADC. 
 
6.5. Bispecific c-MET x EGFR ADCs to broaden the therapeutic window 
When arming antibodies with cytotoxic agents, a careful in vitro evaluation of the molecule’s safety 
profile is required early in the development process. As aforementioned, skin related adverse events are 
described for EGFR inhibitors due to basal expression in normal tissue. (Lacouture, 2006) As a 
consequence, more severe toxicities could be expected for EGFR targeting ADCs. The c-MET/HGF axis 
is involved among others in development and regeneration of the liver. (Birchmeier et al., 2003) Hence, 
primary keratinocytes and a hepatocellular carcinoma cell line were chosen as a model for in vitro safety 
assessment studies. 
 
In order to circumvent adverse events in normal tissue for their EGFR targeting ADC approach, Phillips 
and colleagues for example selected an antibody, ABT-806, which recognizes a tumor-specific, misfolded 
EGFR epitope. (Phillips et al, 2016; Reilly et al, 2015) The corresponding ADC, ABT-414, displayed high 
cellular binding to the glioblastoma cell line U87MGde2-7 while binding to wild-type EGFR expressing 
A431 cells was reduced when compared to cetuximab. (Phillips et al., 2016) This translated into highly 
potent cytotoxicity in U87MGde2-7 cells whereas IC50 values for the reduction of cell viability of wild-
type EGFR expressing cells was reduced dependent on receptor surface densities. (Phillips et al., 2016) 
In the present study, bsAbs targeting c-MET and EGFR displayed greatly increased tumor selectivity 
when employing affinity attenuated EGFR binding moieties (cf. Figure 26 and Figure 28). In order to 
achieve a second layer of selectivity for the ADC, the tubulin inhibitor MMAE was selected as payload 
for specific targeting of fast proliferating cells. Considering ADCs currently in clinical development, 
auristatins are the most validated payload class. (Leal et al., 2014) Intracellular release of the cytotoxic 
agents was ensured by the use of the cleavable vc-linker which is processed by cathepsin and plasmin in 
the lysosome. (Ritchie et al., 2013) Site-specific conjugation of MMAE C-terminally to both heavy chains 
of the bsAbs was mediated by sortase A. As a result, a homogenous ADC with specific toxin conjugation 
sites and a DAR of 2 was obtained as confirmed by mass spectrometry (cf. Figure 42). While unarmed 
bsAbs displayed no or only detrimental effects on the cell viability of c-MET or EGFR overexpressing cell 
lines, the generated bispecific ADCs demonstrated efficient cytotoxicity in the subnanomolar to single 
digit nanomolar range (cf. Figure 28 and 31). As control construct, cetuximab-ADC and an isotype-ADC 
(anti-HEL) were generated comparably to bispecific ADCs. While the potency for killing EGFR 
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overexpressing cells was slightly reduced for bispecific c-MET x EGFR ADCS in comparison to cetuximab-
ADC, bispecific ADCs demonstrated superiority in c-MET amplified cell lines. Concurrently, bsAbs ADCs 
demonstrated decreased toxicity in primary keratinocytes dependent on the affinity of the EGFR binding 
moiety whereas no significant toxicity could be detected in hepatocellular cancer cells within the 
evaluated concentration range. Interestingly, treatment of keratinocytes with unarmed antibodies 
revealed similar cytotoxicity compared to respective bispecific ADCs. This suggests that reduction in 
keratinocytes viability was caused by inherent EGFR inhibition rather than ADC mediated toxin delivery. 
Since lower replication rates of keratinocytes could lead to less efficacy of the tubulin inhibitor MMAE, 
the treatment time was increased from initially three days to six days. As a result, the efficacy of cell 
killing increased from 50% to 80% whereas the potency did not significantly alter (cf. Figure 30). 
Nevertheless, bispecific ADCs and corresponding unarmed bsAbs displayed similar efficacy and potency 
regarding cytotoxicity in keratinocytes supporting the hypothesis of an antagonistic antibody mode of 
action rather than ADC mediated cell killing (cf. Figure 30). Keratinocyte proliferation is regulated by 
EGFR signaling and antibody-mediated receptor internalization has been shown to severe inhibition of 
the EGFR pathway. (Lacouture, 2006; Mendelsohn & Baselga, 2003) Although the definition of 
therapeutic index is usually based on in vivo data (Muller & Milton, 2012; Panowski et al., 2014), the 
presented in vitro cytotoxicity results in EGFR overexpressing cells and primary keratinocytes were used 
for the calculation of a translational in vitro therapeutic index. The data provides the rationale that 
B10v5x225-M-vc-MMAE and B10x225-M-vc-MMAE broadened the in vitro therapeutic window by the 
factor five to six in comparison to EGFR targeting, bivalent cetuximab-vc-MMAE in cellular cytotoxicity 
experiments. Further evaluation is needed in order to correlate EGFR and c-MET receptor densities with 
potency of bispecific ADCs employing the cytotoxic agent MMAE. 
 
The presented study demonstrates that the use of affinity-optimized binders with either desired higher 
or attenuated affinities in the bispecific format targeting the prominent tumor-associated antigens c-MET 
and EGFR can improve in vitro tumor selectivity while concurrently retaining high efficacy with potential 
superiority to monospecific ADC approaches. Thus, balancing high selectivity with suitable efficacy could 
potentially improve the therapeutic index and consequently the safety profile. In particular the reduction 
of on-target off-tumor toxicities will be a challenge to face since expression of most cancer targets is not 
restricted to the tumor site and prevention of side effects will positively influence patient compliance 
and consequently treatment success. 
 
 
 6. Discussion  96 
6.6. Outlook 
Further studies are needed to confirm that improved in vitro selectivity and retained high efficacy can 
be translated in the highly complex in vivo environment both for unarmed bsAbs and bispecific ADCs 
targeting c-MET and EGFR. Besides the evaluation in selected rodent xenograft models to characterize 
selectivity and efficacy, also in silico modeling approaches could be envisioned. Zheng et al. and Sengers 
et al. recently simulated both the cross-arm binding efficiency and the selectivity of bispecific molecules, 
respectively, based on affinities of the binding moieties. (Sengers et al., 2016; Zheng et al., 2016) 
However, modeling the efficacy of ADCs becomes even more complex considering affinity dependent 
binding of ADCs, internalization rates dependent on the target, the antibody’s affinity and receptor 
surface densities as well as intracellular and extracellular toxin release among other factors. Additionally, 
binder epitopes could potentially influence intracellular trafficking routes. For example binding of the 
anti-c-MET antibody SAIT301 seems to activate an alternative internalization pathway in comparison to 
other anti-c-MET antibodies. (Lee et al., 2014) 
 
Considering the multifactorial nature of cancer and the development of intrinsic and acquired resistance, 
combinatory treatments and targeting of multiple cancer relevant regulators seem to be a viable route 
for future drug design approaches. Bispecific ADCs could potentially counteract EGFR inhibitor related 
resistance mechanisms including c-MET amplification (Engelman et al., 2007), ligand upregulation 
(Straussman et al., 2012; Troiani et al, 2013), the presence of EGFR activating mutations in the kinase 
domain (Martin et al, 2016; Tang et al, 2008) and the mutation of downstream mediators, e.g. KRAS 
(Pao et al). The work described herein represents an illustrative case study for the design and 
characterization of bispecific mAbs and ADCs employing affinity-optimized binding moieties for two 
mutual overexpressed tumor-associated targets for high selectivity as well as high anti-tumor efficacy. 
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8.1. Supporting Information 
For the affinity maturation of the parental anti-c-MET binder F06, the sequence analysis results for the 
parsimonious mutagenesis approach and the error prone PCR approach are depicted in Table 12, Figure 
32 and Figure 33. 
 
Table 12: Sequence analysis of affinity matured Fab-F06 by phage display sub-libraries 
For the affinity maturation of the parental anti-c-MET binder F06, the sequence analysis of two sub-library approaches, 
parsimonious mutagenesis and error prone PCR (epPCR), are depicted. The number of analyzable sequences of 96 sequenced 
clones (evaluable sequences) are listed as well as the number of complete, functional Fab-antibody fragments and the theoretical 
diversity. 
 
F06 sub-library 
Evaluable sequences 
Complete Fab-antibody 
fragments 
Theoretical 
diversity 
n [%] n [%] 
Parsimonious mutagenesis 
of F06-CDR-H3 
94 97.9 91 94.8 2.4E+06 
epPCR F06-VH 74 77.1 71 74.0 4.1E+06 
 
 
 
Figure 32: Sequence analysis of panning round 2 output from the F06 parsimonious sub-library. 
Based on the sequence analysis, the changes of amino acids of 57 unique and functional binders based on 96 sequences of anti-
c-MET binders after two rounds of panning from the Fab-F06 parsimonious mutagenesis sub-library are depicted. Each amino 
acid is represented by a single color as shown in the color code. Two positions 111.1 and 112.2 (after IMGT numbering) within 
the CDR-H3 displayed the highest abundance of mutations.  
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Figure 33: Sequence analysis of panning round 2 output from the F06-VH epPCR sub-library. 
Based on the sequence analysis, the changes of amino acids of 74 unique and functional binders based on 96 sequences of anti-
c-MET binders after two rounds of panning from the Fab-F06 error prone PCR sub-library are depicted. Each amino acid is 
represented by a single color as shown in the color code. Positions with high mutation rates were located in framework 1, the 
CDR-H1, and the CDR-H3.  
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For the analysis of c-MET binders, an epitope binning experiment was conducted to reveal anti-c-MET 
binders with overlapping (competing) epitopes. An exemplary biolayer interferogram is depicted in 
Figure 34. 
 
Figure 34: Exemplary raw data from the epitope binning experiment. 
For the epitope binning experiment, the first antibody (e.g. oa CS06) was immobilized on anti-human Fc biosensors. This was 
followed by quenching with an unrelated isotype control antibody (anti-HEL) in order to saturate the biosensor surface with 
Fc. After a short baseline in kinetics buffer, first c-MET ECD was associated and subsequently the second antibody. Antibodies 
that occupy the same or an overlapping epitope, were not able to bind in the second association step (e.g. oa CS06, 224G11 
and anti-HEL whereas oa B10v5 and LY2875358 could bind. 
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Supplemental figures including antibody characteristics, e.g. purity and thermal stability, were depicted 
in Figure 35 to Figure 38. 
 
Figure 35: SDS PAGE analysis of bsAbs. 
Gel electrophoresis of the 16 expressed and purified c-MET x EGFR bsAbs. Gels were stained with coomassie and samples were 
analyzed under non-reduced (A) and reduced conditions (B). BsAbs have a theoretical size of 125 kDa under non-reduced 
conditions. Reduction of bsAbs results in three fragments: the AG-heavy chain, the c-MET light chain and the scFv-GA chain 
(50 kDa, 25 kDa, and 50 kDa, respectively). Some of the lower bands under non-reduced conditions could be explained by artifact 
bands as described by Liu et al. (Liu et al, 2007). 
 
 
Figure 36: SDS-PAGE analysis of one-armed control SEED antibodies. 
Gel electrophoresis of non-reduced and reduced monovalent control antibodies stained by coomassie. The oa Fab-SEEDs have 
a theoretical size of 100 kDa while monovalent scFv-SEEDs have the size of 75 kDa. As indicated by bands, GA-SEED chains formed 
in parts homodimers resulting in scFv-scFv-SEED with a size of 100 kDa. 
 
 8. Appendix  113 
 
Figure 37: Size exclusion chromatography of purified bsAbs. 
Analytical SEC of B10v5x225-M (A), B10v5x225-H (B), CS06x225-M (C), and CS06x225-H (D) after preparative SEC are 
exemplarily depicted. Calculated monomer percentage [%] is indicated and ranged from 95 to 100%.  
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Figure 38: Summary of the thermal shift assay melting curves. 
1 µM antibodies was mixed with a 20 fold excess of the fluorescent dye SYPRO orange. Protein unfolding in response of 
increasing temperature resulted in exposure of hydrophobic patches where the dye can attach. This in turn yielded in increase 
in fluorescence (left graphs). The deviation of the fluorescence (right site) indicates the melting temperature represented by 
maxima. 
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Functional analysis of bsAbs by Western blot for phosphorylated c-MET and EGFR as well as for their 
selectivity, the ability to induce ADCC and internalization (Figure 39 to Figure 41, Table 13). 
 
Figure 39: Phosphorylation of c-MET and EGFR in A549 (A) and EBC-1 (B) cells analyzed by Western Blot. 
After serum starvation for 16 h, A549 (A) or EBC-1 cells (B) were pre-incubated with 300 nM bsAbs or reference mAbs for 4 h 
followed by stimulation with HGF and EGF (50 ng/ml) for A549 cells. Cell lysates were subjected to gel electrophoresis, Western 
blotting and bands were revealed with detection antibodies against total and phosphorylated c-MET and EGFR as well as actin. 
In HGF-dependent A549 cells (A), bsAbs reduced c-MET and EGFR phosphorylation. For EBC-1 cells (B) with c-MET 
amplification, no effect on c-MET phosphorylation was observable. p=phosphorylated 
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Figure 40: ADCC of bsAbs on A431 and EBC-1 cells in comparison to cetuximab. 
A431 cells (A) and EBC-1 cells (B) were treated with antibodies and subsequently with recombinant Jurkat effector cells (in 
ratio 6:1) in which a luciferase was added in the nuclear factor of activated T-cells (NFAT) pathway. Activation of FcγRIIIa 
receptor by mAbs induced conversion of substrate by luciferase yielding in luminescence signal. As a result, high affinity variants 
in bsAb format induced ADCC comparable to cetuximab whereas isotype control did not. Shown are representative graphs of 
two independent experiments with triplicates. Data were plotted as relative luminescence units versus logarithm of antibody 
concentration. 
 
Table 13: In vitro selectivity of bsAbs determined for different cell line combinations. 
The tumor model cell line (EBC-1, A431 or MKN45) were stained with a green membrane dye to allow distinction of the two 
cell populations during the mixing experiment via flow cytometry. Tumor model cells were then mixed with a normal model 
cell line (HepG2 or T47D) in a ratio 1:30. HepG2 cells exhibit low EGFR surface expression and slightly more c-MET surface 
expression levels. T47D in contrast are devoid of c-MET and display basal EGFR expression. A431 is characterized by EGFR 
overexpression (+++) and low c-MET expression (+), EBC-1 and MKN45 are c-MET amplified (+++) with medium EGFR 
expression (++). The cell mixture was incubated with 30 nM mAbs and binding was revealed with anti-human Fc PE-conjugate 
via flow cytometry. The in vitro selectivity was defined as the ratio of tumor to normal tissue model cellular binding, e.g. MFI 
(EBC-1) divided by MFI (T47D). The calculated values for the cell line combinations are summarized in the table below. The 
color code was defined for each column with red indicating low selectivity, shades of yellow as medium selectivity and green 
as high selectivity. Except for A431 and HepG2 cells, for all other combinations bsAbs displayed higher selectivity in comparison 
to monospecific cetuximab. n.d. = not determined. 
 
Construct 
name 
EBC-1 vs. 
HepG2 
A431 vs. 
HepG2 
EBC-1 vs. 
T47D 
A431 vs. 
T47D 
MKN45 vs. 
T47D 
B10x225-L 17 7 92 1911 106 
B10x225-M 15 11 16 147 12 
B10x225-H 14 12 10 75 6 
B10x425 17 4 23 53 11 
F06x225-L 16 21 n.d. 277 22 
F06x225-M 19 10 23 160 13 
F06x225-H 17 19 8 81 5 
F06x425 19 11 16 81 7 
B10v5x225-L n.d. n.d. 116 151 66 
B10v5x225-M n.d. n.d. 25 39 9 
B10v5x225-H n.d. n.d. 16 36 5 
B10v5x425 n.d. n.d. 24 33 7 
CS06x225-L n.d. n.d. 818 1162 329 
CS06x225-M n.d. n.d. 49 46 14 
CS06x225-H n.d. n.d. 22 34 6 
CS06x425 n.d. n.d. 34 31 9 
cetuximab 9 28 5 32 1 
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Figure 41: MFIs for internalization assay by flow cytometry with and without quenching. 
Representative graph for the analysis of internalization induced by 100 nM mAbs in NCI-H441 cells at 37°C and 4°C with and 
without a quenching via flow cytometry. Antibodies were thereby detected with an anti-human Fc AlexaFluor488 conjugate. 
Relative green fluorescence intensities were calculated from duplicates and standard deviations were indicated as error bars. 
Residual surface binding of fluorescently labeled antibodies was quenched with an antibody directed against AlexaFluor488. 
As a result, non-quenched samples displayed nearly comparable MFIs at 4°C and 37°C as expected. Treated cells incubated at 
4°C without quenching displayed only small MFIs indicating incomplete quenching. Difference of total fluorescence of samples 
without quenching to sample at 37°C with quenching indicates the portion which was internalized. During quantitative 
calculation of percent internalization, the minor fluorescence from the sample 4°C with quenching was also included. 
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Analysis of bispecific ADCs by mass spectrometry (MALDI) was depicted in Figure 42. 
 
 
Figure 42: MALDI of bispecific ADCs. 
Evaluation of native bispecific ADCs diluted 1:10 in 50 mM ammonium bicarbonate buffer by MALDI. Samples were applied on 
MALDI plates with C4 ZipTips. For matrix 1, plate was coated with saturated SA solution in ethanol. For matrix 2, plate was 
coated with saturated SA solution in 33% ACN (acetonitrile) and 0.1% TFA (trifluoroacetic acid). Measurement was carried 
out in LP mode and calibrated only with mass 60,000 Da. Measurements were carried out by Merck, Darmstadt, Germany. The 
molecular weight (MW) of GGG-vc-MMAE is 1294.58 Da. 
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Additional graphs for cytotoxicity assays are illustrated in Figure 43. 
 
Figure 43: Cytotoxicity of bsAbs on further cancer cell lines. 
Bispecific ADCs generated by site-directed conjugation of vc-MMAE to both heavy chains were incubated on cancer cell lines 
with low to medium c-MET and EGFR expression including A549 (A), NCI-H596 (B), NCI-H1975 (D), KP-4 (E) and NCI-H441 
(F). ADCs were incubated for 72 h and cell viability was determined with the CellTiter-Glo® assay. Interestingly, lower c-MET 
and EGFR expression correlated with less potent and efficacious cell killing in comparison to c-MET or EGFR overexpressing 
cell lines. Only for NCI-H441 cells (F) carrying a KRAS mutation, nearly no cytotoxicity was detected in the evaluated 
concentration range. Furthermore, cytotoxicity of bispecific ADCs on another c-MET amplified cell line, HCC-827 (C), was 
evaluated. In contrast to EBC-1 and MKN45 cells (cf. Figure 28), cetuximab-vc-MMAE demonstrated similar efficacy in cell 
killing compared to bispecific ADCs.  
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8.2. Abbreviations 
aa Amino acid 
ADC Antibody-drug conjugate 
ADCC Antibody dependent cellular cytotoxicity 
ADCP Antibody dependent cellular phagocytosis 
AFM Affinity maturation 
AHC Anti-human Fc biosensor 
Amp Ampicillin 
APS Aminopropylsilane 
BLI Biolayer interferometry 
bp Base pair 
BSA Bovine serum albumin 
bsAb Bispecific antibody 
CD Cluster of differentiation 
CDC Complement dependent cytotoxicity 
CDR Complementarity determining region 
cfu Colony forming unit 
CH1, 2, 3 Constant domain 1, 2, 3 of the heavy chain 
c-MET Mesothelial epithelial transition, HGFR 
CV Column volume 
Da Dalton 
DAR Drug-to-antibody ratio 
dH20 Distilled water 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribonucleotide triphosphate 
ECD Extracellular domain 
ECL Electrochemiluminescence 
E. coli Escherichia coli 
EGF(R) Epidermal growth factor (receptor) 
ELISA Enzyme-linked immunosorbent assay 
epPCR Error-prone PCR 
Fab Fragment antigen binding 
FACS Fluorescence activated cell sorting 
Fc Fragment crystallizable 
FcRn Neonatal Fc receptor 
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FcγR Fcγ receptor 
FCS Fetal calf serum 
FITC Fluorescein 
FR Framework region 
H Hour 
HC Heavy chain 
HER Human epidermal growth factor receptor 
HGF / SF Hepatocyte growth factor, scatter factor 
HGFR Hepatocyte growth factor receptor, mesothelial epithelial transition; c-MET 
His-tag Histidine tag, usually composed of six histidines 
HPLC High performance liquid chromatography 
HRP / POD Horse reddish peroxidase 
hu / hs Human / homo sapiens 
Ig Immunoglobulin 
ITAM Immunoreceptor tyrosine-based activating motif 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
ka Association rate constant 
KB Kinetics buffer 
KD Equilibrium dissociation constant 
kd Dissociation rate constant 
LB medium Luria-Bertani medium 
LC Light chain 
mAb / pAb Monoclonal antibody / polyclonal antibody 
MALDI-TOF MS Matrix-assisted laser desorption/ionization time of flight mass spectrometry 
MCS Multiple cloning site 
MFI Mean fluorescence intensity 
MMAE Monomethyl auristatin E 
mRNA Messenger ribonucleic acid 
MSA Multiple sequence alignment 
mu Murine, mus musculus 
MWCO Molecular weight cut-off 
n.d. Not determined 
NC Nitrocellulose 
NEAA Non-essential amino acids 
NK cells Natural killer cells 
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NK1 N-terminal HGF fragment 
oa One-armed 
OD Optic density 
PAGE Polyacrylamide gel electrophoresis 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD Phage display 
PDB Protein Data Bank 
PE R-phycoerythrin 
PEG Polyethylene glycol 
PI Propidium iodide 
PVDF Polyvinylidene fluoride 
RIPA buffer Radioimmunoprecipitation assay buffer 
rpm Revolutions per minute 
RT Room temperature 
RTK Receptor tyrosine kinase 
scFv Single-chain variable fragment 
s.d. Standard deviation 
SDS Sodium dodecylsulfate 
SEC Size exclusion chromatography 
sec second 
SEED Strand exchange engineered domain 
SHM Somatic hypermutation 
SNP Single nucleotide polymorphism 
TKI Tyrosine kinase inhibitor 
Tm Melting temperature 
Tris Tris(hydroxymethyl)aminomethane 
v/v Volume per volume 
vc Valine-citrulline (linker) 
VH Variable domain of the heavy chain 
VL Variable domain of the light chain 
w/v Weight per volume 
wt Wild type 
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